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ABSTRACT 
MARGARET ADÈLE SCULL:  
MYXOVIRUS INTERACTION WITH THE HUMAN AIRWAY EPITHELIUM 
(Under the direction of Dr. Raymond J. Pickles) 
 
The conducting airways of the human respiratory tract exhibit numerous physical and 
biological innate defenses that serve to protect the distal lung from infection.  Nonetheless, 
the airway epithelium that lines the conducting airways can also serve as a portal for viral 
infection.  Parainfluenza and influenza viruses infect the human airway epithelium (HAE), 
resulting in disease ranging in spectrum from “common cold-like” illnesses to pneumonia.  
Continued seasonal infections by these viruses further suggest that they have evolved to 
successfully negotiate innate host barriers including regional airway temperature, mucus 
and interferon production.  To determine the impact of these defenses and define viral 
strategies for efficient infection, we characterized parainfluenza and influenza virus infection 
using an in vitro model of HAE.  Our data show that human parainfluenza virus types 1 
(HPIV1) and 2 (HPIV2) infect ciliated cells with little overt cytotoxicity, whereas human 
influenza viruses demonstrate expanded tropism and rapidly induce cytopathic effects.  
Neither HPIV1 nor HPIV2 infection induced interferon and subsequent analysis of HPIV1 
with mutated C proteins indicated that these proteins facilitate robust infection by 
antagonizing the host anti-viral response.   
We next determined viral growth in proximal and distal airways by performing 
experiments at temperatures reflective of the upper (32oC) or lower (37oC) airways.  
Restriction of temperature-sensitive HPIV vaccine candidates in HAE recapitulated in vivo 
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attenuation in non-human primates, validating our model.  While HPIV and human influenza 
virus grew equally between 32oC and 37oC, avian influenza viruses were restricted at 32oC.  
Using reverse genetics, we attributed this restriction to the avian virus glycoproteins — 
hemagglutintin (HA) and neuraminidase (NA).  These data suggest that the avian virus HA 
and NA are not adapted for efficient infection at upper airway temperatures, a feature which 
may limit zoonotic transmission.  The HA of influenza viruses that are well-suited for 
infection of the human airway bind α2,6-linked sialic acid, and our final study suggests a 
specific interaction with a highly sialylated mucin protein, MUC1. Both in vitro and in vivo 
data further suggest that this interaction may facilitate infection and corroborate the notion 
that human influenza viruses have evolved to use this host protein to their advantage.   
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CHAPTER I 
INTRODUCTION 
 
The Public Health Burden of Respiratory Virus Infections 
Respiratory tract infections represent the most common cause of acute illness 
affecting the human population (29, 204).  Lower respiratory tract infection, including 
pneumonia, is also the second leading cause of mortality, accounting for 4.2 million, or 
7.1%, of all recorded deaths world-wide (345).  In the United States, 36.9 million ambulatory 
care visits are attributable to respiratory disease each year, and 500,000 hospitalizations are 
a result of community-acquired pneumonia, representing a significant burden on both the 
health care system and economy (15, 266).  Indeed, a single “flu season” is calculated to 
incur a cost of $87.1 billion dollars including both direct medical costs and loss of 
productivity due to missed work days (203). 
Over 200 different viruses can infect the human airway, producing a wide range 
symptoms and clinical outcomes from self-limiting upper respiratory tract infections such as 
rhinitis and pharyngitis, to lower lung involvement and death of the afflicted (192, 271).  
Progression of disease is related to both pathogen virulence and host susceptibility.  For 
example, severity of disease is often worsened in infants due to the immaturity of their 
immune system (89) and smaller diameter of their airways (178).  The elderly and otherwise 
immunocompromised also experience greater morbidity (200, 247, 327, 335) while in 
patients with chronic lung disease, including cystic fibrosis (CF), chronic obstructive 
pulmonary disorder (COPD) and asthma, respiratory viruses cause up to 85% of 
exacerbations (134, 175).  Still, people of any age or condition are susceptible to respiratory 
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virus infections, and ease of dispersion via coughing or sneezing, resulting in aerosolization 
of virus and deposition on inanimate surfaces, facilitates transmission of respiratory viruses 
between individuals and throughout communities.   
As symptoms that result from viral infection of the airway are often generic, 
laboratory confirmation is required for specific diagnosis.  However, even with enhanced 
screening efforts and more accurate and high-throughput PCR-based means of detection, 
the etiologic agent of disease remains unknown in over 50% of cases (169, 358).  
Confirmed diagnoses suggest that rhinoviruses account for the majority of respiratory 
illnesses (~34%), followed by coronaviruses (~14%), influenza viruses (9%), parainfluenza 
viruses (4%) and respiratory syncytial virus (4%) (83, 204).   
 
Classification and Clinical Course of Myxovirus Infections   
Parainfluenza viruses, as members of family Paramyxoviridae and influenza viruses, 
as members of family Orthomyxoviridae, are collectively referred to as “myxoviruses” (from 
the Greek myxa, meaning ‘mucus’) (12).  Human parainfluenza viruses (HPIV types 1, 2, 3, 
4a and 4b) are further defined as members of subfamily Paramyxovirinae, which includes 
other human pathogens such as measles virus and mumps virus in addition to the recently 
emergent and highly virulent Hendra virus and Nipah virus (1, 53, 291).  Together, HPIV1, -2 
and -3 are the second leading cause of pediatric hospitalizations due to respiratory illness 
following respiratory syncytial virus (RSV), accounting for 2-17% of such hospitalizations 
(60, 127, 249).  While HPIV3 infection often manifests as bronchiolitis or pneumonia, HPIV1 
and HPIV2 are more often associated with croup in children under the age of five (180, 338).  
Still, a broad spectrum of disease has been observed in patients with either HPIV1 or HPIV2 
infection, and clinical syndromes such as rhinitis, pharyngitis and otitis media as well as 
more severe conditions, similar to those more commonly associated with HPIV3 can result 
(60, 117, 118, 249).  Furthermore, despite the fact that parainfluenza virus infection can be 
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detected in up to 92% of infants by 30 months of age, re-infection by homologous subtype of 
HPIV can occur throughout life, even in the presence of virus-specific antibody (129, 340).   
Both HPIV1 and HPIV2 exhibit seasonal peaks in activity, with HPIV1 activity 
elevated September through December biennially and HPIV2 circulating annually between 
April and June and October to November (81).  Seasonality is likely due in part to factors 
such as temperature and relative humidity which may influence virus stability in the 
environment as well as have direct effects on host immunity or indirect effects on patterns of 
human activity that would facilitate spread between hosts (reviewed  in (74); (170)).  
Notably, the number of HPIV3 cases appears to increase in years in which HPIV1 is not 
circulating, though the reasons for this are unclear (81).     
Influenza viruses are classified within family Orthomyxoviridae according to the 
antigenicity of two internal viral proteins, the nucleoprotein and matrix protein, into three 
types: A, B and C.  Seasonal, or epidemic, influenza, which peaks during the winter months, 
is mediated by both type A and type B influenza viruses, with type A being more common 
(246).  Influenza virus infection often results in rapid onset of symptoms, including fever in 
68% and headache in 91% of confirmed cases (206), and can predispose the host to 
primary viral or secondary bacterial pneumonia leading to acute respiratory distress 
syndrome (ARDS) (193, 265, 272).  Conversely, the low frequency of documented infections 
and limited disease severity for type C influenza viruses, characterized by a “common cold-
like” syndrome in infected individuals, make this type less clinically relevant (140, 202).   
 
Myxoviruses as Zoonotic Pathogens 
 In addition to circulating within the human population, cross-species (“zoonotic”) 
transmission is also documented for myxoviruses.  Within the Paramyxoviridae, this is 
limited to Hendra virus and Nipah virus, which recently emerged from fruit bats to cause 
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severe encephalitis in humans (1, 53, 291).  Conversely, type A influenza viruses are well 
recognized for their wide host range and ability to undergo zoonotic transmission (337).   
Influenza A viruses have been isolated from numerous species including seals, 
horses, and pigs, and have been identified in over 105 species of wild birds, constituting a 
vast natural reservoir and increasing the probability of human exposure (45, 224, 314).  
Type A influenza viruses are sub-typed according to the antigenicity of their two surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA) and all sixteen currently known 
HA and nine known NA subtypes have been identified in aquatic bird populations (76, 161).  
Infection in the avian host is normally asymptomatic and localized to the enteric tract with 
the exception of H5 and H7 subtypes which can cause respiratory or systemic disease (76, 
161, 224, 228, 301, 304, 337, 347).  Persistence of influenza viruses within and across 
avian populations is maintained via oral-fecal transmission routes or by ingestion of virions 
that have persisted in the environment (41).   
Replication of influenza virus inside any host can lead to either accumulation of 
mutations introduced by the error-prone viral polymerase (a process termed “antigenic drift”) 
or genetic reassortment with other influenza viruses co-infecting the same cell (termed 
“antigenic shift”).  These mechanisms allow for rapid evolution and potential generation of 
viruses within the quasispecies that may be better equipped to overcome species barriers 
and infect new hosts.  The introduction of influenza viruses possessing novel surface 
antigens into an immunologically naive human population can result in severe illness, while 
further adaptation of this virus for efficient human-to-human transmission can subsequently 
result in a pandemic.  
Three influenza pandemics have been recorded in the past century, the first taking 
place from 1918-1919.  This H1N1-mediated pandemic, referred to as the “Spanish 
Influenza,” is believed to have infected one-third of the world’s population and resulted in the 
death of approximately 50 million people with a case fatality rate of >2.5% (80, 177).  
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Sequences derived from genome fragments of the 1918 virus isolated from archival 
influenza autopsy material suggest 1918 was avian-like and possibly derived from an 
unknown source (250).  Additional analysis of histopathological autopsy samples and 
pathogenicity studies in animal models with the complete, resurrected 1918 virus suggest a 
unique virulence characterized by destruction of the airway epithelium, massive pulmonary 
edema, and hemorrhage, as well as a rapidly-induced and elevated immune response (139, 
235, 316, 339).  Descendents of the 1918 virus continued to circulate in the human 
population and later gave rise to the 1957 (H2N2) and 1968 (H3N2) pandemics, which, 
unlike the 1918 virus, were mediated by genetic reassortment (27, 307).   
Additional avian influenza virus infections in people have been reported in the past 
decade, including 433 confirmed cases of H5N1 since 2003 (344).  H5N1 replicates to high 
titer in humans and this enhanced viral load is associated with elevated cytokine levels 
above those normally measured in seasonal influenza cases (24, 47, 52).  The localization 
of severe pathology to the lower lung as well as the high mortality rate, approximating 60%, 
would suggest an H5N1-mediated pandemic would be devastating to the human population 
(361).  However, despite detection of high titers in nose and throat of infected individuals, 
evidence of human-to-human transmission for H5N1 viruses is very limited (65).  
Identification of the molecular determinants that would confer transmissibility to H5N1 
isolates is an area of active research and current data suggest that the viral polymerase 
subunit, PB2 (297) and surface attachment protein, hemagglutintin (HA) (326) are 
determinants of transmissibility in the ferret model of influenza virus infection.  This model 
recapitulates the cellular structure of the human airway as well as clinical signs of disease 
such as sneezing, which may be critical in assessing spread of virus to additional hosts 
(147, 189, 236).   
H7N7 and H9N2 subtypes of avian influenza have also been reported in the human 
population, causing mild respiratory illness or conjunctivitis (77, 153, 234).  Even more 
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recently, H1N1 “swine influenza” infections have been confirmed, dispersed throughout 
seventy-four countries around the globe (346).  While the mortality rate for H1N1 2009 
infection appears to be much lower than H5N1 (<1%), the transmission from human-to-
human appears to be more efficient, resulting in recent elevation of H1N1 2009 to official 
pandemic status (phase 6) by the World Health Organization  (2, 144).   
The presence of these novel influenza viruses in the human population highlights the 
need for continued global surveillance and advancement of vaccine platforms that not only 
target multiple subtypes of influenza but are also conducive to rapid and large-scale 
production.  Still, despite these historical pandemics and recent events, transmission of 
avian influenza viruses into the human population is still believed to be relatively inefficient.  
This is due to a multitude of host range barriers that restrict the ability of avian influenza 
viruses to infect and replicate productively in human epithelial cells, including, but not limited 
to receptor specificity, host temperature and the presence of host cell factors that restrict 
activity of avian polymerase subunits (181, 197, 281).  Current effort in the field is focused 
on identifying host factors that restrict avian influenza virus infection of the human airway 
epithelium as well as defining the molecular adaptations within the virus that would confer 
the ability to infect and transmit.  Additional discussion of host range restriction of avian 
influenza viruses is incorporated into our description of myxovirus infection strategy later in 
this chapter.   
 
The Target for Infection: Human Airway Epithelium 
The airway epithelium of the human respiratory tract forms a contiguous barrier, 
extending from nose to alveoli, which lies at the interface between the external environment 
and underlying host tissues.  Approximately 10,000-14,000 liters of air move through the 
conducting airways of the human lung on a daily basis, bringing the surface of the 
epithelium into contact with environmental toxins, allergens and wide array of fungal, 
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bacterial and viral pathogens such as parainfluenza and influenza viruses (132, 323).  To 
prevent infection, as well as to preserve integrity of the epithelium and promote efficient gas 
exchange, the airway epithelium exhibits a multitude of innate defense mechanisms.  These 
mechanisms are both physical and biological in nature and act at both the extracellular and 
intracellular level.  Despite these innate defense mechanisms, the incidence of human 
infection by both parainfluenza and influenza viruses is proof that these viruses have 
evolved to negotiate the mucosal barrier and antagonize host pathogen recognition to 
successfully infect and replicate in target epithelial cells.  Our current knowledge regarding 
innate defense mechanisms of the airway epithelium and myxovirus strategy for infection of 
the respiratory tract is reviewed below.      
    
Innate Defense I: The Mucosal Barrier 
Secreted mucus:  Mucus and mucus clearance are critical components of the 
innate immune system of the respiratory tract and represent the first line of defense against 
lung injury or respiratory infection (148).  Mucin glycoproteins (or “mucins”) are a major 
constituent of mucus and are critical for normal lung function through the lubrication and 
hydration of the airway, as well as by trapping particulate matter and pathogens for removal 
via mucocilliary clearance or presentation to immune cells (92, 110). Secreted mucins 
MUC5AC and MUC5B are produced predominantly by the submucosal glands and by 
mucous/goblet cells present throughout the conducting airways (168, 255).  Fully 
synthesized mucins are stored in the cytoplasm of goblet cells within secretory vesicles, 
termed granules.  Mucin-containing granules are released via exocytosis both at low, 
constitutive levels to maintain normal homeostasis and in response to cytokines, bacterial 
exoproducts, nucleotides, neurotransmitters and proteases (130).  Once secreted, these 
mucin glycoproteins mix with ions and water as well as other host proteins, lipids and 
glycoconjugates to form mucus (132, 255).  Hypersecretion of mucus occurs in response to 
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acute infection (rhinovirus (126, 357); Sendai virus (131)); however, extensive mucin 
production can lead to occlusion of the airway and reduced air flow (212).  Elevated mucus 
production, resulting in reduced clearance and enhanced pathogenicity of infection, is also 
described in chronic inflammatory conditions, such as asthma or COPD, which exhibit goblet 
cell hyperplasia (4, 5, 245).   
In addition to secreted mucins, mucus gels also contain enzymes, organic 
molecules, scavenging proteins, and anti-microbial peptides such as defensins that 
contribute to the adherence and removal or destruction of toxins and pathogens.  These 
anti-microbial agents may be expressed by ciliated cells, alveolar macrophages, or secretory 
cells, and resulting concentrations can be very high, on the order of 1-10ug/ml in airway 
lavage fluid (37, 168, 313).  Exosome-like vesicles were also recently identified in mucus 
secretions of human airway epithelial cells in culture (145).  Exosomes isolated from other 
cell types, including dendritic cells (309), microglia (242) and platelets (116), and biological 
fluids such as breast milk (3) and serum (44), have been found to be immunomodulatory 
and may also mediate intercellular communication via transport of mRNA and microRNAs 
from the cell of origin to other more distal cells (322).  While the presence, regulation and 
role of exosomes in the airway in vivo has not been investigated, the ability of these 
exosomes to inhibit influenza virus in vitro suggests that these vesicles may also contribute 
to innate defense against specific viral pathogens in the lung (145).   
Mucus clearance:  Material trapped in mucus gels is subsequently cleared from the 
lung via mucociliary transport and defensive reflexes such as coughing or sneezing.  
Mucociliary transport is made possible by the viscoelastic properties of the mucus gel itself 
and association of the gel with cilia, present at the apical surface of underlying ciliated cells, 
which beat continuously in coordinated unison (51).  Conversly, coughing and sneezing are 
effected following stimulation (inflammatory or mechanical in nature) of the terminal 
processes of sensory nerves embedded in the basement membrane of the respiratory 
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epithelium and subsequent signal to the central nervous system (17, 54, 132).  The 
importance of cough is highlighted by the reduced severity of disease in patients with 
defective ciliary function, as in primary ciliary dyskinesia (PCD), compared to those with CF 
who exhibit both inhibitied mucociliary and cough clearance (148).  While these mechanisms 
facilitate removal of pathogens from the airways, it should be noted that during periods of 
viral shedding, these mechanisms may also promote transmission between hosts (16) 
Glycocalyx:  In addition to secreted mucus, the apical surface of underlying cells is 
protected by a dense glycocalyx layer, comprised in large part by mucins that are tethered 
to the apical surface of host cells.  Most tethered mucins are large glycoproteins (2-20x105 
kDa) and are characterized by a variable number of tandem repeats which contain 
numerous potential O-glycosylation sites (294). Fifty to ninety percent of total mucin mass is 
due to glycosylation, and the diversity of carbohydrate structures likely promote interactions 
with an equally diverse array of airway pathogens (110).  Tethered mucins identified in the 
human respiratory tract include MUC1, MUC4 and MUC16, of which MUC1 is the most 
abundant and well characterized  (64, 110, 241).  MUC1 is present in nasal, 
tracheobronchial, bronchiolar and alveolar epithelial tissues in humans and is highly 
expressed on the apical surface of human ciliated airway epithelium (HAE) in vitro (262, 
300).  In addition to providing steric protection by blocking direct access to the apical 
membrane, recent evidence suggests that mucins also participate in signal transduction and 
may mediate an intracellular response to infection.  Signaling occurs through the 
cytoplasmic tail (CT) of transmembrane mucins which is highly conserved, with 82-87% 
homology at the amino acid level across species, suggesting an important universal function 
of these mucin glycoproteins (31, 71, 294, 295).  The cytoplasmic tail of MUC1 can be 
phosphorylated in response to bacteria and can be been found in association with numerous 
kinase and non-kinase proteins, including proto-oncogenes such as β-catenin (269).  While 
the downstream pathways and effector molecules that are activated by mucins are not well 
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defined, recent work suggests that MUC1 may signal to negatively regulate a pro-
inflammatory response initiated through toll-like receptor stimulation (319).   
        
Innate Defense II: Cellular Response 
 Pathogens that are able to successfully penetrate these extracellular mucosal 
barriers encounter a variety of cell types within the epithelium which differ in their individual 
function and distribution throughout the airway.  These cells not only contribute to host 
innate defense through the maintenance of the anti-microbial mucus and glycocalyx barrier 
discussed above, but are also equipped to initiate a cellular response leading to anti-viral 
and pro-inflammatory cytokine expression and subsequent recruitment of additional immune 
cells to the airway lumen.  Through these mechanisms, the airway epithelium orchestrates 
both the innate and adaptive immune response to infection. 
Pathogen recognition and signal transduction:  Pathogen recognition by airway 
epithelial cells is mediated through pattern recognition receptors (PRRs) which are also 
typically expressed by numerous phagocytic and antigen presenting cells (128).  Three 
classes of PRRs have been described: toll-like receptors (TLRs), retinoic acid-inducible 
gene 1 (RIG-I)-like receptors (RLRs) and nucleotide-binding domain and leucine-rich-repeat-
containing proteins (NLRs).  While all PRRs detect evolutionarily conserved motifs (termed 
“pathogen-associated molecular patterns” (PAMPs)) associated with microbes or “danger 
signals” associated with cellular stress, each PRR is defined by its unique ligand specificity 
and downstream signaling pathway (25, 179).  Numerous PRRs have been identified in 
human airway epithelial cells, including toll-like receptors 1-6 and 9 (70, 99, 149, 252), RIG-
I, Mda5 (225) and Nalp1 (156).  The expression of individual PRRs by specific epithelial cell 
types (ciliated vs. non-ciliated), however, is not well defined.  Differential expression across 
epithelial cell-types could potentially mediate different cellular responses to the same 
pathogen, which would be predicted, in turn, to influence cell tropism of infection.  Overall, 
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the expression and functional regulation of PRRs in the airway epithelium is tightly 
controlled to avoid persistent activation in the context of constant exposure to environmental 
stimuli.  The identification of molecules that inhibit TLR signaling (319) as well as the 
reduced sensitivity of TLRs to activation by microbial compounds as a result of lower 
expression levels is evidence of this (190).   
TLRs are localized to membranes either at the apical surface or within 
endosome/lysosomes while RLRs and NLRs act as cytosolic sensors.  Activation in the 
context of viral infection can be triggered by viral proteins associated with the virion structure 
(157), or by the viral genome and byproducts of replication such as dsRNA (6, 356).  Signal 
transduction proceeds through adaptor molecules, such as MyD88 or TRIF in the case of 
the TLRs or IPS-1 in the case of RIG-I, to activate downstream latent transcription factors 
(NFkB, ATF2-c-Jun, interferon regulatory factor 3 (IRF3), and IRF7) that regulate both pro-
inflammatory and anti-viral gene transcription, including type I IFN expression (142, 199).  
Alternatively, activation of NLRs such as Nalp1, -3 and -4 yields formation of a complex, 
termed the “inflammasome,” comprised of the adaptor molecule, ASC, NLR family member, 
and pro-caspase 1 which is activated by the complex (78).  Activated caspase 1 then 
cleaves pro-IL1β and/or IL-18 present in the cytosol into its biologically active form to be 
secreted from the cell.  Notably, expression of pro-IL1β is driven by TLR-induced activation 
of NFkB, suggesting TLR stimulation is a prerequisite for NLR-induced activation of this 
cytokine (135).  Collectively, these cytokines act both at the level of the epithelium as well as 
to activate resident innate immune cells (macrophages and dendritic cells) and recruit 
circulating leukocytes to the lung to facilitate viral clearance.  While TLRs and RLRs have 
been well characterized and are shown to mediate host responses to a variety of respiratory 
viral pathogens (32, 102, 157, 225, 278), our knowledge regarding the contribution of NLRs 
to airway defense against particular viruses is limited (7, 125, 310).   
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Interferon:  Interferon (IFN) is a key component of the host innate immune response 
to viral infection, leading to the establishment of an anti-viral state in mammalian host cells, 
but also contributing to immune cell activation and regulation of cell growth and apoptosis 
(119).  Three classes of interferon have been described: type I IFN (which includes IFNβ 
and multiple species of IFNα) is the major class of interferon that is induced in the infected 
cell, type II IFN (IFNγ), is generated by activated T cells and natural killer cells, and type III 
(IFNλs) which is similar to type I IFNs in its downstream effects, but may be less potent and 
more restricted to certain cell types  (39, 154, 196, 279).  Type I IFN is secreted from the 
infected epithelial cell and acts in both an autocrine and paracrine manner by engaging IFN 
receptors on the cellular plasma membrane.  Receptor binding stimulates signal through the 
Jak/Stat pathway, leading to the formation and nuclear translocation of Stat complexes 
which then initiate transcription from IFN-stimulated response elements (ISREs) (94).  Over 
300 IFN-stimulated genes (ISGs) have been identified, including Mx, PKR and RNaseL, 
which inhibit viral replication and protein synthesis and induce RNA cleavage among other 
poorly defined mechanisms to antagonize the virus (248).  Nonetheless, the importance of 
interferon in viral infection is underscored by the identification of virus-encoded interferon 
antagonists that have evolved to counter this response through a variety of mechanisms.    
Cell shedding and apoptosis: In addition to initiating an anti-viral and pro-
inflammatory cytokine response, epithelial cells often shed into the lumen of the airway as a 
consequence of infection (133).  The process of cellular detachment from the epithelium 
during shedding, which in turn induces apoptosis (non-inflammatory cell death), is referred 
to as “anoikis” (13, 79).  Through anoikis, the host is able to eliminate the infected cell, 
simultaneously limiting viral production and inflammatory conditions within the airway 
(inferred from lower cytokine levels) (43, 285).  This process also facilitates preservation of 
epithelium integrity, in contrast to necrotic processes which result in destruction of the 
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epithelium and are pro-inflammatory by nature.  Influenza virus infection-induced necrosis 
has been described in normal human bronchial epithelial cells and further study with 
rhinovirus suggests that airway damage, as a consequence of viral infection, may facilitate 
secondary bacterial colonization (14, 261), underscoring the detrimental effects of viral 
infection and damaged epithelium.   
 
Myxovirus Infection Strategy 
Attachment and entry—myxovirus and host sialic acid interactions:  Initial 
inoculation of the human respiratory tract by HPIV or influenza viruses likely occurs in the 
upper airways (defined anatomically as the nasal sinuses and nasopharynx).  The proximal 
airways are easily accessed by large droplet aerosols or by way of digital inoculation of the 
airway mucosa, whereas lower regions of the airway (extending from the larynx and trachea 
to the alveoli) require small droplet aerosols or direct exposure to high titer inocula (33, 111, 
219).   
Attachment of the virus to the luminal surface and subsequent entry into target host 
cells is mediated by interaction between virus surface glycoproteins, HN in the case of 
HPIVs and HA in the case of influenza viruses, and terminal sialic acids on unidentified host 
cell proteins.  The specificity of these viral attachment proteins for sialic acids in particular 
linkages differs, however.  Both HPIV1 and HPIV3, for example, bind to sialic acid in an 
α2,3-linkage, although they do not interact with all glycans containing sialic acids in this 
conformation and further evidence suggests a specific interaction with modifications of 
Neu5Acα2-3Galβ1-4GlcNAc (9).  HPIV3 also requires a longer oligosaccharide or sulfation 
on the adjacent galactose (Gal) to promote binding (9, 303).  Notably, avian influenza 
viruses also utilize α2,3-linked sialic acid, although the precise nature of these linkages 
differs from those which interact with HPIV and appear to be less abundant throughout the 
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human respiratory tract, possibly contributing to avian influenza virus restriction in infection 
of the human host (9, 281).  Avian influenza viruses that have mediated pandemics, as well 
as human influenza viruses now endemic in the human population utilize sialic acid in an 
α2,6 linkage, presumably to overcome such host barriers (56, 183).  These switches in sialic 
acid preference can be achieved by a single amino acid mutation within the receptor binding 
domain (RBD) of the influenza virus HA, although the required genetic changes to confer 
receptor switching have not been defined for all 16 HA subtypes and may be more or less 
likely to occur depending on the starting sequence of the RBD and viability of required 
intermediate mutations (100, 257).     
Distribution of α2,3- and α2,6-linked sialic acids at the cellular level (detected by 
lectin binding) correlates with cell tropism of HPIV3 and influenza viruses determined by 
probing for viral antigen in an in vitro model of airway epithelium (312, 359).  Specifically, 
α2,3 localizes predominantly to ciliated cells and α2,6 is found on both ciliated and non-
ciliated cells (312, 359).  Although lectin specificity for sialic acid linkages may differ from 
that of actual viral attachment proteins, the evolution of influenza viruses towards α2,6 sialic 
acid usage, correlates with increased tropism for non-ciliated cells (218, 312).  
While the interaction between viral HN / HA and sialic acid is indisputable, the 
underlying host molecules that present relevant sialic acids to these viruses remain 
unknown.  Despite the specificity of the HN / HA for particular sialic acids, the airway lumen 
is rich in glycoconjugates containing sialic acid moieties and the abundance of sialic acid 
residues throughout the respiratory tract suggest that not all interactions favor the virus.  
The viral sialidase, which is either endogenous to the activity of the HN (for parainfluenza 
virues), or works in tandem with HA in the case of influenza viruses, cleaves the virus from 
erroneous attachment to sialic acids that impede initial entry or spread (187).  This is 
demonstrated by the requirement of viral sialidase activity for initial infection of well-
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differentiated pseudostratified airway epithelial cultures with a robust mucus and glycocalyx 
layer (187) and for efficient release of progeny virions following replication.  The latter is 
illustrated by the aggregation of influenza viruses at the cellular membrane in the presence 
of neuraminidase inhibitors (101, 226, 227).  Together, the balance between binding and 
receptor cleavage is critical for efficient viral infection (329).     
Genome organization, replication, and evasion of the cellular response:  While 
both parainfluenza and influenza viruses represent enveloped, negative sense RNA viruses 
that bind sialic acid and target the human respiratory tract for infection, their genome 
organization and replication strategies inside the host cell are distinct.   
The parainfluenza virus genome consists of a single, negative-sense RNA molecule, 
15-19,000 nucleotides (nt) in length that encodes six genes (3’ N-P/C/V-M-F-HN-L 5’).  Each 
gene encodes a single known viral protein with the exception of the P gene which encodes a 
subset of accessory proteins: C proteins from an overlapping reading frame in the +1 
position relative the P open reading frame and/or a V protein either from the primary 
transcript in the case of HPIV2, or by an RNA editing mechanism involving pseudotemplated 
addition of G nucleotides (11).  HPIV replication occurs in the cytoplasm of the infected cell 
where the viral genome acts as the template for both transcription of subgenomic mRNAs 
and replication through a positive-sense antigenomic intermediate (341).  The genomic and 
antigenomic sequences must be encapsidated by nucleocapsid protein, N, forming the 
RNase-resistant ribonucleoprotein complex (RNP), in order to constitute active template 
(57).  The RNP is then recognized by the virus-encoded RNA-dependent RNA polymerase, 
L, and the non-catalytic cofactor, P which together initiate all viral RNA synthesis at the 
extreme 3’ end of the genome (57).  Due to frequent dissociation of the viral polymerase at 
intergenic regions within the genomic template, a gradient of transcription results where 
proteins encoded by genes proximal to the 3’ end are more abundant, correlating to their 
requirement in the virus life-cycle (114).  During infection, transcription is thought to occur 
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before replication in order to generate sufficient N protein to encapsidate subsequent 
nascent strands of genomic RNA (213).  Each N protein associates with a nucleotide 
hexamer, and this association is critical for promoter efficiency (termed the “rule of six”) 
(108, 341).   
 Unlike HPIV, influenza virus has a segmented genome (consisting of 8 segments for 
type A influenza viruses), encodes a total of 11 known proteins, and executes both 
transcription and replication in the host cell nucleus (160).   Viral RNA synthesis in the 
nucleus is catalyzed by viral proteins PB1, PB2 and PA, which together form the polymerase 
complex.  The polymerase complex in association with NP-coated viral RNA forms the 
influenza virus RNP complex, much like that of HPIV; however, unlike HPIV RNPs, influenza 
virus RNPs are sensitive to RNase, suggesting structural differences exist (160).   
Influenza virus RNP components interact with numerous host cell proteins, such as 
ran binding protein 5 and α-importin, to access the nucleus and utilize short host RNA 
polymerase II transcripts as primers to initiate its own mRNA synthesis (termed “cap 
snatching”) (68, 73, 251).  Non-optimized interactions between avian influenza virus RNPs 
and host cell proteins contributes to host range restriction (251).  Restriction of avian 
influenza virus replication in mammalian cells was first linked to the PB2 subunit of the RNP 
complex in 1977 (8) and further study has shown that the residue at position 627 in PB2 is 
important in conferring increased polymerase activity in these cells (109, 302).  Specifically, 
mutation of the amino acid present at position 627 in PB2 from glutamic acid (conserved in 
avian influenza viruses) to lysine (conserved in human influenza viruses) enhances 
pathogenicity (282) and recent work suggests this change may allow the avian influenza 
virus  to escape from an unidentified dominant inhibitory activity in human cells (197).   
In addition to mutation, influenza viruses evolve via genetic reassortment, mentioned 
earlier in this chapter.  The segmented nature of the genome facilitates reassortment with 
segments from other influenza virus strains which have co-infected the same cell.  While not 
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all combinations are viable (50), this mechanism has potential to yield novel gene 
constellations, giving rise to unique influenza virus strains with the potential to infect new 
host species.    
Despite these differences in genome organization and replication strategy, both 
parainfluenza and influenza viruses encode proteins during infection which function to inhibit 
activation of PRRs and downstream effectors in order to facilitate their propagation in the 
host.  While these viral “accessory” proteins are often non-essential for replication in cell 
lines in vitro, they constitute important virulence factors that contribute significantly to 
pathogenesis  (22, 86).  The accessory proteins encoded by the paramyxovirus P gene, 
including the C and V proteins, are capable of inhibiting production of and cellular response 
to the type I IFN response through a variety of mechanisms (10, 94, 95).  The C proteins of 
HPIV1, for example, have been shown to inhibit IRF3 activation and subsequent IFN 
production and also inhibit IFN signaling—likely linked to their ability to prevent nuclear 
translocation of STAT1 and STAT2 (38, 325).  Similarly, HPIV2 V protein targets STAT2 for 
degradation, preventing signaling induced by type I IFN, but leaving the cell sensitive to type 
II IFN (11).  Human PIV3 C protein inhibits both type I and type II IFN by blocking STAT1 
phosphorylation, although it is unknown whether this is a direct C-STAT1 interaction or 
because C targets JAK1, 2 or TYK2 leading to the impairment of pT-STAT (176).  While 
most targets of the paramyxovirus accessory proteins are cytoplasmic, a related protein 
encoded by Nipah virus is localized to the nucleus where it sequesters Stat 1 (254, 276, 
277).  In addition to antagonizing the host IFN response, these viral proteins have also been 
attributed functions in abrogating apoptosis and suppressing viral RNA replication that may 
act to reduce the amount of viral genomic products in the cell which are often the ligands for 
PRRs (22, 62). 
The NS1 protein of influenza viruses performs many similar functions to the C and V 
proteins of the paramyxoviridae, including abrogation of IFN induction and signaling (103, 
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225, 233) and regulation of viral translation (263) as well as potential suppression of the 
host RNA interference pathway (66, 104, 150).  The precise mechanisms through which 
NS1 performs these functions, however, are strain dependent and the multifaceted 
approach of NS1 in effecting these functions may also facilitate infection of a variety of host 
species (112, 113).  Notably, avian influenza virus NS1 proteins have activity against the the 
type I interferon response in mammalian cells (112).  
 
Vaccines and therapeutics for the prevention and treatment of myxovirus infection:  
Prophylactic vaccination aims to protect the host from severe disease in the context 
of natural infection by priming the host immune response with pathogen-specific antigen.  
Vaccines were first conceived of by Edward Jenner in 1786 and have proven to be effective 
tools in reducing individual disease burden and even eradicating infectious agents, first 
achieved with smallpox in 1977.  Despite this achievement, a licensed vaccine or virus-
specific therapy has not been developed for any HPIV subtype.  Because a single vaccine, 
simultaneously targeting all five PIVs, is presently infeasible, efforts have primarily targeted 
HPIV3, the most prevalent subtype, inducing the most severe disease (249, 338).  
Emphasis has been on mucosal vaccination based on the failure of a formalin-fixed PIV3 
vaccine to afford protection, and evidence that pre-existing mucosal antibody was protective 
in adults challenged with wild-type PIV1 (146, 290).  Several candidates, including a live 
chimeric HPIV3 and cold-adapted HPIV3, termed cp45, have shown promise in clinical trials, 
demonstrating both safety and immunogenicity (138, 267).  Vaccine candidates for other 
HPIVs are now being generated through the importation of attenuating mutations identified 
in HPIV3 and other related viruses via reverse genetics.  In conjunction with attenuating 
mutations, these vaccine candidates are also often engineered to include mutations which 
confer a temperature-sensitive (ts) phenotype, thus increasing the safety profile of 
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vaccination with live virus by limiting spread to the lower airways based on differences in 
regional airway temperature.   
In contrast to HPIV, vaccines for influenza viruses have been available for decades.  
Current approaches utilized during influenza vaccine generation include inactivated and live 
attenuated technology.  Inactivated preparations, amplified in embryonated chicken’s eggs 
before concentration and fixation, are administered as “whole,” “split” or “subunit” form, the 
last consisting of purified viral glycoproteins.  Antibodies directed against HA and NA are 
associated with protection and the subunit formulation also has fewer side effects compared 
to “whole,” especially in children (61).   Recently a cold-adapted live attenuated influenza 
virus vaccine, FluMist®, which contains ts mutations in the viral proteins that comprise the 
polymerase complex, has also been licensed for use in healthy individuals between 2 and 
49 years of age (26).   
Despite these available vaccines, continual viral antigenic drift requires that the 
trivalent formulation (consisting of two influenza A strains, an H3N2 and H1N1, and one 
influenza B strain) be updated on an annual basis to ensure an antigenic match with 
circulating strains.  Mismatch with circulating strains or failure to vaccinate on an annual 
basis may render the host susceptible to infection, even if the individual was vaccinated in 
past years (34).  Furthermore, production of the annual vaccine is a lengthy process and is 
currently dependent on the available supply of embryonated chicken’s eggs, thus limiting 
production quantity.  This is of particular concern with respect to pandemic planning, in 
which the subtype mediating the pandemic may not be identified far enough in advance to 
generate sufficient stockpiles of vaccines.  Thus, more robust means of production, 
including the use of cell lines and advancement of effective vaccines against other subtypes 
or broadly cross-reactive products is a current focus of influenza vaccine research (155).   
In addition to vaccines, two classes of influenza virus-specific anti-viral therapies 
have also been generated, targeting either the viral neuraminidase (oseltamivir, zanamivir) 
 20 
or M2 ion channel (rimantidine, amantidine).  Nonetheless, M2 blockers are not effective 
against influenza type B virus infections and there is documented evidence of rapid 
emergence of resistance (including in recently identified H5N1 isolates) for all four drugs 
(42, 115, 205, 280).  Resistant strains also remain transmissible, although there is evidence 
for reduced viral fitness associated with resistance (40, 352).    
Overall, a more detailed understanding of how these viruses interact with their target 
for infection, the human airway epithelium, will elucidate mechanisms of pathogenesis 
including correlates of host immunity and viral virulence factors which provide targets for the 
advancement of novel therapeutics and vaccine strategies.   
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ABSTRACT 
Human parainfluenza virus type 1 (HPIV1) is a significant cause of pediatric 
respiratory disease, both in the upper and lower airways.  An in vitro model of human 
ciliated airway epithelium (HAE), a useful tool for studying respiratory virus-host interactions, 
was used in this study to show that HPIV1 selectively infects ciliated cells within the HAE 
and that progeny virus is released from the apical surface with little apparent gross 
cytopathology.  In HAE, type I interferon (IFN) is induced following infection with a HPIV1 
mutant expressing defective C proteins with a F170S amino acid substitution, rHPIV1-CF170S, 
but not following infection with wild-type HPIV1.  IFN induction coincided with a 100- to 
1000-fold reduction in virus titer, supporting the hypothesis that the HPIV1 C proteins are 
critical for inhibition of the innate immune response.  Two recently characterized live 
attenuated HPIV1 vaccine candidates expressing mutant C proteins were also evaluated in 
HAE.  The vaccine candidates, rHPIV1-CR84G/∆170HNT553ALY942A and rHPIV1-
CR84G/∆170HNT553AL∆1710-11, which contain temperature-sensitive (ts) attenuating (att) and non-
ts att mutations, were highly restricted in growth in HAE at permissive (32°C) and restrictive 
(37°C) temperatures.  The viruses grew slightly better at 37°C than at 32°C, and rHPIV1-
CR84G/∆170HNT553ALY942A was less attenuated than rHPIV1-CR84G/∆170HNT553AL∆1710-11.  The level 
of replication in HAE correlated with that previously observed in African green monkeys, 
suggesting that the HAE model has potential as a tool for pre-clinical evaluation of HPIV1 
vaccines, although how these in vitro data will correlate with vaccine virus replication in 
seronegative human subjects remains to be seen.
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INTRODUCTION 
Human parainfluenza viruses (HPIVs) are enveloped, non-segmented, single-
stranded, negative-sense RNA viruses belonging to the family Paramyxoviridae.  This group 
of viruses includes HPIV serotype 1 (HPIV1), HPIV2, and HPIV3, which collectively are the 
second leading cause of pediatric respiratory hospitalizations following respiratory syncytial 
virus (RSV) infections (136, 210).  HPIV1 is responsible for approximately 6% of pediatric 
hospitalizations due to respiratory tract disease (136).  Clinical manifestations range from 
mild disease, including rhinitis, pharyngitis, and otitis media, to more severe disease, 
including croup, bronchiolitis, and pneumonia (60, 117, 118, 136, 180, 249).  Currently, 
licensed vaccines for the prevention of disease caused by any HPIV serotype are not 
available. 
 The HPIV1 genome is 15,600 nucleotides in length and contains six genes in the order 
3´-N-P/C-M-F-HN-L-5´ (217).  Each gene encodes a single protein, with the exception of the 
P/C gene, which encodes the phosphoprotein, P, in one open reading frame (ORF) and up 
to four accessory C proteins, C′, C, Y1 and Y2, in a second ORF.  The C proteins initiate at 
four separate translational start codons in the C ORF in the order C′, C, Y1, and Y2 and are 
carboxy co-terminal (136), although it is unclear whether the Y2 protein is actually 
expressed during HPIV1 infection (243).  C proteins are expressed by viruses of the genera 
Respirovirus, Morbillivirus and Henipahvirus but not by viruses of the genera Rubulavirus 
and Avulavirus.  The C proteins of Sendai virus (SeV), a member of the Respirovirus genus 
and the closest homolog of HPIV1, are perhaps the most extensively studied and have been 
shown to have multiple functions, including inhibition of the host innate immune response by 
acting as interferon (IFN) antagonists (87, 96, 151). 
 To date, the HPIV1 C proteins have not been extensively studied, although recent 
studies provide evidence for a role for these proteins in the evasion of the host innate 
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immune response.  In A549 cells, a human lung adenocarcinoma epithelial cell line, it was 
previously shown that type I IFN production was not detected during infection with wild-type 
HPIV1 (HPIV1 wt) (324).  Since type I IFN was induced during infection of A549 cells with a 
recombinant HPIV1 (rHPIV1) mutant with C proteins bearing a F170S amino acid 
substitution (rHPIV1-CF170S), a role for the C proteins as antagonists of the type I IFN 
response was suggested (324).  This function was demonstrated to affect the innate 
immune response at the level of type I IFN induction and IFN signaling (324).  Another study 
independently confirmed the role for the HPIV1 C proteins as antagonists of the type I IFN 
response, demonstrating that HPIV1 infection could inhibit STAT1 nuclear translocation and 
overcome an established IFN-induced antiviral state in MRC-5 human lung fibroblast cells 
and, furthermore, that HPIV1 C-protein expression was sufficient to inhibit STAT1 nuclear 
translocation in A549 cells (38).  In contrast to the first study, the latter study demonstrated 
that type I IFN was induced during infection of MRC-5 cells with HPIV1 wt (38), which 
suggests that inhibition of type I IFN induction is cell type specific.  Therefore, further studies 
are required to better define the host IFN response in relevant cell types that are infected 
during HPIV1 infection in humans.  This is particularly important because vaccine 
candidates with defective C proteins are being prepared for clinical trials, as described 
below. 
 In vitro models of the human airway epithelium (HAE) that closely mimic the 
morphological and physiological features of the HAE in vivo are now well characterized 
(238, 360).  These models use freshly isolated human airway cells grown at an air-liquid 
interface (ALI) to generate a differentiated, pseudostratified, mucociliary epithelium that 
bears close structural and functional similarity to HAE in vivo.  Such models were previously 
used to demonstrate that paramyxoviruses such as RSV and HPIV3 preferentially infect 
ciliated cells, suggesting that these cells play a critical role in paramyxovirus replication and 
pathogenesis in the respiratory tract (359, 360).  In addition, HAE models have been used to 
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evaluate the attenuation of RSV vaccines (348). 
 In the present study, we attempted to validate the in vitro HAE model for PIV1 
infection.  In order to do this, we first evaluated the levels of replication, cell tropism, and 
gross pathogenic effects of HPIV1 wt infection in HAE in an experimental setting (including 
infection with a low multiplicity of infection [MOI] and multicycle growth) that mimics virus 
infection of the lower conducting cartilaginous airways of humans.  Second, we evaluated 
the abilities of HPIV1 wt and rHPIV1-CF170S mutant viruses to induce a type 1 IFN response 
and examined the role of the induced IFN in restricting the replication of HPIV1 in HAE 
cultures.  In this way, the phenotypes previously associated with HPIV1 C mutants in cell 
culture and in vivo were characterized in HAE cultures.  These data suggested that HPIV1 
replication in the HAE model is predictive of HPIV1 infection and growth in vivo.  Therefore, 
we next compared the levels of attenuation of replication of two HPIV1 vaccine candidates 
in the airways of AGMs (19, 20, 191, 216) to that seen in the HAE model.  This comparison 
revealed that the levels of replication of the two vaccine candidates are similar in HAE cells 
and in AGMs and, in addition, unexpectedly revealed the ability of the HAE system to detect 
an attenuating effect of mutations in genes such as L that are not revealed by other in vitro 
cell culture systems.  The ability of the HAE model to predict that attenuation of vaccine 
viruses for humans are completed, and the levels of replication of the vaccine candidates in 
AGMs, in HAE cells, and in humans can be compared.  Clinical studies for one of the 
vaccine candidates, rHPIV1-CR84G/∆170HNT553ALY942A, are currently in progress.  The current 
findings suggest that HAE cultures are a useful model system for the preclinical evaluation 
of live attenuated HPIV vaccines. 
 
 
MATERIALS AND METHODS 
Cells and Viruses 
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Human airway tracheobronchial epithelial cells were isolated from airway specimens 
from patients without underlying lung disease, provided by the National Disease Research 
Interchange (Philadelphia, PA), or as excess tissue following lung transplantation under 
University of North Carolina at Chapel Hill (UNC) Institutional Review Board-approved 
protocols by the UNC Cystic Fibrosis Center Tissue Culture Core.  Primary cells derived 
from single patient sources were expanded on plastic to generate passage 1 cells and 
plated at a density of 3 x 105 cells per well on permeable Transwell-Col (12-mm diameter) or 
2 x 105 cells per well on permeable Millicell (12-mm diameter) supports.  HAE cultures were 
grown in custom media with provision of an air-liquid interface for 4 to 6 weeks to form 
differentiated, polarized cultures that resemble in vivo pseudostratified mucociliary 
epithelium, as previously described (239).  LLC–MK2 cells (ATCC CCL 7.1) and HEp–2 cells 
(ATCC CCL 23) were maintained in Opti–MEM I (Gibco–Invitrogen, Inc., Grand Island, NY) 
supplemented with 5% fetal bovine serum and gentamicin sulfate (50 µg/ml).  Vero cells 
(ATCC CCL-81) were maintained in Opti-PRO SFM (Gibco-Invitrogen, Inc.) supplemented 
with 50 µg/ml gentamicin sulfate and 4 mM L-glutamine.  Media used for HPIV1 propagation 
and infection in LLC–MK2 cells contained 1.2% TrypLESelect, a recombinant trypsin (Gibco-
Invitrogen, Inc.), without fetal bovine serum, in order to activate the HPIV1 F protein. 
Biologically-derived HPIV1 wt strain Washington/20993/1964, the parent for the 
recombinant virus, was isolated previously from a clinical sample in primary African green 
monkey kidney cells and passaged two additional times in primary AGM kidney cells (211) 
and once in LLC-MK2 cells (20).  This preparation has a wild-type phenotype in AGMs, was 
previously designated HPIV1LLC1 (20), and will be referred to here as HPIV1 wt or its 
recombinant version, rHPIV1 wt.  The construction of the rHPIV1 mutants, rHPIV1-CF170S, 
rHPIV1-CR84G/∆170HNT553ALY942A, and rHPIV1-CR84G/∆170HNT553AL∆1710-11, was described 
previously (19, 21).  Each of the mutant viruses is named according to the mutations it 
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contains: CF170S refers to the indicated amino acid substitution in the C protein and confers a 
non-temperature-sensitive (ts) attenuation (att) phenotype; C∆170 refers to a six-nucleotide 
deletion spanning codon 170 in C and confers a non-ts att phenotype; CR84G and HNT553A 
refer to amino acid substitutions in C and HN that, in combination, confer a non-ts att 
phenotype but individually have no attenuation phenotype; LY942A refers to the indicated 
amino substitution in L and confers a ts att phenotype; and L∆1710-11 has the deletion of the 
indicated residues in L and confers a ts att phenotype.  The CF170S mutation is silent in the 
overlapping P protein.  The rHPIV1-CF170S mutant tested both here and in previous studies 
contains the non-attenuating HNT553A mutation (19, 324).  Since previous studies referred to 
this virus simply as rHPIV1-CF170S (19, 324), we will employ the same nomenclature here for 
the purpose of comparison.  Purified virus stocks were obtained by infecting LLC-MK2 cells 
and purifying the supernatant by centrifugation and banding in discontinuous 30% to 60% 
(wt/vol) sucrose gradients, steps designed to minimize contamination by cellular factors, 
especially IFN.  Purification also removes exogenous trypsin from the virus preparation; 
however, since the viruses were prepared in trypsin medium, it is likely that the F proteins of 
the inoculum virus were cleaved.  The vesicular stomatitis virus (VSV) used was a 
recombinant VSV-green fluorescent protein (GFP), originally obtained from John Hiscott 
(299).  Stocks of VSV were propagated in Vero cells and sucrose purified as indicated 
above. 
Virus titers in samples were determined by 10-fold serial dilution of virus in 96-well 
LLC-MK2 monolayer cultures, using 2 to 4 wells per dilution.  After 7 days at 32°C, infected 
cultures were detected by hemadsorption with guinea pig erythrocytes, as described 
previously (288).  Virus titers are expressed as log10 50% tissue culture infectious dose per 
ml (log10 TCID50/ml).  VSV stock titers were determined by plaque assay on Vero cells under 
0.8% methyl cellulose overlay. 
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Viral inoculation of HAE  
HAE cultures were washed with phosphate-buffered saline (PBS) to remove apical 
surface secretions, and fresh media was supplied to the basolateral compartments prior to 
infection.  HPIV1s were applied to the apical surface of HAE for inoculation at a low-input 
MOI (0.01 TCID50/cell) or high MOI (5.0 TCID50/cell), and VSV was applied to the basolateral 
surface at an MOI of 4.2 PFU/cell, in a 100µl inoculum.  The inoculum was removed 2 h 
post-inoculation at either 32°C or 37°C.  The cells  were then washed once for 5 min with 
PBS and incubated at 32°C or 37°C, as indicated.  S amples were harvested from the apical 
or basolateral surfaces of HAE for determination of virus titer or amount of type I IFN 
produced.  Apical samples were collected by incubating the apical surface with 300µl of 
medium for 30 min at 32°C or 37°C, after which the remaining fluid was recovered.  
Basolateral samples were collected directly from the basolateral compartment, and the 
volume removed was replaced with fresh media.  Samples were stored at -80°C prior to 
analysis. 
 
Histology and immunostaining of paraffin-embedded sections 
HAE cultures were fixed in 4% paraformaldehyde (PFA) overnight and embedded in 
paraffin, and 5µm histological sections were prepared.  Sections were then either stained 
with haematoxylin and eosin for analysis by light microscopy or were subjected to standard 
immunofluorescence protocols.  Briefly, sections were blocked with 3% bovine serum 
albumin (BSA) in PBS++ (containing 1mM CaCl2 and 1mM MgCl2) and incubated with 
primary antibodies diluted in 1% BSA.  Primary antibodies included a 1:4,000 dilution of 
rabbit anti-HPIV1 obtained from fluid present in subcutaneous chambers of rabbits 
immunized with purified HPIV1 (hemagglutination inhibition titer of 1:2,048), as described 
previously (55), and mouse anti-acetylated alpha tubulin (1: 2,000; Zymed, San Francisco, 
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CA).  Secondary antibodies used were fluorescein isothiocyanate (FITC)-conjugated goat 
anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), and Texas 
Red-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc.).  After 
a final wash, cells were overlaid with VectaShield mounting medium (Vector Laboratories, 
Inc., Burlingame, CA).  Images were acquired using a Leica DMIRB inverted fluorescence 
microscope equipped with a cooled-color charge-coupled device digital camera 
(MicroPublisher; Q-Imaging, Burnaby, BC, Canada). 
 
En face staining and confocal microscopy 
HAE cultures were fixed overnight in 4% paraformaldehyde and permeabilized with 
2.5% Triton-X 100.  The cultures were then blocked with 3% BSA-PBS++, and apical 
surfaces were incubated with primary antibodies diluted in 1% BSA.  An additional primary 
antiserum used for en face staining was a rabbit anti-HPIV1 polyclonal antiserum obtained 
by vaccinating whiffle-ball implanted rabbits.  The primary rabbit anti-HPIV1 serum was used 
at a 1:100 dilution, and the mouse anti-acetylated alpha tubulin antibodies were used at a 
dilution of 1:500.  Secondary antibodies were FITC-conjugated goat anti-rabbit IgG and 
Alexa fluor 594 goat anti-mouse IgG (Molecular Probes).  Fluorescent confocal xy optical 
sections were obtained using a Zeiss 510 Meta laser scanning confocal microscope. 
 
Type I IFN bioassay 
The amount of type I IFN produced by infected HAE was determined by an IFN 
bioassay according to previously published methods (232).  Briefly, clarified cell culture 
medium supernatants were treated at pH 2.0 for 24 h at 4°C to inactivate virus and acid-
labile type II IFN, and the pH was adjusted to 7.0 by the addition of 2M NaOH.  Type I IFN 
concentrations were determined by measuring the restriction of replication of VSV-GFP on 
HEp-2 cell monolayers in comparison to a known concentration of a human IFN-β standard 
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(AVONEX; Biogen, Inc., Cambridge, MA).  IFN-β standard (5,000 pg/ml) and IFN-containing 
samples were serially diluted 10-fold in duplicate in 96-well plates of HEp-2 cells.  After 24 h, 
the cells were washed and infected with VSV-GFP at 6.5x104 PFU/well.  Control cultures (no 
VSV-GFP, no IFN; VSV-GFP, no IFN) were performed in quadruplicate on each plate.  After 
an additional 24 h, plates were read for total GFP expression on a Typhoon phosphorimager 
using a Typhoon 8600 scanner (Molecular Dynamics Inc., Sunnyvale, CA) control program 
(fluorescence settings and 526-SP green fluorescein filter).  The dilution at which the level of 
GFP expression was approximately 50% of that in untreated cultures was determined as the 
end-point.  The end-point of the AVONEX standard was compared to the end-point of the 
unknown samples, and IFN concentrations were determined and expressed as mean ± 
standard errors (pg/ml).  According to the manufacturers, using the World Health 
Organization natural IFN-β standard, the AVONEX IFN-β has a specific activity of 
approximately 1 IU of antiviral activity per 5 pg. 
 
IFN mRNA qRT-PCR  
The levels of IFN-α and IFN-β mRNA in HAE cultures infected with HPIV1 wt or 
rHPIV1 mutants relative to those of mock-infected cultures were determined by quantitative 
reverse transcription (qRT)-PCR, as previously described (292).  Briefly, total intracellular 
RNA was extracted from cell cultures using the RNeasy total RNA isolation kit (QIAGEN, 
Valencia, CA).  RNA was reverse transcribed using an oligo (dT) primer and reagents from 
the Brilliant qRT-PCR kit (Stratagene, La Jolla, CA).  The PCR primers and Taqman probes 
used to detect human IFN-β, two specific sets of human IFN-α, and β-actin have been 
described previously (292).  IFN-α primer set 1 was specific for human IFN-α1, -6 and -13 
and IFN-α set 2 was specific for human IFN-α4, -5, -8, -10, -14, -17 and -21.  Duplex q-PCR 
reactions were performed to allow comparison between IFN and the housekeeping gene, β-
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actin.  The probe for β-actin was labeled with the reporter dye 5-carboxyfluorescein (FAM) at 
the 5’ end, and all IFN probes were labeled with the reporter dye 5’ HEX at the 5’ end and 
BHQ1 at the 3’ end.  Reaction mixtures contained a passive reference dye, which was not 
involved in amplification of IFN or β-actin, but was used to normalize the probe reporter 
signals.  Positive control curves were generated using preparations known to contain high 
levels of IFN cDNA to ensure reaction efficiency.  Each reaction signal was corrected 
individually for β-actin signal.  In addition, signals from all reactions from virus-infected 
samples were corrected against the signal generated in a mock-infected well, resulting in a 
β-actin-corrected measurement of expression over mock. 
 
 
 
RESULTS 
Characterization of rHPIV1 wt replication in HAE cultures 
It was previously shown that infection of HAE with RSV and HPIV3 was specific to 
the ciliated cells of the surface epithelium and was not associated with overt cytotoxicity, 
whereas infection with influenza A virus resulted in complete destruction of HAE cultures 
within 48 h (348, 360).  In the present paper, we characterized both the ability of HPIV1 wt 
to infect HAE and the response to infection in these cultures.  rHPIV1 wt efficiently infected 
HAE cells following apical inoculation with rHPIV1 wt at low MOI (0.01 TCID50/cell) (Figure 
1).  HPIV1 could be detected in HAE cells by en face immunostaining for HPIV1 antigen 
(Figure 1A), and the increase in apical wash titers from day 0 to day 1 post-infection (p.i.) 
provided evidence of active replication and secretion of rHPIV1 wt (Figure 1).  By day 3 p.i., 
virus had efficiently spread throughout the culture, with significant numbers of cells staining 
positive for HPIV1 through day 7 p.i. (Figure 1A).  Virus titers correlated with the numbers of 
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cells staining positive for viral antigen in the en face immunostaining (Figure 1).  rHPIV1 also 
replicated efficiently in a single-step growth curve following apical inoculation at a high-input 
MOI (5.0 TCID50/cell) (Figure 2A).  These growth curves were performed in the absence of 
added trypsin (Figure 1 and 2).  Since HPIV1 typically requires added trypsin for cleavage 
and infectivity when grown in cell lines, such as Vero cells, this suggests that a trypsin-like 
enzyme capable of cleaving HPIV1 F is provided by HAE cultures.  Influenza virus, another 
virus requiring serine protease activity at the apical surface for multi-cycle replication, also 
spread efficiently in HAE models in the absence of exogenous trypsin (186, 312).  Attempts 
to isolate the required proteases that are responsible for cleaving viral proteins present in 
such models have identified some of these proteases (36), but there are most likely many 
proteases present in the HAE.  Viral titers during infection were determined in both the 
apical and basolateral compartments, representing virus shed into the airway lumen and the 
serosal side of the epithelium, respectively.  In general, viruses causing disease limited to 
the respiratory tract release virus via the apical surface only, whereas viruses released from 
both the apical and basolateral surfaces are typical of viruses that are able to spread 
systemically and cause disease in other tissues.  This was demonstrated here by comparing 
growth curves for rHPIV1 wt to those for VSV (Figure 2).  As might be expected for a virus 
that is strongly pneumotropic, rHPIV1 wt was detected in apical washes but not in 
basolateral compartments.  In contrast, VSV, which is capable of systemic infection, was 
released into both sites after basolateral inoculation (Figure 2A and C). 
The ciliated cells of the HAE have been shown to be major targets for other 
respiratory viruses including influenza, severe acute respiratory syndrome coronavirus, and 
paramyxoviruses such as RSV and HPIV3 (186, 284, 312, 359, 360).  Similarly, we show 
here that HPIV1 wt infects ciliated cells in HAE cultures, as observed by immunostaining of 
histological sections of HAE (Figure 3A and C).  HAE supports HPIV1 wt infection, and the 
pattern of infection seemed to mimic that observed for other paramyxoviruses such as RSV 
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and HPIV3.  Therefore, HAE are a good model for studying HPIV1 infection.  This model is 
further used here to characterize innate host responses in human airway epithelial tissues to 
infection and to determine the attenuation phenotypes of potential HPIV1 vaccine 
candidates.  In this study, infection with rHPIV1 did not induce any gross changes in 
morphology or the integrity of the epithelium or any other evidence of cytopathic effect within 
48 h of inoculation in comparison to mock-treated cells (Figure 3B).  
 
Induction of type I IFN during virus infection in HAE 
The HPIV1 wt C accessory proteins inhibit the type I IFN response during infection, 
and this function is eliminated by a point mutation, F170S, in the C ORF, which is present in 
all four species of C protein, C', C, Y1, and Y2 (38, 324).  In A549 cells, type I IFN was 
detected during infection with rHPIV1-CF170S but not rHPIV1 wt (324).  We therefore 
compared levels of replication and IFN induction by rHPIV1-CF170S and rHPIV1 wt in HAE.  
As was observed for HPIV1 wt, rHPIV1-CF170S targeted ciliated cells in HAE (Figure 3A).  In 
addition, rHPIV1-CF170S grew at least as efficiently as HPIV1 wt in a high-MOI single-cycle 
growth curve (Figure 2).  However, although both viruses reached similar peak titers, the 
kinetics of replication were somewhat different.  rHPIV1-CF170S reached a peak in titer by 24 
h p.i., at which point its titer was 100-fold higher than that of rHPIV1 wt.  In contrast, rHPIV1 
wt titers rose steadily until 72 h p.i. (Figure 2).  The differences in the kinetics of virus 
replication between the two viruses in HAE correlated with en face staining, which 
demonstrated that a higher proportion of cells were positive for viral antigen following 
infection with rHPIV1-CF170S compared to that following infection with rHPIV1 wt at both 24 
and 48 h p.i. (Figure 3C).  This finding was consistent for two independent donor sources of 
HAE (data not shown).  To investigate the initial higher replication of rHPIV1-CF170S, we 
redetermined titers of mutant and wild-type virus stocks for three different cell lines, LLC-
MK2, A549 and Vero cells. This showed that there were no cell line-specific differences in 
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titers or infectivities between the two viruses.  Furthermore, the ratios of infectious virus to 
hemagglutination titer were similar for the three viruses, indicating that they were 
comparable in infectivity (data not shown).  Thus, the increased level of replication of the 
mutant virus did not appear to be due to a difference in the amount of input virus or its 
infectivity but may reflect a difference in the level of gene expression (see Discussion). 
Type I IFN could be readily detected following high MOI infection of HAE with 
rHPIV1-CF170S but not rHPIV1 wt (Figure 4).  Specifically, type I IFN secretion was detected 
in the apical and basolateral compartments of rHPIV1-CF170S-infected HAE by 48 h p.i., as 
determined by a type I IFN bioassay (Figure 4A and B).  In addition, significant IFN-β mRNA 
expression was detected as early as 24 h p.i. in this virus group, as determined by qRT-PCR 
(Figure 4C), whereas IFN-α mRNA was not detected in any group (data not shown).  VSV 
was used as a positive control for IFN induction, and low levels of type I IFN protein and 
IFN-β mRNA were detected by 24 h following VSV infection (Figure 4).  These results 
indicate that there is both lumenal and basolateral/systemic release of type I IFN after 
infection of HAE with rHPIV1-CF170S or VSV.  The expression of IFN-β but not IFN-α 
following infection with rHPIV1-CF170S is consistent with our previous findings using A549 
cells, and implies a strong block of IFN-mediated signaling (38, 324).  The lack of expression 
of IFN-β by HAE cells following infection with rHPIV1 wt also is consistent with results with 
A549 cells but differs from previous results reported for MRC-5 cells (38, 324).  To 
investigate the role of the released type I IFN in the spread of HPIV1 in HAE, we next 
initiated infection at a lower MOI (0.01 TCID50/ml) in longer-term infections. 
 
Evaluation of the role of type I IFN in multi-cycle replication of rHPIV1-CF170S in HAE 
During natural HPIV1 infection, infection is likely initiated at a low MOI via luminal 
inoculation of the airways.  Therefore, in order to mimic natural infection, replications of 
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HPIV1 wt and mutant virus were evaluated using a multiple-cycle growth curve in HAE at 
37°C at a low MOI of 0.01 (Figure 5).  Both rHPIV1 wt and rHPIV1-CF170S grew efficiently in 
HAE, reaching peak titers of 8.5 and 8.1 log10 TCID50/ml, respectively.  The kinetics of 
replication and extent of infection mirrored those observed in the high-MOI growth curves 
(Figure 2A and B and 3C).  rHPIV1 wt reached a peak titer at day 4 p.i., which remained at a 
plateau of about 8.5 log10 TCID50/ml until day 7 p.i. (Figure 5).  In comparison, rHPIV1-CF170S 
reached a peak titer of 8.1 log10 TCID50/ml much earlier, at day 2 p.i., and virus replication 
then dropped dramatically by day 4 p.i. to plateau at 5.6 log10 TCID50/ml (Figure 5).  In 
addition, determinations of type I IFN concentrations in apical compartments by bioassay 
demonstrated no detectable type I IFN during HPIV1 wt infection, whereas type I IFN was 
detected from days 2 to 4 p.i. in cells infected with rHPIV1-CF170S.  Interestingly, the 
decrease in virus titer during rHPIV1-CF170S infection followed the detection of type I IFN 
secretion.  We have shown that cells infected with rHPIV1-CF170S are able to express type I 
IFN, and secreted IFN likely acts on neighboring cells to establish an antiviral state.  Since 
HPIV1 is sensitive to an established type I IFN-induced antiviral state (324), these data 
suggest that type I IFN secretion from virus-infected cells protected neighboring cells from 
virus infection.  This protection can be seen in the approximately 300-fold reduction of 
rHPIV1-CF170S replication in comparison to rHPIV1 wt (as indicated by the shaded area in 
Figure 5). 
 
Replication of HPIV1 vaccine candidates in HAE 
Since the HAE culture model is a useful in vitro tool for evaluating HPIV1 replication 
in a setting that closely resembles that of in vivo replication in seronegative humans, this 
model could be used for pre-clinical evaluation of HPIV1 vaccine candidates.  In order to 
determine if the level of virus replication in AGMs is reflected in the level of virus replication 
in HAE cells, two attenuated HPIV1 mutants, rHPIV1-CR84G/∆170HNT553ALY942A and rHPIV1-
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CR84G/∆170HNT553AL∆1710-11 (named according to their attenuating mutations; see Materials and 
Methods), were chosen for study in the HAE model.  These viruses were chosen since they 
were previously characterized in vivo (Table 1) (21) and are currently being considered as 
live attenuated virus vaccine candidates for HPIV1.  Clinical trials using rHPIV1-
CR84G/∆170HNT553ALY942A are currently in progress.  These viruses were previously shown to 
possess a ts phenotype with in vitro shut-off temperatures (e.g., the lowest temperature at 
which there is a ≥100-fold reduction in replication compared to that of the wild-type virus) of 
38°C and 35°C, respectively, and both mutants were attenuated for replication in AGMs 
(21).  Here, we evaluated their replication in vitro in HAE.  In order to simulate a natural virus 
infection, HAE were inoculated with the vaccine candidates at low MOI, and replication was 
compared to rHPIV1 wt replication at 32°C and 37°C, temperatures indicative of those in the 
upper and lower respiratory tracts, respectively (Figure 6).  Viral titers determined in the 
apical washes over a seven-day period showed that rHPIV1 wt replicated efficiently at both 
temperatures, reaching peak titers of 8.5 and 9.1 log10 TCID50/ml, respectively by day 4 p.i. 
at 32°C and 37°C.  However, both of the vaccine candidate viruses were severely restricted 
for replication in HAE and, unexpectedly, grew to higher titers at 37°C than at 32°C (Figure 
6A and B).  At 32°C, both viruses demonstrated little to no replication, even though this 
temperature is fully permissive for both viruses in monolayer cell lines, while at 37°C, there 
was low-level replication with mean peak titers of 5.1 and 3.2 log10 TCID50/ml for rHPIV1-
CR84G/∆170HNT553ALY942A and the rHPIV1-CR84G/∆170HNT553AL∆1710-11, respectively (Figure 6B).  
Thus, the rHPIV1-CR84G/∆170HNT553AL∆1710-11 virus demonstrated a higher degree of 
attenuation than did rHPIV1-CR84G/∆170HNT553ALY942A.  Since both vaccine candidates were 
more attenuated than the virus containing only the CF170S point mutation, which was 
previously shown to share the same phenotype as C∆170 (19, 324), these data demonstrate 
that HAE cells are also sensitive to the attenuation phenotype specified by other mutations, 
 37 
specifically, mutations in the L gene.  The attenuating effect of these mutations was not 
revealed by any other in vitro method.  Interestingly, there was no type I IFN detected in the 
apical or basolateral compartments of cultures infected with these viruses (data not shown), 
which is likely due to the low levels of virus replication.  Based on these data, it is possible 
that these viruses will be over-attenuated in humans.  However, the level of virus replication 
in the human upper respiratory tract in vivo remains to be determined.  These data correlate 
well with previous data demonstrating the level of attenuation of these viruses in AGMs 
(Table 1)  (21) and suggest that the HAE model might be a valuable pre-clinical tool.  
However, the ultimate validation of the HAE model for HPIV1 will require the screening of a 
larger sample of viruses with various levels of attenuation and comparison of this 
information with similar data on their levels of replication in seronegative humans.    
 
 
DISCUSSION 
HAE models provide useful tools for studying respiratory viruses in vitro.  These cell 
culture systems mimic many morphological features of the human conducting airway 
epithelium, permitting the study of virus-host interactions in a relevant species as they occur 
at the site of virus infection.  In this study, we have evaluated the ability of HPIV1 wt to infect 
HAE, and subsequently, we have determined a role for the HPIV1 C proteins in the 
regulation of the innate immune response in this system.  HPIV1 wt readily infected HAE 
and replicated to high titer but failed to induce the production of type I IFN.  The virus was 
released exclusively at the apical surface of HAE, like many other respiratory viruses that do 
not cause viremia (or spread systemically) (312, 359, 360).  In contrast, VSV, which is not a 
common human pathogen but which is associated with systemic disease, albeit mild, in 
humans (173), was released at both the apical and basolateral surfaces.  Ciliated cells of 
the HAE have been shown to be the target for many respiratory viruses including influenza 
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virus, SARS coronavirus and paramyxoviruses such as RSV and HPIV3 (186, 284, 312, 
359, 360).  Furthermore, ciliated cells were previously identified as being initiators of 
cytokine secretion during RSV infection (198).  We have shown here that HPIV1 can 
efficiently infect HAE cells and that it specifically targets ciliated cells.  These studies 
indicate that the HAE model is well suited to study the pathogenesis of HPIV1 mutants.  One 
such HPIV1 mutant, rHPIV1-CF170S, expresses defective C proteins and induces moderate to 
high levels of type I IFN, which in turn restricts the replication of rHPIV1-CF170S in HAE.  
Thus, the HPIV1 C proteins are critical regulators of the innate immune response in 
differentiated primary human epithelial cells in vitro. 
Most viruses, including HPIV1, are susceptible to antiviral effects induced by IFN, 
and for this reason, many viruses have evolved strategies to evade the IFN response (58, 
93, 95, 324, 336).  In humans, IFN-β is the major type I IFN subtype produced, along with 
IFN-α1, as the first step in the IFN response (166, 354).  Following virus infection, 
cytoplasmic viral RNA is recognized by host cell proteins such as the retinoic acid inducible 
gene-I (RIG-I) protein (123, 240, 356).  RIG-I subsequently associates with and activates 
mitochondrial antiviral signaling (also known as IFN-β promoter stimulator 1 protein or virus-
induced signaling adaptor protein) (273, 350).  In epithelial cells, viral dsRNA is also 
recognized by the Toll-like receptor (TLR)-3 (30) present in endosomes, resulting in the 
activation of TRIF-mediated pathways (75, 274).  The activation of both the RIG-I and TLR-3 
pathways leads to the activation of kinases (IKK-ε and TBK-1) that phosphorylate IFN 
regulatory factor-3 (IRF-3), resulting in IRF-3 dimerization and nuclear translocation.  IRF-3, 
along with nuclear factor-κB (NF-κB) and ATF-2/c-Jun, bind to the IFN-β gene promoter to 
activate IFN-β transcription (355).  IFN-β is then released from the cell and binds to type I 
IFN receptors on the surface of virus-infected or neighboring cells to switch on the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway (93, 
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98, 163, 264, 306, 336).  This pathway culminates in the transcriptional induction of type I 
IFN response genes, which comprise more than 300 genes that are able to exert a broad 
range of antiviral, antiproliferative and immunomodulatory functions and include proteins 
such as dsRNA-activated protein kinase (PKR), 2‘,5‘ oligoadenylate synthetase (OAS) and 
the Mx proteins (163).  In this way, type I IFN can mediate the host immune response in 
virally infected cells and establish an antiviral state in neighboring uninfected cells in order to 
limit replication.  The paramyxoviruses express nonstructural accessory proteins that are 
able to inhibit various stages of the type I IFN response.  For example, the V proteins of 
several parainfluenza viruses (e.g., HPIV2 and simian virus 5), RSV NS1 and NS2 proteins, 
and SeV and HPIV1 C proteins have been shown to inhibit IRF-3 activation (10, 35, 151, 
292, 293, 324).  In addition, the C proteins of SeV, HPIV1 and HPIV3 and the V proteins of 
HPIV2 and simian virus 5 have been shown to block the IFN signaling cascade by various 
mechanisms, including STAT binding, the inhibition of STAT activation, and STAT 
destabilization/degradation (38, 69, 85, 88, 96, 152, 176, 230, 305, 324). 
The role of the HPIV1 C accessory proteins in inhibiting the type I IFN response was 
recently characterized in vitro (38, 324); however, it was uncertain whether these in vitro 
observations would translate to similar functions in vivo.  In HAE, both rHPIV1 wt and 
rHPIV1-CF170S replicated efficiently and reached similar mean peak titers.  However, rHPIV1-
CF170S reached its peak titer by day 2 compared to day 4 for rHPIV1 wt, which was true at 
both high and low MOIs.  Furthermore, immunostaining of HAE infected at high MOI also 
demonstrated a clear quantitative difference between the viruses at day 2 p.i., with many 
more cells staining positive in the rHPIV1-CF170S-infected cultures than in the rHPIV1 wt-
infected cultures.  Interestingly, a similar phenomenon was previously observed in 
monolayer cultures with a SeV mutant containing the same mutation in the SeV C proteins 
(86).  The F170S mutation in SeV had the effect of increasing gene transcription four-fold 
compared to that of its parent virus, with corresponding increases in RNA replication and 
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virus replication (86).  This presumably accounts for the initial increased level of viral 
replication and viral antigen synthesis (detected by immunofluorescence) observed here for 
rHPIV1-CF170S in HAE cells.  
The antiviral role of type I IFN became evident in HAE infected at low MOI, and the 
quantitative impact of the type I IFN response was next assessed.  HPIV1 wt virus replicated 
to high titers, and type I IFN was not induced.  The HPIV1 wt virus titer persisted at a high 
level, presumably due to the absence of IFN production in the cultures throughout the 
duration of the study.  In contrast, rHPIV1-CF170S replicated efficiently until IFN was detected, 
and titers then decreased by a factor of 100 to 1,000.  While IFN is not the sole factor 
involved in viral clearance, the difference in replication between the two viruses in this model 
system is most likely due to the induction of IFN in HAE infected with rHPIV1-CF170S, as 
indicated by the shaded area in Figure 5.  It is likely that the type I IFN secreted by virus-
infected HAE cells is acting on the neighboring uninfected cells to activate the JAK-STAT 
signaling pathway and ultimately establish an antiviral state in these cells by inducing the 
expression of type I IFN response genes.  This would lead to some level of inhibition of virus 
replication and spread and would explain the decrease in virus titers that we observed.  
Recently, STAT1 activation in mouse airway epithelial cells was associated with the 
inhibition of cell-to-cell spread of SeV and the protection of uninfected cells from infection 
(283).  Interestingly, rHPIV1-CF170S induced the expression of IFN-β mRNA, while the 
expression of IFN-α species was below the level of detection. This confirms findings 
observed in A549 cells and would be consistent with rHPIV1-CF170S retaining the ability to 
inhibit IFN-mediated signaling through the JAK/STAT pathway, which is necessary for the 
expression of most of the species of IFN-α and for amplification of the IFN response.  
The 100- to 1,000-fold difference in replication of rHPIV1-CF170S and HPIV1 wt in 
HAE was similar to that observed in the upper and lower respiratory tract of AGMs (Table 1), 
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suggesting that HAE provide a reliable model of the role that type I IFN plays in restricting 
replication of HPIV1 in vivo (19).  It is evident that IFN production was associated with a 
reduction in virus replication; however, it was not sufficient to completely inhibit virus growth.  
A recent study using influenza A virus wild-type and NS1-deficient viruses to infect murine 
epithelial cells yielded similar quantitative effects (215).  The level of production of IFN-β 
was significantly elevated during infection with a human influenza A virus mutant expressing 
a defective NS1 protein, a known inhibitor of RIG-I mediated type I IFN induction, compared 
to wild-type influenza A virus, and IFN-β production correlated with a reduction in the level of 
replication of this virus in murine airway epithelial cells (215).  The role of the HPIV1 C 
proteins in inhibiting the type I IFN response makes these proteins good targets for 
attenuating viruses by mutagenesis, and A549 cells and HAE cultures appear to be suitable 
systems to study the effect of such mutations on replication.  Mutations of the C proteins are 
included in current HPIV1 vaccine candidates (21). 
The levels of replication of two HPIV1 vaccine candidates in HAE were evaluated to 
determine whether replication of HPIV1 vaccine viruses in these cells might be predictive of 
their level of replication in humans.  Two live attenuated vaccine candidates for HPIV1, 
namely, rHPIV1-CR84G/∆170HNT553ALY942A and the rHPIV1-CR84G/∆170HNT553AL∆1710-11 (21), are 
being considered for evaluation in humans and each mutant contains mutations in C that 
specify the same IFN phenotype and attenuation phenotype as the CF170S point mutation (19, 
216, 324).  In addition, both vaccine viruses contain a ts attenuating mutation in the L 
polymerase gene that restricts replication at 37°C.  Both vaccine candidates replicate 
efficiently at 32°C in Vero cells, the substrate for vaccine manufacture.  We had anticipated 
that each vaccine candidate would replicate efficiently at 32°C in HAE but would be 
restricted in replication at 37°C due to the presen ce of the ts mutation.  Surprisingly, the 
viruses were completely attenuated for replication in HAE at 32°C following inoculation at 
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low MOI and grew to very low levels at 37°C.  The C and L gene mutations may collaborate 
to restrict replication at 32°C by a mechanism that  is undefined but can be addressed in 
HAE using mutants in which the various attenuating mutations are segregated.  However, it 
is important that there was an additive effect in the level of attenuation specified by the 
combination of attenuating mutations in the P/C and L genes.  This demonstrates the HAE 
cells are sensitive to attenuation specified by different mechanisms and underscores its 
validity as a tool for preclinical testing of viral vaccine candidates.  How these findings in 
HAE relate to replication in humans will be determined in clinical trials.  Both vaccine 
candidates appear to be safe for evaluation in humans based on their highly restricted levels 
of replication in AGMs and HAE, but one or both might be over-attenuated for humans.  
rHPIV1-CR84G/∆170HNT553ALY942A replicated to slightly higher titers at 37°C than rHPIV1-
CR84G/∆170HNT553AL∆1710-11, but was still significantly attenuated compared to rHPIV1 wt.  IFN 
was not detected in cells infected with these viruses, which is most likely due to their highly 
restricted growth resulting in poor induction of the innate immune response.  Comparing 
data from this in vitro study with those from previous in vivo studies, we have shown that 
attenuation, i.e. restriction in replication in HAE, correlates with the reduction in mean peak 
titers in AGMs (Table 1) (19, 21).  Although it is possible that these viruses will be over-
attenuated in humans, we have selected the rHPIV1-CR84G/∆170HNT553ALY942A candidate for 
further clinical evaluation since it is attenuated in AGMs, it replicates to some extent in HAE, 
and it protects AGMs against challenge with HPIV1 wt.  In addition to evaluating the 
potential of this virus as a vaccine, clinical trials will provide information on whether virus 
replication in the HAE model correlates with the level of attenuation of the virus in humans.  
A strong correlation would highlight the usefulness of the HAE model as a preclinical 
research tool and enable more efficient screening of HPIV1 and potentially other 
paramyxovirus vaccine candidates.    
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Figure 1.  rHPIV1 wt infects HAE cells, spreads throughout the culture and replicates 
efficiently.  HAE cells were mock-infected or infected with rHPIV1 wt at low MOI (0.01 
TCID50/cell).  At days 1 to 7 p.i., cells were fixed and stained en face for HPIV1 antigen 
(green) (A), and virus titers in the apical compartments were determined (B).  Virus titers 
shown are the means of 3 to 11 cultures from a single donor ± S.E.  The limit of detection is 
1.2 log10TCID50/ml, as indicated by the dashed line. 
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Figure 2.  Comparison of single cycle virus growth curves in HAE inoculated with 
rHPIV1 wt (A) or rHPIV1-CF170S (B) at an MOI of 5.0 TCID50/cell or with VSV (C) at an 
MOI of 4.2 PFU/cell, at 37°C.  Virus titers in the apical and basolateral compartments were 
determined at 8, 24, 48 and 72 h p.i.  Virus titers shown are the means of cultures from two 
donors ± S.E., and the limit of detection is 1.2 log10TCID50/ml. 
 
 46 
 
 
Figure 3.  HPIV1 infection of ciliated cells without overt cytotoxicity.  HAE were 
inoculated with HPIV1 wt or rHPIV1-CF170S at an MOI of 5.0 TCID50/cell or were mock-
infected, and cells were processed at 24 and 48 h p.i. for histological analysis in cross 
section by immunofluorescence (A) or hematoxylin and eosin staining (B) at 40x 
magnification or stained en face (C).  For histological immunofluorescence (A, C), antibodies 
to HPIV1 (green) and acetylated alpha tubulin (red) were used to detect virus antigen and 
ciliated cells, respectively.  Scale bars represent 20µm (A, B) and 40µm (C). 
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Figure 4.  Comparison of the type I IFN response in HAE inoculated with rHPIV1 wt 
and rHPIV1-CF170S.  HAE were inoculated with rHPIV1s (MOI = 5.0 TCID50/cell), VSV (MOI = 
4.2 PFU/cell) or were mock-infected, and type I IFN mRNA and secreted protein were 
quantitated at 8, 24, 48 and 72 h p.i.  A type I IFN bioassay was used to quantitate levels of 
secreted type I IFN in the apical (A) and basolateral compartments (B) compared to an IFN-
β standard.  Type I IFN concentrations are expressed in pg/ml ± S.E., and are the means of 
data from duplicate cultures.  The IFN-β standard has a specific activity of approximately 1 
IU of antiviral activity per 5 pg.  The limit of detection for type I IFN was 20.2 pg/ml.  IFN-β 
mRNA expression was quantitated by qRT-PCR (C).  Total RNA was extracted from HAE at 
8, 24, 48 and 72h p.i., and IFN-β mRNA was measured by qRT-PCR using specific primers 
and Taqman probes that have been previously described (292).  For each sample, the level 
of IFN-β mRNA was relative to that of β-actin and expressed as the increase compared to 
that for the mock-inoculated sample. 
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Figure 5.  Virus replication and type I IFN production during multi-cycle growth curves 
in HAE inoculated with rHPIV1 wt and rHPIV1-CF170S at an MOI of 0.01 TCID50/cell at 
37°C.  Virus titers (log10 TCID50/ml; line graph) and type I IFN concentrations (pg/ml; bar 
graph) in apical washes were determined on each day from day 0 to 7 p.i.  The titers shown 
are means of duplicate donor cultures ± S.E.  The limit of detection for virus titers was 1.2 
log10TCID50/ml and for type I IFN was 31.1 pg/ml.  The area shaded in gray represents the 
overall difference in virus replication between rHPIV1 wt and rHPIV1-CF170S after day 2 p.i. 
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Figure 6.  The ability of HPIV1 vaccine candidates to replicate in HAE at 32°C and 
37°C was determined by multi-cycle growth curves.  HAE were inoculated with rHPIV1 
wt, rHPIV1-CR84G/∆170HNT553ALY942A or rHPIV1-CR84G/∆170HNT553AL∆1710-11 at an MOI of 0.01 
TCID50/cell at 32°C and 37°C.  Virus titers (log10 TCID50/ml) in apical and basolateral 
compartments were determined each day from days 0 to 7 p.i.  The virus titers shown are 
the means of triplicate donor cultures ± S.E. for apical washes (samples from the basolateral 
compartments were negative for virus), and the limit of detection is 1.2 log10TCID50/ml.
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Table 1.  Virus replication of HPIV1 wt and rHPIV1 mutants in African green monkeys 
and human airway epithelial cells. 
 
 
Lower respiratory tract of 
AGMsa 
 Apical surface of HAE cells 
(37°C) b  
 
 
Virus 
Mean peak 
virus titer  
(log10 
TCID50/ml) 
Reduction in 
replication vs 
HPIV1 wt (log10) 
 Virus titer, Day 
5 (log10 
TCID50/ml) 
Reduction in 
replication vs 
HPIV1 wt (log10) 
 
1 
 
HPIV1 wt 
 
3.9 
 
- 
  
8.6 
 
- 
2 rHPIV1-CF170S 2.7 1.2  5.8 2.8 
3 rHPIV1-
CR84G/∆170HNT553ALY942A 
0.6 3.3  4.3 4.3 
4 rHPIV1-
CR84G/∆170HNT553AL∆1710-11 
≤0.5 ≥3.4  2.5 6.1 
a Data has been previously published (21). 
b Virus titers were determined in low MOI growth curves in HAE cells (Figures 4 and 5). 
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ABSTRACT 
The human parainfluenza viruses (HPIVs) are common causes of severe respiratory 
viral disease in infants and young children.  To date, a licensed vaccine is not available for 
any HPIV.  In the present study, we characterized wild-type HPIV2 (rHPIV2-WT) infection in 
a well-established in vitro model of human airway epithelium (HAE) and revealed that the 
virus replicates to high titer, is shed only apically, targets ciliated cells and induces minimal 
cytopathology.  Since HPIV2 mutants are currently being developed as live attenuated 
vaccine candidates, we next sought to determine if infection of HAE with a HPIV2 vaccine 
candidate reflects replication in non-human primates.  An experimental HPIV2 vaccine 
strain, rHPIV2-VAC, that contains both temperature sensitive (ts) and non-ts attenuating 
mutations, was previously found to be restricted in replication in the upper (URT) and lower 
respiratory tract (LRT) of African green monkeys (AGMs) and to be protective against wild-
type HPIV2 challenge.  rHPIV2-VAC was reduced in replication by more than 30-fold 
compared to rHPIV2-WT in HAE cultures at 32oC and exhibited little productive replication in 
cultures at 37oC, reflecting a similar restriction of replication in the cooler URT and warmer 
LRT of AGMs.  These data indicate that the HAE model provides a convenient experimental 
system for examining the cell tropism, cytotoxicity, and attenuation phenotypes of HPIV2 
vaccine candidates as well as for characterizing the innate host responses of human airway 
epithelial tissues to infection.  Since clinical trials are the only true tests of vaccine safety 
and efficacy, the results from this study encourage continued evaluation of rHPIV2-VAC in 
clinical trials. 
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INTRODUCTION 
Human parainfluenza virus type 2 (HPIV2) is an enveloped, non-segmented, 
negative-strand RNA virus of the Rubulavirus genus in the Paramyxoviridae family (136). 
Similar to respiratory syncytial virus (RSV), influenza virus, HPIV1 and HPIV3, HPIV2 is an 
important cause of severe lower respiratory tract disease, including croup, pneumonia and 
bronchiolitis, in children less than 6 years old.  HPIV2 alone is responsible for approximately 
3% of all pediatric hospitalizations for respiratory tract diseases, in addition to causing 
significant morbidity in infected infants and children who do not require hospitalization (210).  
Licensed vaccines are currently not available for any of the HPIVs, despite their impact on 
public health.   
Our goal is to develop a live attenuated recombinant HPIV2 vaccine that is safe, 
genetically stable, and protective in young children against lower respiratory disease caused 
by HPIV2. The live attenuated strategy offers several advantages over inactivated or subunit 
formulations, including the ability to illicit broad protective immune responses consisting of 
local and serum antibodies as well as CD4+ and CD8+ T cell responses (208). Furthermore, 
live attenuated vaccines administered intranasally have been shown to infect and replicate 
in the respiratory tract in the presence of maternal antibody, permitting immunization of 
young infants, and to cause an acute, self-limiting infection that is readily eliminated from the 
respiratory tract (208). Finally, intranasal administration of live attenuated virus vaccines 
induces a mucosal antigen-specific immune response in the URT, which is a major 
component of resistance to respiratory viruses on epithelial surfaces (120).  Several 
intranasally administered live attenuated virus vaccines or vaccine candidates, including the 
influenza A virus vaccine (FluMist®), the parainfluenza type 3 (PIV3)-cold passage mutant 
(cp45), and the RSV rA2cp248/404/1030∆SH mutant derived using reverse genetics, have 
demonstrated both safety and immunogenicity in humans (207), (28, 137, 138).   
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The investigational live attenuated HPIV2 vaccine examined in this study, designated 
as rHPIV2-VAC, contains three attenuating elements: a T to C substitution at nucleotide 15, 
15T-C, in the 3’ genomic promoter; a substitution in L, LY948L; and a deletion in L, Ldel1724 (143, 
222, 223, 289).  The 15T-C mutation in rHPIV2-VAC was originally identified as a 
spontaneous mutation following in vitro passage of wild type (wt) HPIV2 in LLC-MK2 cells.  
This mutation is non-temperature sensitive (non-ts) and efficiently attenuates the virus in 
both the upper (URT) and lower (LRT) respiratory tract of African green monkeys (AGMs) as 
well as in the LRT of hamsters (222).  The LY948L mutation was originally identified as a ts att 
mutation in the L polymerase of the HPIV3cp45 vaccine candidate (287).  The stability of the 
mutant HPIV2 LY948L sequence was enhanced by genetically engineering an alternative 
codon assignment that would require three nucleotide changes to revert to the original, wild-
type tyrosine amino acid assignment.  This substitution mutation resulted in a ts phenotype 
as well as an att trait in the LRT of AGMs (222, 223). Lastly, the deletion of codons 1724 
and 1725 in L of HPIV2 (Ldel1724) resulted from the initial observation that importation of an 
LS1724I att mutation from bovine PIV3 into HPIV2 was highly attenuating (223, 287). Since 
deletion mutations are much less likely to revert under selective pressure than point 
mutations, efforts were made to achieve the same level of attenuation by creating the 
deletion mutant Ldel1724.  The resulting rHPIV2- Ldel1724 virus was ts and enhanced the att 
phenotype of the virus in hamsters when combined with the 15T-C mutation (223).  The 
rHPIV2-VAC vaccine candidate virus, containing all of these mutations, was found to be ts in 
vitro, with a replication shut-off temperature of 37°C, and manifested restricted replication in 
the URT and LRT of AGMs (222).  The mean peak titer of rHPIV2-VAC was reduced 4000-
fold in the LRT of infected AGMs compared to rHPIV2-WT (222).  rHPIV2-VAC induced a 
moderate rise in detectable HPIV2 hemagglutination-inhibition (HAI) antibodies in AGMs 
and immunization protected AGMs against wild-type HPIV2 challenge in both the UTR and 
LRT (222). 
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HPIV2 replicates primarily in epithelial cells of the human respiratory tract. The 
conducting airways of the nasal and tracheobronchial regions of the human respiratory tract 
are lined by a pseudostratified mucociliary epithelium, which consists predominantly of 
columnar ciliated cells that overlay a basal cell layer and are interspersed with mucus-
secreting goblet cells. Development of this epithelium involves the establishment of cell–
matrix and cell–cell interactions, altered gene expression, changes in ion transport, and 
cellular polarization that forms two distinct and highly specialized membrane domains, apical 
and basolateral (82). In vitro models of the human airway epithelium (HAE) can be derived 
from freshly isolated human airway cells grown at an air-liquid interface where they 
differentiate into a multilayered, polarized epithelium.  Unlike transformed cell lines, HAE 
cultures closely mimic morphological and physiological characteristics of the human airway 
epithelium in vivo, including mucus production and ciliary motion (188, 238).  The HAE 
model has been used to investigate infection characteristics of viral infection such as 
direction of entry into the cell (apical versus basolateral) and virus release, type of target 
cell, and level of cytopathology for a number of respiratory viruses, including human 
coronaviruses, influenza A virus, RSV, HPIV1 and HPIV3 (23, 284, 312, 359, 360). For 
example, paramyxoviruses RSV, HPIV1 and HPIV3 were shown to preferentially infect 
ciliated cells without causing cytopathology, suggesting that these cells play a critical role in 
paramyxovirus replication and pathogenesis in the respiratory tract (23, 359, 360), whereas 
influenza A viruses cause extensive cytopathology in HAE and in vivo (308, 312). Models of 
HAE have also been useful for studying virus-epithelial cell interactions in differentiated, 
human respiratory tissue in the absence of the cytotoxic activities of the adaptive immune 
response.  
In the present study, we utilized the HAE model to characterize HPIV2 infection of 
the human conducting airway epithelium with respect to level and duration of replication, cell 
tropism, cytopathology, direction of viral entry and release, and cellular response to 
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infection. Our data demonstrate that HPIV2 exhibits several characteristics that are also 
seen upon infection with other paramyxoviruses that cause respiratory disease in humans, 
including infection exclusively of the ciliated cells, polarized release of virus from the apical 
surface, and robust replication in the absence of gross morphological changes to the 
epithelium. HAE models have also previously been used to evaluate the attenuation of RSV 
and HPIV1 vaccine candidates (23, 348). Robust infection of HAE by wild-type HPIV2 in the 
present study allowed further investigation of the HPIV2 vaccine candidate rHPIV2-VAC, 
prepared from an experimental vaccine lot currently in clinical trials.  Comparison between 
the level of restriction of replication in the HAE model with that in vivo in AGMs revealed that 
magnitude of restriction in HAE correlates closely with that in the airways of AGMs. Our 
current findings suggest that HAE cultures are a useful model system for the preclinical 
evaluation of live attenuated HPIV vaccines.  
 
 
MATERIALS AND METHODS 
Cells and viruses 
Human airway tracheobronchial epithelial cells were isolated from airway specimens 
of patients without underlying lung disease.  Tissues were provided by the National Disease 
Research Interchange (NDRI, Philadelphia, PA) or by the UNC Cystic Fibrosis Center 
Tissue Culture Core as excess tissue following lung transplantation according to protocols 
approved by the University of North Carolina at Chapel Hill Institutional Review Board.  
Primary cells derived from single patient sources were first expanded on plastic and then 
plated on collagen-coated, permeable Transwell-COL (12-mm diameter) supports at a 
density of 3 x 105 cells per well.  Human airway epithelium (HAE) cultures were grown in 
custom media with provision of an air-liquid interface (ALI) for 4 to 6 weeks to form 
differentiated, polarized cultures that resemble in vivo pseudostratified mucociliary 
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epithelium, as previously described (238).  Rhesus monkey LLC-MK2 cells (ATCC CCL 7.1) 
and human HEp-2 cells (ATCC CCL 23) were maintained in OptiMEM I (Gibco–Invitrogen, 
Inc., Grand Island, NY) supplemented with 5% FBS and gentamicin sulfate (50 µg/ml).  
The HPIV2 recombinants described here are based on the biologically-derived 
HPIV2 strain V9412-6 (V94), which was isolated from a nasal wash specimen from an 
infected infant and was kindly provided by Dr. Peter Wright of Vanderbilt University. The 
sequence for the V94 strain was determined previously (Genbank accession #AF533010). 
The rHPIV2-WT virus was derived from an antigenomic cDNA copy of the HPIV2 V94 
genome (120); the genome of the rHPIV2-VAC vaccine virus is engineered from rHPIV2-
WT, as described previously (222, 223, 289).  This vaccine virus, which was referred to in 
our previous publication as rHPIV2-15C/948L/∆1724 (222), contains three attenuating 
elements:  a mutation at nucleotide 15, 15T-C, in the 3’ genomic promoter; a substitution in L, 
LY948L; and a six nucleotide deletion in L, Ldel1724.  Purified virus stocks were obtained by 
infecting LLC-MK2 cells and purifying virus in the cell culture supernatant by centrifugation 
and banding in discontinuous 30/60% (w/v) sucrose gradients in order to minimize 
contamination by cellular factors such as interferon (IFN). 
 
Viral inoculation of HAE 
The apical surfaces of HAE cultures were washed with phosphate-buffered saline 
(PBS) to remove mucus secretions, and fresh media was supplied to the basolateral 
compartments prior to infoculation.  rHPIV2 viruses diluted in culture medium were applied 
to the apical surface of the HAE cultures at high MOI (5.0 TCID50/cell) in a 200 µl inoculum.  
After incubation for two hours at either 32°C or 37 °C, the inoculum was removed and the 
cells were washed three times for 5 min with PBS, and then incubated at 32°C or 37°C, as 
indicated.  Virus released into the apical compartment was harvested by performing apical 
washes with 425 µl of media for 30 min at 32°C or 37°C. Basolateral samples were collected 
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directly from the basolateral compartment, and the volume removed was replaced with fresh 
media. Samples were collected at 0, 8, 24, 48, 72, 96 and 144 hours post-inoculation stored 
at -80°C prior to analysis.  Virus present in the a pical and basolateral samples was 
quantified by 10-fold serial dilution on LLC-MK2 monolayer cultures in 96-well plates.  After 
7 days at 32°C, infection of the cultures was detec ted by hemadsorption with guinea pig 
erythrocytes (49, 289).  The titers are expressed as log10 TCID50/ml (50% tissue culture 
infectious dose per ml).   
 
En face staining and fluorescence microscopy 
HAE cultures were fixed overnight at 4°C in methano l:acetone (50/50), then 
permeabilized with 2.5% Triton X-100. The fixed cells were blocked with 3% bovine serum 
albumin (BSA) in PBS++ (containing 1mM CaCl2 and 1mM MgCl2) prior to incubating the 
apical surfaces with antibodies diluted in 1% BSA.  HPIV2-positive cells were detected using 
rabbit anti-HPIV2 hyperimmune serum (1:100 dilution), obtained by vaccinating rabbits with 
purified wild-type HPIV2, followed by addition of fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit IgG (1:500 dilution; Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA).  Images were acquired using a Leica DMIRD inverted fluorescence 
microscope equipped with a cooled color charge-coupled device digital camera 
(MicroPublisher; Q-Imaging, Burnaby, British Columbia, Canada). The percentage of the 
epithelium positive for viral antigen as an index of percentage of infected cells was 
quantified over 5 images per culture by black and white pixilation of each image and 
computer calculation of percent black pixels after inverting the image. The technique 
determines percentage of black pixels in a defined area and does not account for 
differences in fluorescent intensity.   
 
Histology and immunostaining of paraffin-embedded sections 
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HAE cultures fixed in methanol:acetone were embedded in paraffin and sliced into 
5µm histological sections. Sections were stained with hematoxylin and eosin (H&E) for 
analysis by light microscopy or were subjected to standard immunofluorescence protocols. 
For immunofluorescence, sections were blocked with 3% BSA in PBS++ and then incubated 
with primary antibodies, rabbit anti-HPIV2 (1:100) and mouse anti-acetylated alpha tubulin 
(1:2000; Zymed, San Francisco, CA), diluted in 1% BSA. Primary antibodies were detected 
with FITC-conjugated goat anti-rabbit IgG and Rhodamine Red-conjugated goat anti-mouse 
IgG2b (Jackson ImmunoResearch Laboratories, Inc.) diluted 1:500. After washing, cells 
were overlaid with FluorSave mounting medium (EMD Chemicals, Inc.). Fluorescent images 
were aquired using a Leica DMIRD inverted fluorescence microscope, as above. 
 
Type I IFN bioassay 
The amount of type I IFN produced by infected HAE was determined by IFN 
bioassay according to previously published methods (23, 232).  Briefly, 2 M HCl was added 
to apical wash samples to bring the sample pH to 2.0 for inactivation of virus and acid-labile 
type II IFN.  After 24 h at 4°C, pH 2.0-treated sam ples were adjusted to pH 7.0 by adding 2 
M NaOH.  The IFN-containing apical wash samples were then serially diluted 2-fold in 
duplicate in 96-well plates of HEp-2 cells, along with a human IFN-β standard (5,000 pg/ml; 
Avonex; Biogen, Inc., Cambridge, MA).  After 24 h, the cells were infected with 2 x 104 
PFU/well of recombinant vesicular stomatitis virus (VSV-GFP), originally obtained from John 
Hiscott (299). After an additional 24-48 h, GFP expression was measured using a Typhoon 
8600 scanner (Molecular Dynamics Inc., Sunnyvale, CA). Type I IFN concentrations in the 
samples were determined by comparing the restriction of replication of VSV-GFP on HEp-2 
cell monolayers to a known concentration of the IFN-β standard. The dilution at which the 
level of GFP expression was approximately 50% of that in untreated cultures was 
considered the end point. To calculate the concentration of IFN in the samples, the end 
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point of the IFN-β standard was compared to the end point of the unknown samples.   
 
Cell shedding and adenylate kinase cytotoxicity assays 
 The loss of cells from the infected HAE cultures was calculated based on 
measurements of the dsDNA content of apical wash samples using a Quant-iT PicoGreen 
dsDNA Assay Kit (Invitrogen, Inc).  Briefly, samples were diluted 1:5 in TE buffer and then 
mixed with PicoGreen reagent.  Fluorescence was determined by a Synergy HT Multi-Mode 
microplate reader (Bio-Tek Instruments, Inc.) and actual dsDNA content was calculated 
based on fluorescence determined in a titrated dsDNA standard. An estimate of 6 pg of 
dsDNA per cell (162) was used to provide an approximation of the number of cells shed in a 
given sample.   
Cellular toxicity due to HPIV2 infection was determined by measuring the amount of 
adenylate kinase (AK) leakage into the apical compartment of the HAE.  AK is an 
intracellular enzyme that is released from the cell only when the cell membrane is damaged; 
an increase in the level of AK activity in the apical wash is proportional to the number of 
dead or damaged cells in the culture.  To measure cytotoxicity in HPIV2-infected HAE 
cultures, aliquots of the apical wash samples collected at each time point were centrifuged 
immediately after collection to eliminate cell debris prior to freezing the sample supernatant.  
AK release was determined in the apical wash supernatant samples using the ToxiLight 
BioAssay kit (Lonza Rockland, Inc., Rockland, ME) according to the manufacturer’s 
directions.  AK activity upon reaction with the ToxiLight reagent was detected using a 
luminescence microplate reader and SoftMax Pro software (Molecular Devices, Sunnyvale, 
CA).  
 
Replication of rHPIV2 mutants in the respiratory tract of AGMs 
 Studies in HPIV2 seronegative African green monkeys (AGMs) were previously 
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performed and reported again here for comparative purposes (222).  The AGMs were 
inoculated intranasally and intratracheally with 106.0 TCID50 of recombinant HPIV2 at each 
site and nasopharyngeal swabs and tracheal lavage samples were collected for up to 10 
days as described previously (222). The virus titer in each sample was determined by serial 
dilution on LLC-MK2 monolayers at 32°C as described  above.  
 
 
RESULTS 
Characterization of HPIV2 infection in primary cultures of well-differentiated human 
airway epithelium   
HPIV2 replicates in the epithelial cells of the human respiratory tract.  Our initial 
experiments in this study sought to characterize wild-type HPIV2 (rHPIV2-WT) infection 
using an in vitro model of the human airway epithelium (HAE).  HAE were inoculated at the 
apical surface with rHPIV2-WT at high MOI (5.0 TCID50/cell) and virus released both apically 
and basolaterally was quantified over time. Detection of virus in the apical compartment 
provided evidence of rapid and robust replication and shedding of rHPIV2-WT in HAE 
cultures. Titers of rHPIV2-WT increased 100-fold within the first 24 hrs following apical 
inoculation and reached a peak of approximately 106 TCID50/ml in the apical wash samples 
on day 2 (Fig. 1A), suggesting rHPIV2-WT was able to productively infect HAE. In contrast 
to the high levels of virus detected in the apical wash, little or no virus was detected in the 
basolateral compartment at any time point (Fig. 1A). These data correlate with clinical data 
indicating rHPIV2-WT is a highly pneumotropic virus with little evidence of disease outside 
the respiratory tract.    
The kinetics of HPIV2 replication and shedding from the apical surface loosely 
correlated with the number of cells staining positive for viral antigen by en face 
immunostaining for HPIV2 antigen (Fig. 1, B and C).  By day 1 post-infection, viral antigen 
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was detected throughout the cultures.  However, despite high MOI inoculation and detection 
of infected cells dispersed across the entire HAE culture, the actual percentage of the 
epithelium that was positive for viral antigen approximated only 8%, indicating not all 
available target cells were readily infected. Infection of HAE with rHPIV2-WT produced 
maximum titers on days 1-3 post-infection, which was demonstrated both by high levels of 
apical virus shedding and by the proportion of cells positive for HPIV2 antigen at those time 
points.  The number of infected cells dropped after day 3; the mean percentage of infected 
area in the cultures was reduced to half of its peak by day 6 post-infection (Fig. 1C).  The 
reduction in numbers of cells infected correlated with a reduction in viral titer determined at 
day 6 post-infection, suggesting that a loss of virus-producing cells contributed to reduced 
virus production in HAE.  Still, significant numbers of cells still stained positive for HPIV2 
through day 6 post-infection, and some virus shedding was detectable in the apical 
compartment through the final day of sampling.   
 
Comparison of the growth of rHPIV2-VAC to rHPIV2-WT in HAE cultures 
Our initial data indicated that the HAE model supported HPIV2 infection and could 
thus be used to characterize the attenuation phenotype of rHPIV2-VAC in human primary 
airway epithelium. rHPIV2-VAC was previously found to be ts in vitro, with greater than 100-
fold reduction in replication at 37°C compared with  replication at 32°C.  Furthermore, 
rHPIV2-VAC was highly restricted in replication in both the URT and LRT of AGMs, but the 
restriction of replication was greater in the warmer LRT (222). To compare the replication of 
rHPIV2-VAC with that of rHPIV2-WT in HAE, cultures were inoculated in parallel at an MOI 
of 5.0 TCID50/cell and maintained at either the temperature of the human upper airways 
(32oC, permissive) or distal lung (37oC, restrictive) (Fig. 2).  Virus titers determined in the 
apical washes over a 6-day period demonstrated nearly identical replication kinetics for 
rHPIV2-VAC and rHPIV2-WT at 32oC.  However, while both viruses reached peak titer by 3 
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days post-infection (Fig. 2A, left), the actual titer of rHPIV2-VAC was more than 30-fold 
lower than that of rHPIV2-WT.   
At the restrictive temperature of 37°C, which is cl oser to the temperature of the 
human lower respiratory tract, replication of rHPIV2-WT was not significantly different than 
at 32°C.  This correlates with the ability of HPIV2  to cause both URT and LRT infection in 
humans (136). In stark contrast, replication of rHPIV2-VAC was even more highly restricted 
at 37°C than at 32°C, with little or no virus shedd ing detected in any of the cultures (Fig. 2A, 
right).  The more severe restriction of replication of the HPIV2 mutant at 37°C was expected 
due to the contribution of the two ts mutations in the L polymerase. The lack of detectable 
replication of rHPIV2-VAC at this temperature in HAE in the absence of cell-mediated 
immune responses, illustrated by the rapid reduction in virus titer between day 0 (inoculum) 
and day 1 post-infection, suggests that this vaccine candidate will be restricted in replication 
in the human LRT. Like wild-type HPIV2, the vaccine candidate virus rHPIV2-VAC was not 
shed from the basolateral surface at either temperature (Fig. 1A and data not shown). 
 
HPIV2 infects ciliated cells in HAE cultures without causing gross morphological 
changes 
The nasal and tracheobronchial regions of the conducting airways are lined by a 
pseudostratified mucociliary epithelium consisting of multiple cell types including ciliated 
cells and mucus-secreting goblet cells.  Ciliated cells are the predominate cell type present 
and have been shown to be the major target for infection by other respiratory viruses such 
as influenza virus, severe acute respiratory syndrome coronavirus (SARS-CoV), and 
paramyxoviruses such as RSV, HPIV1 and HPIV3 (23, 186, 284, 312, 359, 360). In order to 
determine the specific cell types targeted by HPIV2 and to characterize the effects of 
infection on airway epithelial cell morphology, HPIV2-infected HAE cultures were fixed and 
paraffin embedded for histological analysis in cross section. The target cell type of HPIV2 
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infection was determined by examining histological cross sections of infected HAE by 
immunofluorescence using antibodies to acetylated alpha-tubulin, a marker for ciliated cells, 
and antibodies against HPIV2 proteins. Upon examination of multiple sections, virus was 
detected only in ciliated cells, though not every ciliated cell in any culture was infected (Fig. 
2B).  The rabbit anti-HPIV2 antiserum used reacts with a host cell antigen in mock-infected 
cells present adjacent to the cilia, but this localized staining is clearly distinct from the pan-
cytoplasmic staining of the viral antigens.  HPIV2 antigen was diffusely distributed 
throughout the cytoplasm of ciliated cells.  As was observed for rHPIV2-WT, rHPIV2-VAC 
also targeted ciliated cells of the HAE (Fig. 2B).  
Hematoxylin and eosin stained cross sections revealed that infection with HPIV2 did 
not induce any gross changes in morphology or in the integrity of the epithelium when 
compared to the mock-infected cultures (Fig. 2B).  HAE sections from cultures fixed on the 
final day of sampling (day 6) showed that neither rHPIV2-WT nor rHPIV2-VAC infection of 
HAE is associated with overt cytotoxicity or with the formation of syncytium.  In addition, 
mucociliary function determined by visual inspection of the infected HAE at each time point 
using a light microscope, did not appear to be significantly compromised by HPIV2 infection.  
 
Induction of type I interferon during HPIV2 infection of HAE 
Epithelial cells lining the airways express or release a number of innate immune 
defense molecules, including cytokines and chemokines, that may play a role in clinical 
disease symptoms as well as signaling initiation of the immune response to infection.  
Barlett and Hennessey et al. previously showed that infection of HAE with wild-type HPIV1 
fails to induce significant levels of type I interferon (IFN) secretion, while infection with an 
HPIV1 mutant that encodes a defective IFN antagonist C protein induces high levels of IFN 
(222)  The induction of IFN correlated with the restriction of replication of the HPIV1 mutant 
in the HAE model.  In the present study, we also compared the level of type I IFN production 
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by HAE in response to infection with rHPIV2-WT and vaccine candidate rHPIV2-VAC to 
determine whether IFN played a role in the reduction of virus titers.  Little type I IFN was 
detected in the apical compartments of the cultures maintained at either 32oC or 37oC during 
six days of virus replication with either rHPIV2-WT or rHPIV2-VAC with IFN being detected 
on only one day (Day 4, 35 pg/ml, lower limit of detection = 30 pg/ml).  This observation 
implies a strong block in the induction of IFN operative in both wild type and mutant HPIV2, 
which has also been observed upon HPIV2 infection of transformed cell lines (10, 11, 171, 
220, 221, 229-231, 244, 321). 
 
Cell shedding and cytotoxicity 
Severe respiratory viral disease is commonly associated with airway inflammation 
and epithelial cell injury. While much of this virus-induced injury may be related to immune 
responses to infection, some injury and morphological changes may be independent of 
immune cells.  Therefore, we also evaluated whether infection with HPIV2 induced cell 
cytotoxicity or cell loss in HAE that was undetectable on a gross level. To quantify cell loss 
in HPIV2-infected HAE, the apical surfaces of the cultures were washed to collect extruded 
cells. The estimated number of cells shed from the culture epithelium was calculated from 
measurements of the double-stranded (ds) DNA content of the apical wash (Fig. 4, black 
squares).  For all of the infected HAE cultures there was an increase in the number of cells 
in the apical wash 24 hrs following HPIV2 infection, even for cultures (rHPIV2-VAC at 37oC) 
in which virus replication was not detected.  This indicates that cell shedding does not reflect 
magnitude of virus replication.  In contrast, under normal conditions uninfected airway 
epithelium is a stable mucosal surface with relatively low rates of cell proliferation; multiple 
experiments have demonstrated that dsDNA detected in apical washes of mock-infected 
cultures is typically less than 35 ng/apical wash, representing approximately 6,000 cells 
(data not shown).  For both rHPIV2-WT and rHPIV2-VAC, cell shedding from the infected 
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HAE was highest one to two days post-infection. When HAE were similarly infected with 
HPIV3, infected ciliated cells were shed from the culture over time without affecting the 
integrity of the epithelium (359).  Quantification of shed cells following HPIV3, RSV and SV5 
infection of HAE also indicates peak cell shedding takes place between 2-4 days post-
infection.  The numbers of cells shed in response to infection, however, was pathogen-
specific, with SV5 inducing the highest levels followed by RSV.  Notably, cells shed following 
HPIV3 infection were similar in number and kinetics to our data reported here for HPIV2 
(data not shown; Fig. 3).   
 Cell death or cytotoxicity can also be evaluated by the quantification of plasma 
membrane damage.  One ubiquitous cellular protein that is rapidly released into culture 
medium only upon damage to the plasma membrane is adenylate kinase (AK); therefore, 
measuring AK activity in the apical wash allows rapid quantification of cells whose plasma 
membrane has been damaged by cytotoxic effect.  AK activity was measured in apical wash 
samples and is expressed as relative luminescence units (RLU).  In the rHPIV2-WT infected 
HAE cultures (Fig. 3 A & C), AK release peaked later than cell shedding, at day 4 post-
infection, correlating with the time point that virus titers from the apical surface started to 
decline. Infection with the vaccine candidate induced minimal AK release (Fig. 3 B & D), 
substantially less than rHPIV2-WT, which indicates that the magnitude of virus replication 
correlates with the magnitude of AK release.  Levels of replication that approach 106.0 
TCID50/ml appear to be needed to cause AK release that is detectible by our assay.  The 
relatively transient increase in AK release was not associated with significant alterations in 
the structural components of the epithelium in any of the cultures (Figures 2 and 3, plus data 
not shown). 
 
Comparison of virus replication of rHPIV2-WT and rHPIV2-VAC vaccine candidate in 
African green monkeys and HAE 
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Nonhuman primate (NHP) models are typically used to gauge vaccine safety and 
immunogenicity as well as to generate preclinical vaccine efficacy data from experimental 
challenges of immunized NHPs.  The investigational rHPIV2-VAC vaccine candidate has 
been characterized extensively in African green monkeys (AGMs), an established NHP 
model for HPIV2, and was found to be highly attenuated, immunogenic, and protective 
against challenge with wild-type HPIV2 (222).  As an additional tool for preclinical evaluation 
of HPIV2 vaccine candidates, primary HAE cultures offer a useful in vitro model to directly 
compare replication of live attenuated viruses in a setting that closely resembles that of in 
vivo replication in seronegative humans. In order to determine whether the HAE model 
reflects the att phenotypes of HPIV2 wild type and mutant viruses in AGMs, the replication 
of rHPIV2-VAC in HAE cultures was compared with replication in the URT and LRT of 
AGMs.  Upon comparison of mean peak virus titers in AGMs with virus titers from HAE 
apical washes at day 3 post-infection, we discovered a surprisingly close correlation 
between attenuation of rHPIV2-VAC in AGMs and restriction of replication in HAE cultures 
(Table 1).  The reduction in replication of rHPIV2-VAC versus rHPIV2-WT in the URT of 
AGMs was 1.6 log10 compared with a 1.5 log10 reduction in replication in apical washes from 
HAE cultures at the equivalent temperature of 32°C.   The reduction in replication was 
similarly close between the AGM LRT (3.9 log10) and HAE apical washes at 37°C (4.1 log 10).  
The strong correlation in the reduction of replication between these two models suggests 
that HAE cultures might be a valuable preclinical tool for predicting attenuation in vivo.  
Furthermore, the restricted replication of rHPIV2-VAC in both an in vitro model of HAE and 
an in vivo primate model support the use of this virus as a live attenuated vaccine candidate.   
 
 
DISCUSSION 
The focus of this study was to characterize wild-type HPIV2 infection in an in vitro 
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model of HAE and assess the utility of this model for evaluating phenotypes of candidate 
live attenuated vaccines.  Although animal models have given important clues to the level of 
attenuation of potential vaccine strains, we sought to establish a tissue culture system that 
would be predictive of attenuation in seronegative humans. Towards this goal, we used a 
well-differentiated HAE model generated from human primary epithelial cells which mimics 
the conducting airway epithelium and enables study of respiratory virus infection in 
differentiated cells of the natural host species.  We compared a HPIV2 vaccine candidate 
and a wild-type HPIV2 virus in HAE, both of which have been evaluated extensively in vitro 
and in vivo in AGMs.  In addition to evaluating the HAE model for predicting virus 
attenuation, we also investigated cellular cytotoxicity of HPIV2 infection and characterized 
several factors that affect viral pathogenesis in the respiratory epithelium, including the 
target cell type, polarity of virus release, and innate epithelial immune responses.  
 The concept that HAE can be used as a tool to screen potential vaccine candidates is 
supported by multiple studies in which attenuating mutations in several other respiratory 
viruses, including influenza A and B, RSV, HPIV1 and HPIV3, all limited growth in HAE 
compared to that of their parent strain (22, 23, 348, 349). Furthermore, data from these 
studies demonstrated a correlation between attenuation in HAE and attenuation in both 
animal models and clinical trials in humans.  Specifically, attenuation of HPIV1 vaccine 
candidates in AGMs was recapitulated in HAE, indicating potential for evaluating respiratory 
virus vaccine candidates in this model (23).  A second HPIV1 study, which evaluated the 
growth of an attenuated mutant rHPIV1-P(C-), confirmed that the level of replication in HAE 
mimics level of replication in AGMs for HPIV1 (22).  Strong evidence for the use of HAE 
models as a screening tool for respiratory virus vaccine candidates also comes from 
evaluation of the attenuation of RSV vaccines in primary polarized adenoid epithelial cells. A 
good correlation was found between level of growth of live attenuated RSV vaccine 
candidates in HAE with levels of attenuation both in animal models and in human adults and 
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children (348). Importantly, limited growth in HAE was predictive of attenuation in the most 
susceptible seronegative children (348).  
 In the current study, we found that HAE is fully permissive for HPIV2 infection and 
observed that ciliated cells are the major cell type targeted by HPIV2, consistent with other 
respiratory viruses, including influenza virus, SARS-CoV, RSV, HPIV1 and HPIV3 (23, 186, 
284, 359, 360).  HAE further supported HPIV2 replication with amplification of virus titer and 
can therefore be used as a model for HPIV2. Comparison of a live attenuated vaccine 
candidate with rHPIV2-WT revealed that replication of the rHPIV2-VAC vaccine virus was 
restricted in HAE at a level that closely mirrors its attenuation in vivo in AGMs. Mean peak 
titers of rHPIV2-VAC were 30 to 40-fold below rHPIV2-WT in both in vivo and in vitro models 
of the upper respiratory tract.  Likely, this is due to the 15T-C mutation in the 3’ genomic 
promoter, which was non-ts in vitro but was att in vivo in AGMs.  The restriction of rHPIV2-
VAC replication in HAE at 32oC was not observed in the non-polarized LLC-MK2 cell line, 
where its replication was equivalent to rHPIV2-WT at permissive temperatures (data not 
shown). In both HAE and AGM models of the lower respiratory tract, peak rHPIV2-VAC 
replication was more attenuated (approximately 10,000-fold below rHPIV2-WT) due to the 
additional contribution of the ts mutations in the L polymerase. The strong correlation 
between HAE and AGM data further strengthens the concept that HAE models can be used 
to determine the attenuation phenotypes of potential respiratory virus vaccine candidates.  
Moreover, the attenuation of rHPIV2-VAC in HAE suggests that it may be sufficiently 
restricted in growth to be safe in humans.  Experimental live attenuated vaccines for the 
human PIVs must be highly attenuated strains that cause minimal side effects to ensure 
safety in the infant vaccinees. This presents a challenge for the development of live 
attenuated vaccines because the magnitude of virus replication in the respiratory tract 
correlates directly with both the severity of acute respiratory illness and with the degree of 
immunogenicity (209).  Therefore, balancing sufficient attenuation to prevent illness with 
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levels of immunogenicity that will be protective is critical.  Data from clinical trials with RSV 
and HPIV3 vaccine candidates provide an indication of the level of attenuation that does not 
cause disease in seronegative infants, typically a mean peak titer in the upper respiratory 
tract that is approximately 2 logs below that of the wild-type parent virus (107, 137, 138).  
The results of this study show a consistent, high level of attenuation for rHPIV2-VAC that is 
unlikely to cause severe lower respiratory disease in humans. 
The ability to cause an acute, self-limiting infection that is readily eliminated from the 
respiratory tract is critical for a live attenuated vaccine candidate.  In addition to its restricted 
replication, we observed a decline in virus shedding for rHPIV2-VAC after the peak of 
infection in the absence of cellular immune responses. The ability of rHPIV2-VAC to infect 
HAE at 32oC and replicate to a peak titer of approximately 104.5 TCID50/ml indicates that this 
virus will be able to productively infect the upper respiratory tract, thereby enabling it to 
trigger an adaptive immune response in the vaccinated individual.  Furthermore, the steady 
reduction in titer on days 4 and 6 (an 80-fold reduction from the peak titer at day 3) suggests 
that replication of rHPIV2-VAC can be reduced in HAE even in the absence of a robust 
cellular or humoral immune response. This may further indicate that significant clinical 
disease from rHPIV2-VAC will be limited.  Initially, we suspected that this decrease in virus 
shedding might be due to the production of cytokines and other immune mediators by the 
epithelial cells. Although HPIV infection is resolved in the host through both innate and 
adaptive immune mechanisms directed at the virus, previous studies with HPIV1 mutants 
showed that type I IFN produced by epithelial cells alone may be capable of limiting 
replication of viruses susceptible to the antiviral effects of IFN (23).  However, our evaluation 
of the type I IFN response showed no link between IFN production in HAE cultures and the 
reduction of HPIV2 replication, though this does not rule out a contribution of other innate 
epithelial cell responses to limiting virus replication.  In the future, the HAE model, which 
lacks immune cell-mediated innate and adaptive immunity or neutralizing antibodies, may be 
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useful in examining innate immune responses of epithelial cells in the airway that may limit 
the extent and duration of virus infection. 
In addition to cytokine production, in vivo infection with respiratory viruses can cause 
dramatic changes in the epithelial barrier, including damage of epithelial cells, increased 
mucin production, ciliary dysfunction, cell shedding, increased paracellular permeability, and 
airway inflammation. In response to infection with HPIV2, cell shedding and cytotoxicity 
assays detected some alterations in the HAE.  Cell extrusion from the apical surface of the 
HAE was detected by 24 hours post-infection in all cultures.  rHPIV2-VAC exhibited high 
levels of cell shedding despite its restricted replication, suggesting that this effect is 
independent of the level of virus replication and may be triggered by host cell recognition of 
a structural component associated with input virus.  Typically, cells that are shed into the 
airway lumen undergo detachment-induced cell death, also called anoikis; acceleration of 
this process might serve to limit infection while still maintaining the integrity of the 
epithelium. Cell shedding at the apical surface of HAE has also been observed upon 
infection with SARS-CoV and HPIV3, and many of the extruded cells in these studies were 
shown to be virus-infected (284, 359). Zhang et al. reported that the coordinated beating of 
the cilia, which moves luminal secretions directionally (i.e., mucociliary transport), might also 
facilitate the spread of HPIV3 infection in HAE (359). Whether this increase in cellular 
turnover is induced by the virus to facilitate its spread or by the host to eliminate infected 
cells from the epithelium has not been determined.   
In contrast to the rapid shedding of cells upon HPIV2 infection, cytotoxicity was 
detected later, peaking at day 4 p.i., loosely corresponding with the beginning of a decrease 
in virus titers. This could be due to either death of infected cells by cytopathic effect of virus 
infection or by cellular apoptotic mechanisms. This cell death combined with decreasing 
titers and the observation that uninfected cells remained in the cultures suggest a means of 
limiting virus spread. In contrast to rHPIV2-WT, rHPIV2-VAC exhibited minimal cytotoxicity 
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determined by AK release assays, corresponding to lower levels of replication. Despite our 
ability to detect membrane permeability and loss of cells, histological examination of HPIV2-
infected cultures revealed that their integrity was not detectably altered compared to 
uninfected cultures from the same donor.  HAE had a normal appearance following HPIV2 
infection and neither syncytium formation nor alterations in cilial beat were observed.  The 
characteristic syncytium formation noted with non-polarized epithelial cell lines infected with 
RSV and PIV3 also does not occur in HAE models (359, 360). These data indicate that 
HPIV2, similar to other paramyxoviruses examined in HAE cultures (HPIV1, HPIV3, RSV), 
does not produce obvious cytopathology in airway epithelial cultures in the absence of a 
host cellular immune response.  In contrast to HPIV and RSV infections, influenza virus 
infection destroys HAE cultures within 48 hours, causing disruption of cilial beat and loss of 
columnar epithelial cells (270, 308, 312).  The rapid and extensive cytopathology in HAE 
cultures is consistent with the cytonecrosis and desquamation of respiratory epithelial cells 
into the lumen that occurs in vivo (308)  This suggests that while influenza A was cytopathic 
even in the absence of an immune response, cytopathology induced in vivo by RSV and the 
HPIVs may be largely immune-mediated.  
In the polarized HAE model, the apical compartment represents the airway lumen, 
while the basolateral compartment represents the serosal side of the epithelium.  Because 
HPIV vaccines are being developed for intranasal inoculation, vaccine strains must be able 
to productively infect apical, or luminal, cell surfaces for intranasal administration without 
spreading significantly beyond that site. Our studies confirmed that inoculation of the apical 
surface of HAE is a productive route of infection for rHPIV2-VAC, which supports intranasal 
inoculation as a route of vaccination.  Furthermore, following apical inoculation with either 
rHPIV2-WT or rHPIV2-VAC, infection and virus shedding appear to be limited to the apical 
side of the polarized HAE cultures. This restricted virion release is not unexpected as 
asymmetric budding is typical of many viruses that infect polarized epithelial cells lining the 
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respiratory or digestive tracts. Virus release from the apical surface of an epithelial cell 
results in shedding into the lumen and away from underlying tissues, increasing likelihood 
that infection will remain localized to epithelial surfaces in the respiratory tract.  The 
restriction of virion release to apical surfaces has also been seen previously with the related 
parainfluenza viruses HPIV1 and HPIV3, as well as RSV and influenza A virus, and is 
consistent with the pattern of infection limited to the respiratory tract that is typically seen 
throughout the course of disease during human infection (23, 359).  In contrast, basolateral 
release favors establishment of a systemic infection because the basolateral membrane 
abuts the underlying stratum of the epithelia, facilitating access to the tissues and 
vasculature. A number of viruses that are released basolaterally are associated with 
development of systemic infections including herpesviruses, rhabdoviruses, and retroviruses 
(23, 253, 315).  Although apical budding is probably not the only mechanism that restricts 
systemic spread of a virus since virions may still be capable of traversing the epithelial 
membrane barrier through transcytosis or disruption of cell layers, restricted entry and 
release of many viruses is consistent with the hypothesis that it is a pathogenesis 
determinant. The observation that rHPIV2-VAC is also released from the apical surface is 
important for vaccine development because it will be unlikely to cause viremia or spread to 
systemic organs in vaccines.   
In summary, the rHPIV2-VAC investigational vaccine has been characterized 
extensively in vitro and in African green monkeys and was found to be highly attenuated and 
phenotypically stable.  Furthermore, rHPIV2-VAC provided significant protection against 
HPIV2 challenge, and preliminary immunogenicity data in non-human primates indicate than 
this investigational vaccine may induce protective immunity in humans.  This study extended 
analysis of rHPIV2-VAC to a human model system that may be predictive of replication in 
the airways of seronegative children.  The close correlation between limited growth of 
rHPIV2-VAC in vivo and in HAE compared to WT virus provides further evidence that this 
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virus will be safely attenuated in humans.  It further indicates that HAE may be an effective 
screening step for comparing attenuation and other phenotypes of vaccine candidates. 
While the level of virus replication in the human upper respiratory tract in vivo remains to be 
determined, these characteristics of infection in an in vitro model of the human airway 
epithelium suggest that rHPIV2-VAC may be a promising candidate vaccine for HPIV2. 
rHPIV2-VAC is currently being evaluated in clinical trials as a live attenuated vaccine 
candidate for HPIV2.  It will be valuable to compare data generated in HAE models to levels 
of replication in seronegative humans in clinical trials in order to fully assess the utility of the 
HAE model for preclinical evaluation of recombinant live attenuated respiratory virus 
vaccines.  
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Figure 1. rHPIV2-WT infects HAE and is shed from the apical surface.  HAE were 
inoculated at the apical surface with rHPIV2-WT at high MOI (5.0 TCID50/cell).  (A) Virus 
shed into both the apical and basolateral compartments was determined at the indicated 
times post-inoculation.  Virus titers shown are the means of 6 cultures from 2 donors (3 
cultures per donor) +/-SE.  The limit of detection is 1.2 log10TCID50/ml.  (B) HAE were 
infected with rHPIV2-WT or mock infected, fixed at the indicated times post-inoculation and 
stained en face for HPIV2 antigen (green).  (C) Quantification of the percentage of HPIV2-
positive HAE (FITC-positive surface area) per culture over time after apical inoculation with 
rHPIV2-WT. 
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Figure 2.  Comparison of HAE infection with rHPIV2-WT and the vaccine candidate 
rHPIV2-VAC.  HAE cells were inoculated with rHPIV2-WT or rHPIV2-VAC at an MOI of 5.0 
TCID50/cell.  Cultures were incubated at 32°C (permissive  temperature) or 37°C (restrictive 
temperature), as indicated. (A) Comparison of single cycle growth curves in HAE inoculated 
with rHPIV2-WT or rHPIV2-VAC (vaccine candidate).  Virus titers were determined in the 
apical compartments over a six-day time course.  Virus titers shown are the means of 6 
cultures from two donors (3 cultures per donor) ± S.E., and the limit of detection is 1.2 
log10TCID50/ml.  (B) HPIV2 infects ciliated cells in HAE cultures.  HAE cultures were 
inoculated with rHPIV2-WT or rHPIV2-VAC at an MOI of 5.0 TCID50/cell or were mock-
infected.  Antibodies to HPIV2 (green) and acetylated alpha tubulin (red) were used to 
detect virus antigen and ciliated cells, respectively, in paraffin embedded sections of 
infected HAE. (C) Representative histological cross-sections of infected HAE stained with 
hematoxylin and eosin.  No obvious cytopathic effects or cell-cell fusion was observed.   
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Figure 3.  Cell shedding and cytotoxicity induced by HPIV2 infection.  The estimated 
number of cells shed from the culture epithelium (black squares, scale on left y-axis) is 
calculated from measurements of the dsDNA content of the apical wash samples at the 
indicated times post-infection.  Cytotoxicity (open circles, scale of right y-axis) was quantified 
by measuring adenylate kinase activity in apical wash samples.  Adenylate kinase in the 
sample activated a bioluminescent detection reagent (ToxiLight BioAssay Kit), which was 
detected using a luminometer; activity is expressed as relative luminescence units (RLU).  
Virus titers in the apical samples are shown as dashed lines for reference and use the same 
scale as Figure 2A. 
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Table 1.  Comparison of virus replication of rHPIV2-WT and rHPIV2-VAC in African 
green monkeys and human airway epithelium 
 
 
Respiratory tract of African green 
monkeysa  Apical surface of HAE cells
c 
Mean peak 
virus titerb (log10 
TCID50/ml) 
Reduction in 
replication vs 
WT (log10) 
 
Virus titer at 72 
hpi 
(log10 TCID50/ml) 
Reduction in 
replication vs 
WT (log10) 
HPIV2 
virus 
URT LRT URT LRT  32°C 37°C 32°C 37°C  
rHPIV2-
WT 3.9 4.8 NA NA 
 6.0 5.6 NA NA 
rHPIV2-
VAC 2.3 0.9 1.6 3.9  4.5 1.5 1.5 4.1 
a
 African green monkeys were inoculated IN and IT with 106.0 TCID50 of the indicated virus at 
each site. Nasopharyngeal swabs were collected on days 1-10 post-infection and tracheal 
lavage samples were collected on days 2, 4, 6, 8, and 10 post-infection. Virus titers were 
determined by limiting dilution on LLC-MK2 cells at 32°C. 
b Mean of the peak virus titers for the individual monkeys in each group irrespective of 
sampling day. The lower limit of detection was 0.5 log10 TCID50/ml. URT, upper respiratory 
tract (nasopharyngeal swab); LRT, lower respiratory tract (tracheal lavage). 
c
 Virus titers were determined in high MOI growth curves in HAE cells (Fig. 2).  Titers shown 
are from apical wash samples collected at 72 hours post-infection (hpi). 
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ABSTRACT  
Transmission of avian influenza viruses from bird to human is a rare event even 
though avian influenza viruses infect the ciliated epithelium of human airways in vitro and ex 
vivo.  Using an in vitro model of human ciliated airway epithelium (HAE), we demonstrate 
that while human and avian influenza viruses efficiently infect at temperatures of the human 
distal airways (37oC), avian, but not human, influenza viruses are restricted for infection at 
the cooler temperatures of the human proximal airways (32oC).  These data support the 
hypothesis that avian influenza viruses, ordinarily adapted to the temperature of the avian 
enteric tract (40oC), rarely infect humans, in part due to differences in host airway regional 
temperatures.  Previously, a critical residue at position 627 in the avian influenza virus 
polymerase subunit, PB2, was identified as conferring temperature-dependency in 
mammalian cells. Here, we use reverse genetics to show that avianization of residue 627 
attenuates a human virus, but does not account for the different infection between 32oC and 
37oC. To determine the mechanism of temperature restriction of avian influenza viruses in 
HAE at 32oC, we generated recombinant human influenza viruses in either the 
A/Victoria/3/75 (H3N2) or A/PR/8/34 (H1N1) genetic background that contained avian or 
avian-like glycoproteins.  Two of these viruses, A/Victoria/3/75 with L226Q and S228G 
mutations in hemagglutinin (HA) and neuraminidase (NA) from A/Chick/Italy/1347/99 and 
A/PR/8/34 containing the H7 and N1 from A/Chick/Italy/1347/99, exhibited temperature 
restriction approaching that of wholly avian influenza viruses.  These data suggest that 
influenza viruses bearing avian or avian-like surface glycoproteins have a reduced capacity 
to establish productive infection at the temperature of the human proximal airways.  This 
temperature restriction may limit zoonotic transmission of avian influenza viruses and 
suggests that adaptation of avian influenza viruses to efficient infection at 32oC may 
represent a critical evolutionary step enabling human-to-human transmission.   
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INTRODUCTION 
Influenza viruses circulating in the human population are predominately type A and 
B, with type A being more common (246).  All influenza type A viruses originate from aquatic 
birds and successful introduction of these avian viruses into the human population, by either 
direct adaptation or reassortment with already circulating human viruses, has led to 
influenza pandemics of historical significance (reviewed in (122, 250, 337); (268)).  Still, 
documented evidence of transmission of avian influenza viruses directly from birds to 
humans is rare, partly because species barriers restrict avian influenza virus infection of the 
epithelial cells of the human respiratory tract, the primary site of influenza virus infection and 
spread.   
Influenza A viruses possess a hemagglutinin (HA) attachment protein that binds 
sialic acid residues to facilitate infection of target epithelial cells.  The HA of human influenza 
viruses preferentially binds to terminal sialic acid (SA) residues with α2,6 linkages, whereas 
avian influenza viruses preferentially bind to SA with α2,3 linkages (56, 84, 185, 256).  The 
prevalence of α2,6 SA but paucity of α2,3 SA in the human respiratory tract has been 
considered to restrict infection by avian influenza viruses (281).  Recent reports, however, 
have detected significant levels of α2,3 SA on human airway epithelium both in vitro and ex 
vivo, including in nasopharyngeal and tracheobronchial tissue (186, 218, 219, 312).  This SA 
distribution also correlated with avian influenza virus infection in vitro and ex vivo and raised 
the possibility that avian viruses could infect the upper airways in vivo.  Therefore, although 
it is universally accepted that human-to-human transmission of avian influenza viruses 
requires adaptation of HA to switch from α2,3 to α2,6 SA usage, the cumulative data 
published to date indicate that SA linkages and their respective distribution in the human 
airways are not the sole barrier to avian influenza virus infection (184, 298, 317).  Other host 
factors and viral genes are likely also important determinants of infectivity. 
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One such host factor that may limit zoonotic transmission is the difference in host 
temperatures between avian and human tissues that are susceptible to influenza virus 
infection.  Avian influenza viruses are adapted for replication in the avian enteric tract at 40-
41oC.  While the surface temperatures of the human respiratory tract are variable, a 
temperature gradient clearly exists in which the surface temperature of the proximal large 
airways (i.e., nasal and tracheal) average 32 +/- 0.05oC while temperatures of the smaller, 
distal airways (i.e., bronchioles) are closer to that of the core body temperature, 37oC (167, 
194).  While multiple transmission routes have been described for influenza viruses, the 
proximal airways likely represent a predominant site for human influenza virus inoculation as 
they provide a large exposed surface area of virus-susceptible epithelial cells (111).  These 
cells are directly accessible by large droplet aerosols and by way of digital inoculation of the 
nasopharynx and conjunctival mucosa (33, 219).  Inefficient infection by avian influenza 
viruses, even in the presence of α2,3-linked SA, may be due to the cooler temperature of 
the proximal airways compared to that of the distal airways/lung regions where H5N1 avian 
influenza viruses appear to replicate efficiently (320).    
Avian influenza viruses are attenuated at temperatures below 37oC and cold 
sensitivity of avian viral RNA replication in cell lines was linked to the presence of a glutamic 
acid at amino acid 627 in the avian virus polymerase subunit, PB2, instead of a lysine in the 
human virus PB2 (181).  Lysine substitution at residue 627 of H5N1 viruses improved virus 
replication in mice (109).  In addition to PB2, work utilizing human-avian reassortant viruses 
in MDCK cells provided initial evidence that avian glycoproteins, HA and neuraminidase 
(NA), may mediate temperature-dependent effects on viral growth (141).  To our knowledge, 
other viral genes have not been well characterized, nor the HA and NA further evaluated, in 
their contribution to temperature sensitivity of avian influenza viruses. 
To characterize the temperature dependency of avian vs. human influenza viruses in 
a relevant model of the target cell types of the human airways, we utilized an in vitro model 
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of human ciliated airway epithelium (HAE).  This model closely mimics the morphological 
and physiological features of the human airway epithelium in vivo and has been previously 
used to investigate infection by diverse respiratory viruses (22, 23, 284, 359, 360).  In 
humans, ciliated airway epithelium is present throughout the airways, extending from the 
nasal cavity and large proximal airways into the distal bronchiolar airway regions.  
Previously, we have shown that both human and avian influenza viruses replicate well in 
HAE and that human and avian influenza virus cell tropism correlates with the respective 
distribution of the specific sialic acid linkages (312).  However, these previous studies were 
conducted at 37oC, reflecting conditions encountered in the distal airways (312). Others 
have also utilized these airway cell systems to characterize influenza virus replication of 
wild-type and recombinant viruses at 35oC (50, 186, 331).  In the present study, we utilize 
the HAE model, in combination with influenza virus reverse genetics, to investigate the 
influence of temperature on human and avian influenza virus infection, replication and 
spread.  We demonstrate that, compared to human influenza viruses, avian influenza 
viruses are severely restricted for infection of human airway epithelium at the temperature of 
the human proximal airways.  Then, using different strategies to ‘avianize’ human influenza 
viruses, we show that the temperature restriction of avian viruses is closely associated with 
the avian HA and NA glycoproteins.  
 
 
MATERIALS and METHODS 
Cells 
Human airway tracheobronchial epithelial cells isolated from airway specimens from 
patients without underlying lung disease were provided by the National Disease Research 
Interchange (NDRI, Philadelphia, PA) or as excess tissue following lung transplantation 
under University of North Carolina at Chapel Hill (UNC) Institutional Review Board-approved 
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protocols by the UNC Cystic Fibrosis Center Tissue Culture Core.  Primary cells derived 
from single patient sources were expanded on plastic to generate passage 1 cells and 
plated at a density of 3 x 105 cells per well on permeable Transwell-Col (12-mm diameter) 
supports (Corning, Inc.).  HAE cultures were grown in custom media with provision of an air-
liquid interface for 4 to 6 weeks to form differentiated, polarized cultures that resemble in 
vivo pseudostratified mucociliary epithelium, as previously described (238).  Madin-Darby 
Canine Kidney (MDCK) cells were maintained in DMEM (Gibco-Invitrogen, Inc.) 
supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin (Sigma-Aldrich, 
Inc.).   
 
Viruses 
Influenza virus A/England/26/99 (H3N2) was isolated at the Health Protection 
Agency, Colindale, London, UK, during the routine surveillance program and has been 
minimally passaged in MDCK cells (311).   A/Dk/Singapore/97 (H5N3) and A/Dk/England/62 
(H4N6) are typical avian influenza strains that have been passaged in both embryonated 
chicken eggs and MDCK cells during laboratory handling.   Highly pathogenic A/VN/1203/04 
(H5N1) was biologically derived and minimally passaged in embryonated chicken eggs.  
A/Udorn/307/72 (H3N2) was passed in baby hamster kidney (BHK) cells and represents a 
clone expanded once in embryonated chicken eggs.  Recombinant viruses, including wild-
type A/Victoria/3/75 (H3N2) and mutants in either the A/Victoria/3/75 (H3N2) or A/PR/8/34 
(H1N1) background, were generated from cloned cDNA in 293T and MDCK cell co-cultures 
as previously described (72, 214).  Mutant viruses were generated in either the 
A/Victoria/3/75 (H3N2) or A/PR/8/34 (H1N1) genetic background as follows: 1) Vic 627PB2; 
A/Victoria/3/75 containing a lysine to glutamic acid amino acid substitution at position 627; 
2) Vic-226-228HA; A/Victoria/3/75 containing two amino acid substitutions in the HA gene 
(L226Q, S228G) that confer an avian-like receptor binding preference (56, 328); 3) Vic + 
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Chick N1; A/Victoria/3/75 in which segment 6 containing the endogenous N2 NA gene was 
exchanged for the N1 NA gene from avian isolate A/Chick/Italy/1347/99; 4) Vic-226-228HA 
+ Chick N1; A/Victoria/3/75 containing both L226Q and S228G mutations and the avian N1; 
5) PR8 + Vic HA/NA; A/PR/8/34 in which the endogenous H1 and N1 were replaced with the 
H3 and N2 from A/Victoria/3/75 and 6) PR8 + Chick HA/NA (RD3); A/PR/8/34 in which the 
endogenous H1 and N1 were replaced with the H7 and N1 from A/Chick/Italy/1347/99. (RD3 
was previously described as a candidate vaccine strain (343).)  The last two reassortant 
viruses were generated by substituting segment 4 and segment 6 from PR8 with those from 
either A/Victoria/3/75 (H3N2) or A/Chick/Italy/1347/99 (H7N1).  The multi-basic cleavage site 
in the avian H7 HA gene used in these studies was removed prior to rescue of these 
recombinant viruses for safety.  Available accession numbers (GenBank: 
http://www.ncbi.nlm.nih.gov.libproxy.lib.unc.edu) are V01086 for A/Victoria/3/75 HA and 
CAD37074 for A/Chick/Italy/1347/99 HA.     
 
Viral inoculation and growth in HAE 
HAE were rinsed with PBS to transiently remove apical secretions and supplied with 
fresh basolateral medium prior to inoculation.  Virus inoculum was diluted in PBS and 
applied to the apical surface of HAE for 2 hrs at either 32oC, 33oC, or 37oC, as indicated.  
Following incubation, viral inocula were removed and cultures incubated at 32oC, 33oC or 
37oC for the duration of the experiment.  Viral growth kinetics were determined by 
performing apical washes with 300µl of serum-free DMEM for 30min at either 32oC or 37oC.  
Washes were harvested and stored at -80oC prior to analysis.  Viral titers in the apical 
washes were determined by standard plaque assay or tissue culture infectious dose 
(TCID)50 assay on MDCK cell monolayers as previously described (72, 90, 312). 
 
En face staining 
 86 
 At various points post-inoculation (pi), HAE were fixed in cold methanol-acetone 
(50/50) and stored at 4oC. Cultures were then permeabilized with 2.5% triton-X 100/PBS++ 
(containing 1mM CaCl2 and 1mM MgCl2) and blocked with 3% bovine serum albumin (BSA) 
in PBS++ before being probed with mouse anti-influenza virus nucleoprotein (NP; 
Chemicon, Inc.; 1:100) and immunoreactivity detected with fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch 
Laboratories, Inc., 1:500). Fluorescent images were obtained using a Leica DMIRB inverted 
fluorescence microscope equipped with cooled-color charge-coupled-device digital camera 
(MicroPublisher; Q-Imaging, Burnaby, BC, Canada).  The percentage of the epithelium 
positive for viral antigen as an index of percentage of infected cells was quantified over 5 
images per culture by black and white pixilation of each image and computer calculation of 
percent black pixels after inverting the image.  This technique determines percentage of 
black pixels in a defined area and does not account for differences in fluorescent intensity.     
 
Measures of CPE 
Viral-induced cytotoxicity was determined by measuring adenylate kinase activity in 
apical washes using a commercially available assay (Lonza, Inc.).  Apical samples were 
centrifuged prior to freezing to remove any cellular contaminants present in the wash.  
Luminescence detected in samples from infected HAE were normalized to uninfected HAE 
and expressed as fold change over AK measured in uninfected (mock) HAE.  Morphological 
assessment of cytotoxicity in HAE was performed with paraformaldehyde (PFA, 4%)-fixed 
histological sections (5µm) stained with hematoxylin and eosin. 
 
Detection of α2,3 and α2,6 linked sialic acids 
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 HAE maintained at either 32oC or 37oC for 72 hrs prior to sialic acid detection were 
washed, blocked with 3% BSA/PBS++ and probed with biotinylated SNA or MAA lectins to 
detect α2,6 and α2,3 SA, respectively (Vector Laboratories, Inc.; EY-Laboratories, Inc.; 
1:100).  HAE were then fixed in 4% PFA and incubated with streptavidin-alexafluor 488 
(Molecular Probes, Inc.; 1:500) applied to the apical surface to detect lectin binding.   
 
Immunohistochemistry 
 HAE fixed in methanol:acetone, were probed en face with antibody against viral NP 
(Chemicon, Inc.; 1:100) and FITC-conjugated goat anti-mouse IgG1 and IgG2a (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA; 1:500), then embedded in paraffin.  
Histological sections (5µm) were prepared and reprobed for viral antigen using standard 
immunofluorescence protocols.  Briefly, sections were bathed in 2.5% triton-X 100/PBS++ 
for 30min, blocked in 3% BSA/PBS++ and incubated with antibodies in 1% BSA/PBS++.  
Primary antibodies were anti-viral NP (Chemicon, Inc., as above) and anti-alpha acetylated 
tubulin (Zymed Laboratories, Inc.; 1:2000), a marker for ciliated cells.  Secondary antibodies 
were FITC-goat anti-mouse IgG2a and Rhodamine red-conjugated goat-anti-mouse IgG2b 
(Jackson ImmunoResearch Laboratories, Inc.; 1:500).  Sections were prepared with 
FluorSave mounting media (EMD Chemicals, Inc.) and images captured using a Leica 
DMIRB inverted fluorescence microscope equipped with a cooled color charge-coupled-
device digital camera (MicroPublisher; Q-Imaging, Burnaby, British Columbia, Canada). 
 
Statistical Analysis 
Linear mixed models were fitted to the repeated measurements of log-transformed 
viral titer over time that included effects for the four treatment groups (defined by virus and 
temperature), eight time points, and the interaction between treatment and time.  We note 
that in a small number of cases, there were only two treatment groups (defined by 
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temperature) and fewer than eight time points.  A heterogeneous autoregressive correlation 
structure of order one was assumed for the repeated measurements.  A joint test of the 
interaction terms (21 degrees of freedom) provides an assessment of the hypothesis of no 
differences among the four treatment groups with respect to viral titer growth (log scale).   
Provided this test was significant, indicating some differences among the four growth 
curves, pair-wise differences between the three treatment groups versus the a priori 
specified reference group (generally the avian strain at the lowest temperature) were carried 
out for each time point, and significant differences at the 0.05 level were noted.  No 
adjustments for inflated Type I error due to multiple comparisons were made.  Missing 
observations were assumed to be missing completely at random, based on the fact that the 
investigators determined a priori to remove samples at specific time points during the 
experiment. 
 
 
RESULTS 
Human and avian influenza virus infection of human ciliated airway epithelium at 32oC 
and 37oC. 
We and others have previously shown that human and avian influenza viruses infect 
and replicate in HAE (186, 312, 331).  Since our previous experiments were performed at 
37oC, a temperature reflective of human distal airways, we have now compared human and 
avian influenza virus infection and growth in HAE at temperatures reflective of the proximal 
airways (32-33oC) and distal airways (37oC).  HAE were inoculated at either 32oC or 37oC 
with a low multiplicity of infection (MOI; 0.01) of a representative human virus, 
A/Victoria/3/75 (H3N2), or an avian influenza isolate, A/Dk/Eng/62 (H4N6).  Virus growth 
and spread throughout the epithelium at the two temperatures was measured and compared 
 89 
over time and infection further characterized with respect to virus-induced cytopathic effects 
(CPE).    
At the temperature of the distal airways (37oC), the growth kinetics and mean peak 
titers of A/Victoria/3/75 and A/Dk/Eng/62 reached 2.3x108 pfu/ml and 4.7x107 pfu/ml, 
respectively, by 48 hours post-inoculation (hrs pi) (Figure 1A).  At the temperature of the 
proximal airways (32oC), A/Victoria/3/75 showed a modest delay in replication but still 
reached maximal titer of 7.8x107 pfu/ml by 48 hrs pi.  In contrast, A/Dk/Eng/62 grew very 
slowly, with yields at time points up to 48 hrs pi reduced by 3 to 5 logs compared to growth 
for this virus at 37oC or A/Victoria/3/75 at either temperature.    
In comparison to 48 hr titers, A/Victoria/3/75 titers at both temperatures and 
A/Dk/Eng/62 titers at 37oC were reduced at 72 hr pi and every time point thereafter, 
indicating reduced progeny virus production.  A loss of titer was also observed for 
A/Dk/Eng/62 at 32oC, but not before 120 hrs pi.  To determine if loss of titer after reaching 
maximum levels correlated with increased CPE, we quantified adenylate kinase (AK) 
release by dead/dying cells into the apical compartment as a sensitive and global measure 
of cytotoxicity across the entire epithelial cell culture surface.  Figure 1B indicates that 
substantial increases in AK levels, indicative of the onset of CPE, are first detected at 48 hrs 
pi for A/Victoria/3/75 at 32oC and 37oC and A/Dk/Eng/62 at 37oC.  This induction of AK 
coincided with peak viral titer for these viruses under these conditions (compare Figure 1A 
and 1B) and suggested that the loss of titer correlated with the onset of CPE.  Increasing 
levels of AK between 48 and 96 hrs pi were directly associated with continually decreasing 
viral titers, further supporting this claim.    
  A relationship between the kinetics of virus growth in HAE and the level of CPE also 
suggested that CPE was a consequence of viral replication.  This assertion is supported by 
the fact that trends in viral titers at a given time point are mirrored in AK levels detected 48 
hrs later (e.g., compare viral titers at 48 hr pi (Figure 1A) to AK measurements taken at 96 hr 
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pi (Figure 1B)).  Since viral titer and AK levels could be related to the numbers of cells 
infected and/or the degree of virus replication within individual cells we compared titers of 
human and avian influenza viruses (Figure 1A) to the numbers of cells infected by each 
virus at the two temperatures over time.  Immunodetection of viral antigen in inoculated HAE 
showed that human and avian influenza virus antigen was not detected 3 hrs pi, indicating 
that levels of antigen in residual viral inocula were below the limit of antibody detection (data 
not shown).  For A/Victoria/3/75, a few isolated cells were positive for viral antigen by 6 hrs 
pi at 37oC, but by 24 hrs pi considerable numbers of antigen-positive cells were detected 
(Figure 2A).  In agreement with our growth curves in Figure 1A, A/Victoria/3/75 infected 
slightly fewer cells at 32oC compared to 37oC at 24 hrs pi, but importantly, A/Victoria/3/75 
spread efficiently within the epithelium at both temperatures and differences in infection at 
early time points became less significant over time (Figure 2A).   
In contrast to A/Victoria/3/75, A/Dk/Eng/62 antigen was detected in only a few cells 
24 hrs pi at either temperature.  However, it should be noted that antigen-positive cells in en 
face images are viewed linearly (Figure 2A) whereas viral titers are shown on a logarithmic 
scale (Figure 1A).  Thus, an apparently small difference in titer as is seen at 24 hrs pi 
between A/Victoria/3/75 and A/Dk/Eng/62 at 37oC may correspond to a larger difference in 
the number of cells positive for viral antigen.  While our staining also confirmed previous 
data that avian influenza viruses infect fewer human airway epithelial cells in comparison to 
human influenza virus at 37oC (Figure 2A; (312)), the limited extent of A/Dk/Eng/62 antigen 
positive cells at 37oC by 24hr pi was still unexpected given that titers at this time were 
slightly greater than those for A/Victoria/3/75 at 32oC.  Whether this represents a difference 
in yield of infectious virus per infected cell between human and avian viruses is presently not 
clear.  Overall, A/Dk/Eng/62 grew and spread well at 37oC, but was severely restricted for 
growth at 32oC and antigen positive cells were barely detectable before 48 hr pi for this virus 
at lower temperature.   
 91 
HAE cultures infected with A/Victoria/3/75 at either 32oC or 37oC and A/Dk/Eng/62 at 
37oC viewed en face exhibited loss of integrity of the epithelium although the extent of injury 
and time of onset varied (Figure 2A).  Further evaluation of histological cross-sections 
indicated that A/Victoria/3/75 infection at 37oC, which had the highest and earliest induction 
of AK, resulted in the earliest evidence of morphological injury at 72 hrs pi.  HAE infected 
with A/Victoria/3/75 at 32oC or 37oC or A/Dk/Eng/62 at 37oC all showed desquamation of the 
superficial layer of columnar epithelial cells with basal epithelial cells remaining attached to 
the matrix support by 120 hrs pi (Figure 2B). Similar cytopathology has been reported for 
A/Udorn/307/72 influenza virus infection of HAE in vitro and for clinical human influenza 
virus infection in vivo (121, 360).  The detection of AK in apical washes of A/Dk/Eng/62-
infected HAE at 32oC suggested that this virus did eventually compromise cellular integrity 
at the lower temperature, but dramatic morphological effects were not seen at least for up to 
120 hrs (Figure 1B and 2B).  It should be noted, however, that at 120 hrs pi, A/Dk/Eng/62-
infected HAE at 32oC did display some morphological characteristics different from 
uninfected and infected HAE at earlier time-points.  Preliminary assessment indicates that 
expansion of lateral spaces between the columnar epithelial cells had occurred.  Although 
we do not know the significance of these morphological changes, we speculate these 
observations are the initiation of CPE that will ultimately result in similar cellular injury as 
seen for this virus at 37oC and human viruses at both temperatures.   
In sum, for both viruses at both temperatures, detection of maximal numbers of 
antigen-positive cells correlated with high titers (compare Figure 1A and 2A) and increasing 
CPE (Figure 1B).  By 72 and 120 hrs pi considerable loss of cells from the culture was 
evident and this correlated with the drop off in viral titers at these time points (Figure 1A).  
Thus, we conclude that in the context of maximal infection in which there were no additional 
target cells available for infection within the finite surface area of the HAE culture, ongoing 
replication in antigen-positive cells shown at 48 and 72 hrs pi resulted in increased cell 
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death. This CPE led to a reduction in the number of viable, virus-producing cells and in turn, 
to a reduction in progeny virus.  Although A/Dk/Eng/62 induced CPE when sufficient titers 
were generated at 37oC, one consequence of restricted replication of this avian influenza 
virus at 32oC was a reduction in overt CPE in HAE, even at later time points associated with 
considerable viral titers.   
 
Avian influenza virus restriction at 32oC is independent of avian virus strain. 
To determine whether other avian, but not human, influenza viruses display 
temperature dependent phenotypes, we performed multi-step growth curves with more 
human H3N2 isolates (A/Eng/26/99 and A/Udorn/307/72) and A/Dk/Sing/97, an avian isolate 
of different subtype (H5N3).  Growth of both human-derived influenza viruses tested, 
A/Eng/26/99 (H3N2) and A/Udorn/307/72 (H3N2), was not significantly different between 
32/33oC and 37oC (Figure 3A and B).  Indeed, these two additional human influenza virus 
strains showed even less difference in titer between temperatures than was determined for 
A/Victoria/3/75.    
Assessment of growth of avian influenza virus, A/Dk/Sing/97 (H5N3), over a 48 hr 
time course at 37oC showed similar growth kinetics to that of A/Eng/26/99 (H3N2), reaching 
titers of 7x105 pfu/ml and 1.6x106 pfu/ml, respectively (Figure 3A and C).  In contrast, at 
32oC, A/Dk/Sing/97 (H5N3) failed to grow at all (Figure 3C). Clearly, the restriction of 
A/Dk/Sing/97 at 32oC compared to 37oC was an even more striking phenotype than 
A/Duck/Eng/62. As the avian influenza virus strains used in this study were selected at 
random, with no selection for a temperature-dependent phenotype, we propose that low 
temperature restriction of avian influenza viruses, but not human influenza viruses, may be 
broadly characteristic of avian influenza viruses.  The extent of restriction, however, may be 
variable between different virus strains.  
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Since the avian virus isolates used in these experiments are neither derived from 
samples obtained from humans nor passaged in human cells in vitro, we next investigated 
whether growth attenuation at low temperatures would be retained in a highly pathogenic 
H5N1 (A/VN/1203/04) influenza virus isolated from a fatal human case (174). We compared 
infection kinetics of H5N1 (A/VN/1203/04) at 33oC and 37oC on HAE using A/Udorn/307/72 
in parallel cultures as a human influenza virus control.  As described above, A/Udorn/307/72 
grew with similar kinetics at 33oC and 37oC (Figure 3B).  A/VN/1203/04, however, exhibited 
slower replication kinetics at 33oC when compared to that for 37oC (Figure 3D).  Indeed, 
titers were significantly decreased at 33oC vs. 37oC at 24, 48 and 72 hrs pi.  In addition, only 
at 37oC did A/VN/1203/04 approach similar peak titers as the human A/Udorn/307/72 virus 
by the end of the 72 hr time course (Figure 3D).  Histological analyses of A/VN/1203/04-
infected HAE at either temperature showed absence of obvious CPE in sharp contrast to 
A/Udorn/307/72 that obliterated the epithelium by 72 hrs pi (Figure 3E).  The lack of obvious 
CPE after H5N1 infection contrasts reports that H5N1 induced extensive apoptosis in 
mammalian airway cells (63, 159). The fact that we did not observe obvious CPE with this 
highly pathogenic virus warrants further investigation but is in line with the limited cell 
damage shown following infection with A/Dk/Eng/62 for 72 hrs (Figure 2B).  In sum, using 
diverse examples of human and avian influenza viruses we have shown that avian influenza 
viruses, but not human influenza viruses, are restricted for infection and growth in HAE at 
the lower temperature of 32oC. 
 
‘Avianization’ of human virus polymerase restricts growth in HAE at both 32oC and 
37oC.  
Previously, the polymerase subunit PB2 has been shown to play an important role in 
host range restriction of avian influenza viruses in mammalian cells (8, 302, 351).  In 
influenza virus strains that circulate in humans, amino acid residue 627 in PB2 is a lysine, 
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whereas in the majority of avian strains it is a conserved glutamic acid residue.  The 
presence of glutamic acid at PB2 627 (avian-like) has been reported to account for the lower 
replication of avian influenza strains in mammalian cells and has been linked with reduced 
polymerase activity at lower temperature (33oC) in some cell systems (109, 181).  To assess 
the potential impact of this PB2 amino acid residue in restriction of avian influenza viruses at 
32oC, we generated a recombinant A/Victoria/3/75 virus containing the PB2 K627E mutation 
and compared its growth with that of the isogenic wild-type virus in HAE at 32oC and 37oC.  
The K627E mutation resulted in restriction of the virus at both temperatures (Figure 4Ai), 
and although titer at 32oC was 1.3 logs lower than at 37oC at 24 hrs pi, this difference was 
no greater than the differences in growth for wild-type virus at these temperatures (1.5 logs; 
Figure 4Ai).  Moreover, at the later time points analyzed, 48 and 72 hrs pi, the PB2 mutant 
did not show a significant difference in titer between the two temperatures.  These data 
indicate that the K627E mutant virus was restricted for growth in HAE but that restriction was 
not temperature-dependent.  Indeed, quantification of the numbers of infected cells identified 
by en face staining revealed that the K627E mutant virus infected a similar percentage of 
cells compared to wild-type virus at 24 hrs pi (Figure 4Aii) and that the mutant was capable 
of spread since new cells were infected by 48 hrs with similar kinetics to that of wild-type 
A/Victoria/3/75 at both 32oC and 37oC (Figure 4Aii).  Statistically, there was no difference 
between the wild-type and PB2 mutant viruses at either 32oC or 37oC at 48 hrs pi with 
respect to percent influenza virus-antigen positive epithelium.  Together, these data suggest 
that the amino acid residue at PB2 627 influences viral fitness in HAE, but does not confer 
to a human virus the temperature-dependent phenotype of avian influenza virus infection in 
human ciliated airway epithelium. 
 
Human influenza viruses with avian-like glycoproteins display restricted replication 
and spread at 32oC in HAE. 
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Our initial phenotype indicated that A/Dk/Eng/62 was restricted in its ability to spread 
from cell to cell within the epithelium at 32oC (Figure 2A).  Several events in the viral life 
cycle that are critical for spread, including release of progeny virions from previously infected 
cells and attachment and entry into new target cells, are mediated by influenza virus 
glycoproteins.  Thus, we hypothesized that glycoprotein function could be responsible for 
the restricted infection of HAE by avian influenza viruses at the lower temperature of 32oC.  
To test whether HA and/or NA contributed to the restricted phenotype of avian influenza 
viruses at 32oC, we used reverse genetics to generate mutant viruses genetically altered to 
confer avian virus-like glycoprotein specificities on the A/Victoria/3/75 background.  First, 
mutations in HA previously shown to switch sialic acid usage from α2,6 to α2,3 linkages 
(L226Q, S228G) (328) were introduced to generate the Vic-226-228HA virus.  Second, we 
generated a reassortant virus in which the Victoria NA was replaced by that of the avian 
virus A/Chick/Italy/1347/99 to generate Vic + Chick N1.   
We again compared virus replication and spread of the recombinant viruses to that of 
wild-type A/Victoria/3/75 at the two temperatures.  As stated above, replication measured for 
the wild-type virus was slightly compromised at lower temperature, noticeable at 24 hrs pi.  
Restriction at this time point was also observed during infection of HAE with Vic-226-228HA, 
as it had been for the PB2 mutant virus.  Specifically, a 2.5 log decrease in virus growth was 
determined for Vic-226-228HA at 32oC compared to 37oC at the 24 hr time point (Figure 
4Bi).  However, unlike the PB2 mutant virus, the difference between replication at 32oC and 
37oC for Vic 226-228HA was also significant at the 48 hour time point.  Moreover, this 
mutant virus with avian virus-like sialic acid usage spread less efficiently than wild-type at 
32oC so that by 48 hrs pi the number of virus antigen-positive cells was significantly different 
(Figure 4Bii).  In contrast, at 37oC, Vic-226-228HA infected similar numbers of cells as the 
wild-type virus by 48 hrs; indeed, the mutant virus was able to spread significantly more 
efficiently at the higher temperature (Figure 4Bii).   
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Similarly, the reassorted virus Vic + Chick N1 displayed a 2 log decrease in viral titer 
in HAE at 32oC compared to 37oC at 24 hrs pi.  Although this difference was not appreciably 
greater than the difference in titer between temperatures for either wild-type virus or the PB2 
mutant, Vic + Chick N1, unlike wild-type A/Victoria/3/75 and Vic 627PB2, maintained the ~ 
2-log difference in growth at 48 hrs pi (Figure 4Ci), suggesting this virus was more restricted 
at the cooler temperature.  Quantification of numbers of infected cells illustrated that, like 
Vic-226-228HA, Vic + Chick N1 was restricted for spread at 32oC which was significant at 48 
hrs, but was capable of spread similar to wild-type A/Victoria/3/75 at 37oC (Figure 4Cii).  
Together these data suggest that avianizing either the HA or NA glycoprotein of an 
otherwise human influenza virus limits spread and subsequent infection at 32oC compared 
to 37oC.  
We next generated a recombinant influenza virus containing both the 226-228HA 
and Chick N1 and tested infection and growth in HAE at 32oC and 37oC in comparison to 
wild-type A/Victoria/3/75.  At 24 hrs pi, the double glycoprotein-altered virus exhibited similar 
restriction as observed for the other viruses.  Nonetheless, an overall evaluation of the 
double glycoprotein-altered virus suggested that as infection proceeded, this virus was 
profoundly restricted at 32oC compared to 37oC (Figure 4Di), exhibiting > 2 log reduction in 
titer at 48 hrs.  Notably, titers for the wild-type virus differed by less than 0.5 logs between 
temperatures at this time point.  Furthermore, the double glycoprotein-altered virus was still 
significantly restricted at 72 hrs pi when titers at 32oC were compared to those at 37oC.  The 
level of restriction observed for the double mutant was greater than that observed for either 
virus containing each of these mutations/substitutions individually.  Moreover, analysis of 
viral antigen positive cells at 72 hrs by en face staining of infected HAE indicated 
compromised spread of Victoria (226-228HA) + Chick N1 which was more severe at 32oC 
than 37oC (Figure 4Dii).   
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Determination of CPE during these experiments revealed that the double 
glycoprotein-avianized virus only produced CPE at 72 hrs pi when experiments were 
performed at 37oC, whereas wild-type human virus produced CPE earlier and at both 
temperatures (data not shown). These data are consistent with the levels of CPE observed 
for A/Dk/Eng/62 (H4N6) and A/Victoria/3/75 (H3N2) in our initial studies (Figure 1B) and 
suggest that altering the human virus glycoproteins to avian virus-like characteristics has 
profound effects on infection, spread and CPE in the environment of the human ciliated 
airway epithelium.  
 
Avian influenza virus glycoproteins dictate cell tropism and restrict growth of virus in 
HAE at 32oC.  
One potential caveat of the recombinant viruses with avianized HA and/or NA utilized 
in our previous analysis was that they contained HA and NA pairs that had not co-evolved.  
To eliminate the possibility that the restriction we observed with these recombinant viruses 
was due to an imbalance between the activities of the surface glycoproteins that were not 
evolutionarily optimized, we next generated reassorted influenza viruses on a common 
genetic background, possessing human or avian glycoproteins with co-evolved pairings. 
This was achieved using human recombinant A/PR/8/34 (H1N1) in which the wild-type H1 
and N1 glycoproteins were replaced by the H3 and N2 glycoprotein pair from A/Victoria/3/75 
(generating PR8 + Vic HA/NA) or the H7 and N1 glycoprotein pair from 
A/Chick/Italy/1347/99 (generating PR8 + Chick HA/NA, previously termed RD3) (343).  
Since we and others have shown differential cell-type tropism between human and avian 
influenza virus in HAE (186, 312), we next determined if avianizing the human virus HA by 
mutation or substitution (in the presence or absence of an avian NA) recapitulated the cell-
type tropism exhibited by wholly avian influenza viruses in HAE.  As shown by 
immunofluorescent detection in histological sections of infected HAE, PR8 containing 
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A/Victoria/3/75 glycoproteins infected both ciliated and non-ciliated cells in HAE with a 
tropism similar to wild-type A/Victoria/3/75 (Figure 5).  In contrast, A/Victoria/3/75 with two 
avian-like amino acid substitutions in HA and PR8 + Chick HA/NA only infected ciliated cells, 
a tropism that was mirrored by wholly avian virus (186, 312).  These data clearly show that 
the ciliated cell tropism of avian influenza viruses is dictated by properties of the viral 
glycoproteins.  These results correlate with the known increased sialic acid binding 
preference of avian HA for α2,3-linked SA, and to the presence of α2,3-linked SA on ciliated 
cells in HAE (185, 186, 312).    
Growth kinetics in HAE of PR8 + Vic HA/NA and PR8 + Chick HA/NA inoculated at 
equal MOI (0.01) revealed that PR8+Vic HA/NA infection and growth was efficient at both 
32oC and 37oC (Figure 6A).  PR8 + Chick HA/NA grew at 37oC to identical titers as PR8+Vic 
HA/NA at 32oC recapitulating our data obtained for wholly human (A/Victoria/3/75) and 
wholly avian (A/Dk/Eng/62) viruses.  In contrast, PR8 + Chick HA/NA was severely delayed 
in growth at 32oC and generated titers that were >2 logs less than titers obtained for this 
virus at 37oC at both 24 and 48 hrs pi.  Indeed, PR8 + Chick HA/NA, like A/Dk/Eng/62 avian 
influenza virus (Figure 1A), was significantly restricted for growth at 32oC at 12, 24 and 48 
hrs pi compared to growth at 37oC and growth of PR8 + Vic HA/NA at either temperature.    
As observed for wholly human and avian influenza viruses, peak titers were reached 
for PR8 + Vic HA/NA at both temperatures and PR8 + Chick HA/NA at 37oC by 48 hrs pi 
after which a decline in viral titer was apparent.  Again, as noted in our observations with 
human and avian influenza viruses, the loss of viral titers with time correlated with the onset 
of CPE.  While PR8 + Chick HA/NA infection at 32oC did not result in substantial AK release 
until 96 hr pi, increased AK activity was detected in cultures inoculated with this virus at 
37oC.  AK activity measured in cultures at this temperature increased with similar kinetics 
and reached similar levels as AK measured in cultures inoculated with PR8 + Vic HA/NA at 
either temperature.  Furthermore, the kinetics of AK induction demonstrated that again, AK 
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was consequential to viral replication and that, overall, CPE induced by reassortant viruses 
was reflective of CPE measured for human and avian influenza viruses.    
En face staining of HAE at 24 hr intervals after inoculation showed PR8 + Chick 
HA/NA spread to additional target cells at 37oC at a rate similar to that of PR8+Vic HA/NA at 
32oC and correlated with the titers measured for these two viruses under those conditions 
(Figure 6C and D).  At 32oC, however, PR8 + Chick HA/NA spread was severely 
compromised and resembled the infection characteristics shown for A/Dk/Eng/62 (H4N6) in 
Figure 2A.  Thus, by replacing human glycoproteins with those from an avian virus isolate, 
we have recapitulated the effect of temperature on infection and growth kinetics as well as 
the degree of cytotoxicity produced by wholly avian influenza virus interactions in human 
ciliated airway epithelium.  The relative contributions of reduced cell-cell spread and 
reduced CPE by avian-like influenza viruses at temperatures of the proximal airways to in 
vivo infection and pathology will, however, require further investigation. 
 
 
DISCUSSION 
We have performed comparative studies of the infection kinetics of human and avian 
influenza viruses in a model of human ciliated airway epithelium at temperatures reflective of 
the human proximal and distal airways.  Our data show that avian and avianized influenza 
viruses are restricted for infection and growth in HAE at 32oC but not 37oC, while human 
viruses infect and grow efficiently at both temperatures. Based on these data, we suggest 
that while the warmer temperatures of the distal airways enable comparable infection by 
both human and avian influenza viruses, the cooler temperatures of the human proximal 
airways only support efficient and robust infection of the ciliated airway epithelium by human 
influenza viruses.  We speculate that the observed restriction for avian and ‘avianized’ 
viruses in HAE would render avian influenza viruses more susceptible to innate and 
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adaptive immune responses that limit pathogenicity in vivo.  These results have significant 
impact on our understanding of why avian influenza viruses rarely undergo zoonotic 
transmission and why, when the rare human case does occur, that avian influenza virus 
infection and pathology manifest predominately in the warmer distal airways and lungs.   
The inability of avian influenza viruses to replicate efficiently at cooler temperatures 
has been linked to the viral polymerase subunit, PB2 (109, 181).  In the present study, 
mutating position 627 in a human virus PB2 to an avian virus conserved residue resulted in 
growth restriction at both 32oC and 37oC, suggesting that this residue is important for 
general viral fitness in HAE, but is not responsible for the differences in infection seen at 
32oC vs. 37oC.  Two recent reports also found that viruses with 627E in PB2 were 
attenuated regardless of temperature in human bronchial epithelial cells and MDCK cells, 
respectively, although in other cell systems including human small airway epithelial cells, a 
temperature specific effect was found (109, 297).  It should be emphasized that those 
studies were performed in non-differentiated epithelial cells unlike our studies that use 
human differentiated airway epithelial cells.  We and others have previously shown that 
differentiated airway epithelial cell models enable discrimination of attenuated phenotypes of 
respiratory virus infection whereas non-differentiated cells do not (22, 23, 348).  In addition, 
we also show using HAE, that the H5N1 strain A/VN/1203/04, which possesses a lysine at 
position 627 (human adaptation), is still restricted for growth at 32oC, albeit less so than 
avian influenza viruses that have never infected humans.  The attenuation in HAE of this 
H5N1 isolate which possesses a “human” amino acid at residue 627 in PB2 suggests other 
residues in the polymerase subunit or other viral proteins altogether are involved in 
temperature sensitivity of avian influenza viruses. 
In our initial experiments, spread of avian influenza viruses from cell to cell at 32oC 
was compromised in cultures inoculated at low MOI, suggesting a potential role for the 
envelope glycoproteins, HA and NA, in mediating temperature restriction.  Previous work by 
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Kaverin and colleagues also demonstrated temperature effects on growth of human-avian 
reassortant viruses containing avian glycoproteins (141), although this work was performed 
in non-polarized MDCK cells and did not investigate additional correlates of infection such 
as spread and CPE.  In our study, we generated recombinant influenza viruses based on 
the A/Victoria/3/75 or A/PR/8/34 genetic backbone that were engineered to contain avian-
like and/or avian glycoproteins and characterized infection in HAE.  Kinetic studies showed 
that although human influenza viruses that possessed avian or avian-like surface 
glycoproteins were modestly restricted compared to wild-type viruses at 37oC, these mutant 
viruses were able spread like wild-type viruses throughout HAE at this temperature.  Wide-
spread infection throughout HAE was even observed for viruses in which their endogenous 
HA was replaced or mutated to preferentially bind α2,3 SA, restricting tropism to ciliated 
cells.  Efficient replication of Vic-226-228HA at 37oC in our studies corroborates previous 
work by Matrosovich and colleagues in which little effect of HA-specificity ‘switching’ on 
replication was noted unless a very low MOI (0.00004) was used for inoculation (182).  In 
contrast, Wan and Perez described more profound differences in replication in HAE at 37oC 
with recombinant viruses that differed only in their receptor specificity (331).  However, it 
should be noted that their recombinant viruses were based on an H9N2 avian strain that 
yielded relatively low titers, and their initial infections were performed at 35oC before 
incubating at 37oC (331).  
Compared to 37oC, viruses with a preference for binding to α2,3 SA, including Vic-
226-228HA, were restricted for growth and spread in HAE at 32oC.  Notably, the H5N1 strain 
examined in this study also maintains preference for α2,3 SA binding (353); thus, we may 
surmise that this characteristic of A/VN/1203/04 contributes to its attenuation observed in 
HAE.  The contribution of α2,3 SA usage to replication of influenza viruses investigated by 
Hatta et al. in the upper respiratory tract of mice may have been masked in the mouse 
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model (the 627 mutation in PB2 being more apparent) as mice express solely avian virus-
like receptors (α2,3 SA) in their airways (109, 124).   Restriction of α2,3 SA-binding viruses 
in HAE at 32oC was not due to a discrepancy in SA expression since HAE maintained at 
either 32oC or 37oC expressed similar levels of α2,6 and α2,3 SA (as detected by Sambucus 
nigra (SNA) and Maackia amurensis (MAA) lectin staining, respectively; data not shown). 
In conjunction with the HA, the sialidase activity of NA is crucial for successful virus 
penetration of mucus layers for initial infection and subsequent release of progeny virions 
from infected cells (97, 187).  This is especially critical both in vivo and in HAE models in 
which the luminal epithelial cell surface is robust with glycoconjugates displaying abundant 
terminal sialic acid moieties that may act as false receptors for influenza viruses (300).  
Using standard laboratory assays that employ small monovalent soluble substrates for 
cleavage by NA (MUNANA), we were not able to demonstrate any temperature-dependent 
loss of NA activity associated with either human or avian virus (data not shown).  However, 
the ability of the avian virus NA to cleave biologically relevant substrates present in HAE 
may be compromised at 32oC vs. 37oC restricting both initial infection and subsequent 
spread of the virus throughout the epithelium.  This is supported by our data which 
demonstrate restricted growth and spread of reassortant viruses containing avian virus NA, 
including Vic + Chick N1 and PR8 + Chick HA/NA in HAE at 32oC.   
In addition to their independent functions, the balance between the binding affinity of 
the viral HA and the sialidase activity of the NA is also critical for efficient infection.  The 
ability of A/Victoria/3/75 viruses with mutations or substitutions in either the HA or NA alone 
to infect similar numbers of cells and replicate to comparable peak titers as for wild-type 
virus at 37oC implies that these viruses were not crippled by the mismatch between the 
specificities of their HA and NA.   Replication and spread of influenza viruses that possess 
an avian HA paired with its “matched” NA was even more compromised than that of 
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recombinant viruses with individual changes to levels seen with wholly avian viruses. Thus, 
viruses with co-evolved glycoprotein pairs exhibit restricted replication at low temperatures 
and both HA and NA genes contribute to the phenotype.  
Together, these data imply that in the complex environment of the luminal surface of 
the human ciliated airway epithelium, the viral surface antigens have a marked effect on the 
extent of virus infection and that temperature plays an important role in limiting avian, but 
not human, influenza virus infection and spread in the cooler proximal airway regions. Given 
these results, we draw attention to other recently published data using the HAE model in 
which mutations in viruses that are growth attenuated in vivo display similar growth 
attenuation in HAE but not in non-differentiated cell lines, suggesting that HAE possess 
discriminating properties of attenuating phenotypes of mutants of respiratory viruses (22, 
23).  Admittedly, in the present study, despite restriction in both growth and spread, wild-
type avian viruses and human viruses with avian or avian-like glycoproteins did eventually 
reach high titer at 32oC at later time points.  The efficiency of infection and replication of a 
virus that inoculates the airway epithelium, however, is likely a critical factor in determining 
whether the virus is capable of establishing infection in a host that normally possesses 
innate and adaptive immune systems that attempt to limit virus infection and spread.  At 
temperatures of the distal airways, avian influenza viruses displayed similar infection kinetics 
as human influenza viruses and would therefore, in the case of sufficient inoculum reaching 
these distal regions, be as likely to establish infection.  Indeed, the clinical pathology 
findings for humans infected with H5N1 do report distal airway infection in ciliated 
bronchioles and lung regions (320).  Under these conditions of inoculation and infection, 
avian influenza viruses present in the distal airways may still be unable to spread to 
proximal airway regions without additional adaptation to cooler temperatures. One caveat of 
this prediction is that virus may be transported to proximal airway regions by innate mucus 
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clearance mechanisms indicating that caution is required when attempting to identify 
proximal infection by viruses in airway secretions obtained from tracheal swabs.   
In conclusion, the present study substantiates differential host temperature as a 
critical barrier for infection by avian influenza viruses.  Since the ciliated airway epithelium of 
the proximal airways is a major portal for influenza virus infection and spread, accessible by 
multiple inoculation routes (e.g., ocular, nasopharyngeal or aerosol), the inability of avian 
influenza viruses to establish infection and spread in these regions would be predicted to 
reduce the frequency of successful zoonotic transmission.  Furthermore, the ability of human 
influenza viruses to generate high viral titers in the human proximal airways is likely a factor 
in effective human-to-human transmission and the induction of airway epithelial cell 
cytotoxicity as shown in this study may increase particulate matter perhaps associated with 
virus that facilitates inoculation of new hosts.  Rapid induction of cytotopathic effects by 
human, but not avian, influenza virus infection at the temperature of the human proximal 
airways may also contribute to the onset of other host defenses such as sneezing and 
coughing that facilitate clearance of particulate matter/virus from the airways and potentially 
promote transmission between human hosts.  
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Figure 1. Infection of HAE by avian, but not human, influenza viruses is restricted at 
temperatures of the proximal airways.  A) Comparison of multi-cycle virus growth in HAE 
inoculated with either A/Victoria/3/75 at 32oC (closed triangles) or 37oC (open triangles) and 
A/Dk/Eng/62 at 32oC (closed circles) or 37oC (open circles) both at MOI~0.01.  Apical viral 
titers at times shown were determined by standard plaque assay on MDCK cells.  Data 
shown represents the mean titer +/- standard error (SE; n=3-10 cultures).   B) Adenylate 
kinase activity released into the apical compartment of HAE over time after inoculation with 
A/Victoria/3/75 or A/Dk/Eng/62 at 32oC and 37oC as a measure of viral-induced CPE.  Data 
shown represents the mean fold change over adenylate kinase activity derived from mock-
inoculated HAE +/- SE (n=3-8).  Significance is noted (*p<0.05) where viral titers or AK 
levels obtained for A/Dk/Eng/62 at 32oC were statistically different from all other titers/AK 
measurements (Dk/37oC, Vic/32oC and Vic/37oC) at that particular time point. Significance is 
noted (†p<0.05) where AK levels obtained for A/Dk/Eng/62 at 32oC and 37oC were 
statistically different.  
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Figure 2.  Spread and histopathology of avian and human influenza viruses in HAE at 
temperatures of the proximal and distal airway.   A) Representative en face 
photomicrographs of HAE inoculated with either A/Victoria/3/75 or A/Dk/Eng/62 at 32oC or 
37oC, fixed at 6, 24, 48 and 72 hrs pi and stained for viral nucleoprotein (green) to determine 
numbers of cells infected.  Scale bar equals 100µm.  B) Representative histological cross-
sections of HAE at 24, 72 and 120 hrs after inoculation with A/Victoria/3/75 or A/Dk/Eng/62 
at 32oC or 37oC.  H&E counterstain. Scale bar equals 20µm.         
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Figure 3. Temperature-dependent growth of different serotypes of influenza viruses in 
HAE.  Multi-step growth kinetics of (A) human influenza virus A/Eng/26/99 or (C) avian 
influenza virus A/Dk/Sing/97 (MOI~ 0.1) at 32oC (open circles, dashed line) or 37oC (closed 
circles, solid line) in HAE +/- SE (n=3 cultures).  Multi-step growth kinetics in HAE inoculated 
with an MOI ~ 0.03 of (B) A/Udorn/307/72 (H3N2) or (D) A/VN/1203/04 (H5N1) at 33oC 
(open circles, dashed line) or 37oC (closed circles, solid line).  Data represents mean titer 
across two different donors, each performed in duplicate +/- SE.  Viral titers were 
determined by plaque assay in A and B and by TCID50 assay for C and D.  No significant 
differences in growth between temperatures were found for either A/Eng/26/99 or 
A/Udorn/307/72.   A/VN/1203/04 was significantly restricted for growth at 24, 48 and 72 hrs 
pi (*p<0.05).    E) Representative histological cross-sections of HAE infected for 72 hrs at 
37oC with A/Udorn/307/72 or A/VN/1203/04 and compared to mock-inoculated HAE.  H&E 
counterstain. Scale bar equals 20µm.    
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Figure 4. Comparison of replication kinetics and spread of A/Victoria/3/75 with an 
avianized PB2, HA and/or NA to wild-type virus.  Multi-step growth kinetics in HAE 
inoculated with (Ai) PB2 polymerase mutant (K627E), (Bi) HA (L226Q, S228G) mutant, (Ci) 
Vic + Chick N1 reassortant virus, (Di) Vic (226-228)HA + Chick N1 at 32oC (solid line, closed 
circles) or 37oC (solid line, open circles).  Wild-type A/Victoria/3/75 growth curves at 32oC 
(closed triangles) and 37oC (open triangles) are repeated in each panel and shown as 
dotted lines in Ai, Bi, Ci and Di for comparison.  Data represent mean titer across 3-8 
cultures +/- SE. Significance is noted (*p<0.05) where viral titer obtained for the mutant or 
reassortant virus at 32oC was statistically different from all other viral titers (mutant/37oC, 
wild-type/32oC and wild-type/37oC) at that time point.  Significance is noted (†p<0.05) where 
viral titers obtained for the mutant / reassortant virus at 32oC and 37oC were statistically 
different. Quantification of numbers of cells infected (determined by en face staining for viral 
nucleoprotein) in HAE at 24 and 48 hrs pi at 32oC and 37oC for (Aii) PB mutant virus, (Bii) 
HA mutant virus and (Cii) N1 reassortant virus.  Data obtained in parallel for wild-type 
A/Victoria/3/75 is repeated in each graph (striped bars) for comparison to the mutant (solid 
bars).  Data shown represents the mean of the percentage of influenza virus antigen-
positive epithelium across 10 different fields +/- SE.  Differences in viral antigen positive 
epithelium between temperatures for each virus at 48 hrs pi is noted as significant (*p<0.05) 
or insignificant (NS).  A one-way ANOVA model showed no significant differences between 
the wild-type virus and PB2 mutant at 32oC and 37oC at 48 hrs pi.  Dii) Representative en 
face photomicrographs of HAE inoculated with A/Victoria/3/75 or Vic (226-228)HA + Chick 
N1 at either 32oC or 37oC and stained for viral nucleoprotein (green) to determine numbers 
of cells infected 72 hrs pi.  Scale bar represents 100µm.   
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Figure 5. Cell tropism of human, avian and avianized viruses in HAE.  Representative 
cross-sections of inoculated HAE, fixed 24 hrs pi, were probed for viral antigen (NP; green) 
and α-acetylated tubulin, a marker for ciliated cells (red).  Notably, the staining pattern for 
wild-type A/Victoria/3/75 was identical to that of PR8 + Vic HA/NA.  Arrows mark ciliated 
cells infected with either wild-type A/Victoria/3/75 or PR8 + Vic HA/NA; arrow-head denotes 
non-ciliated cells infected by these viruses.  These data indicate that viruses with Victoria 
glycoproteins were able to infect both cell types previously shown by Thompson et al. to 
express α2,6 SA.  Viral antigen was detected only in ciliated cells in cultures inoculated with 
Vic-226-228HA (in the Victoria background with either endogenous N2 or avian N1 or PR8 + 
Chick HA/NA.  Scale bar equals 20µm.   
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Figure 6.  Temperature restriction of avian influenza viruses at 32oC can be mimicked 
by inserting avian envelope glycoproteins into human influenza viruses.  A) Multi-step 
growth kinetics initiated in HAE over time with PR8 + Vic HA/NA at 32oC (closed triangles) or 
37oC (open triangles) and PR8 + Chick HA/NA at 32oC (closed circles) or 37oC (open 
circles) in HAE.  Apical viral titers were determined at the times shown by standard plaque 
assay.  Data shown represents mean titer across 4-8 cultures +/- SE.  B) Adenylate kinase 
activity in apical washes of virus-infected HAE expressed as fold-change over adenylate 
kinase activity in mock-inoculated HAE +/-SE (n=4-8).  Significance is noted (*p<0.05) 
where viral titers or AK levels obtained for PR8 + Chick HA/NA at 32oC were statistically 
different from all other titers/AK measurements (Chick/37oC, Vic/32oC and Vic/37oC) at that 
particular time point.  Significance is noted (†p<0.05) where AK levels obtained for PR8 + 
Chick HA/NA at 32oC and 37oC were statistically different.  C & D) Representative en face 
photomicrographs of viral nucleoprotein immunoreactivity (green) in HAE inoculated with (C) 
PR8 + Vic HA/NA or (D) PR8 + Chick HA/NA at 24, 48 and 72 hrs pi at 32oC (lower rows) or 
37oC (upper rows).   
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ABSTRACT 
 Human influenza A viruses bind to α2,6-linked sialic acids to mediate infection of the 
ciliated airway epithelium.  The identity of the underlying host glycoconjugates that present 
relevant sialic acids to the virus in the context of infection, however, has remained elusive 
despite their potential to influence pathogenesis.  In this study, we provide evidence for a 
direct interaction between the human influenza virus attachment protein, hemagglutinin 
(HA), and a specific host sialylated protein, tethered mucin 1 (MUC1), isolated from human 
airway epithelium in vitro.  The presence of α2,6-linked sialic acid in association with MUC1 
and the abundance of this mucin at the apical surface of epithelial cells suggests this 
interaction is likely to occur in the context of infection and supports the hypothesis that this 
mucin influences influenza virus pathogenesis.  To determine the role of MUC1 during 
influenza virus infection, we generated an in vitro model of human airway epithelium that 
had reduced levels of MUC1 expression (MUC1kd HAE).  Infection of MUC1kd HAE with a 
human influenza virus, A/Victoria/3/75 (H3N2) was reduced while anti-viral and pro-
inflammatory cytokine levels were either unchanged or enhanced above those in control 
HAE.  Subsequent in vivo analysis in mice genetically deleted for Muc1 (Muc1-/-) 
demonstrated reduced morbidity which correlated with lower titers in the lungs of infected 
animals compared to wild-type control mice.  Together, these data suggest that MUC1/Muc1 
facilitates influenza virus infection, although the mechanisms by which this occurs in the 
environment of the human airway epithelium remain to be determined.   
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INTRODUCTION 
Influenza A viruses possess a hemagglutinin (HA) attachment protein that binds 
terminal sialic acid residues on underlying host molecules to mediate infection of target 
epithelial cells in the human respiratory tract.  Use of sialic acid to facilitate infection is a 
well-established characteristic of all influenza A viruses, and specific utilization of sialic acid 
in an α2,6-linkage is advantageous for influenza viruses infecting the human host, 
evidenced by the fact that all pandemic influenza viruses and influenza viruses that have 
become endemic in the human population exhibit α2,6 usage (183, 317).  Recent reports 
have focused on further defining the nature of particular sialic acid residues used by 
influenza viruses and indicate that interaction is also determined in part by glycan topology 
at the cell surface (48).  Still, despite this degree of HA specificity, sialic acid is an abundant 
sugar molecule that is terminally linked to numerous glycolipids and glycoproteins 
throughout the human airway and the requirement of the viral sialidase for efficient initial 
infection and spread throughout the epithelium suggests that not all HA-sialic acid 
interactions benefit the virus (187).  Furthermore, the relevant underlying molecules that 
present sialic acids to the virus in the human respiratory tract have been largely ignored 
despite their potential to influence viral pathogenesis. 
Recently, we identified vesicle-like structures, termed “exosomes” in HAE secretions 
and demonstrated their ability to inhibit influenza virus infection of MDCK cells (145).  This 
inhibition was sialic acid-dependent and specific for influenza virus, as neither parainfluenza 
virus nor respiratory syncytial virus were inhibited by exosomes (145).  Proteomic analysis of 
HAE-derived exosomes identified human airway mucin 1 (MUC1) as one of the proteins 
associated with these vesicle-like structures and further analysis showed an abundance of 
α2,6-linked sialic acid in MUC1-containing exosome fractions (145), suggesting influenza 
virus could potentially interact with this host mucin glycoprotein.   
 116 
Airway mucins may be either secreted from (gel-forming) or tethered to the apical 
membrane of epithelial cells (258).  MUC1 is the most abundant and well-characterized of 
the tethered mucins identified in the human respiratory tract (which also includes MUC4 and 
MUC16) (64, 110, 241).  Specifically, MUC1 is present in nasal, tracheobronchial, 
bronchiolar and alveolar epithelial tissues in humans and is highly expressed on the apical 
surface of human ciliated airway epithelium (HAE) in vitro (262, 300).   Collectively, mucins 
are critical for normal lung function through the lubrication and hydration of the airway, as 
well as by trapping particulate matter and pathogens for removal via mucocilliary clearance 
or presentation to immune cells (92, 110).  MUC1 is structurally well-suited for these 
functions as a large molecule (with a 200 kDa extracellular domain) containing a variable 
number of tandem repeats, each with numerous potential O-glycosylation sites (110, 294).  
This glycosylation accounts for up to 50-90% of total mucin mass and likely mediates 
interactions with a diverse array of airway pathogens that bind these carbohydrate moieties 
(110).          
The role of specific tethered mucins, including MUC1 (denotes human gene, Muc1 
denotes murine gene), in viral infection of the human respiratory tract is not well defined.  
Previous work from our laboratory has shown that gene delivery to the airway epithelium by 
adenovirus is more efficient in a mouse model genetically deleted for Muc1 (Muc1-/-), 
indicating a restrictive role for Muc1 in adenovirus infection (300).  In contrast, Sendai virus 
(mouse parainfluenza virus 1), which uses sialic acid residues to mediate infection, was less 
infectious in the airways of Muc1-/- mice (unpublished data), suggesting that deletion of 
Muc1 has virus-specific consequences.  Outside of the airway, several studies have 
investigated the role of MUC1 isolated from human or bovine breast milk on viral infection. 
Purified MUC1 inhibits infection by human immunodeficiency virus (HIV) (105), and rotavirus 
(158) as well aggregating poxviruses (106) and preventing binding of Norwalk virus capsid 
proteins (260).  
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In this study, we investigated the potential interaction between influenza virus and 
MUC1 and characterized the role of MUC1 in influenza virus pathogenesis.  The role of 
MUC1 in the pathogenesis of a given agent may be attributable to MUC1’s physical traits 
(location, size, glycosylation) and/or its signaling properties.  MUC1-mediated signaling 
occurrs through the cytoplasmic tail which interacts with both kinase and non-kinase 
proteins, resulting in the downstream modulation of transcription factors such as NFκB (46, 
332).  This activity has recently been shown to negatively regulate toll-like receptor signaling 
and supports a role for MUC1 in the inflammatory cytokine response to infection (300, 319).   
While it is clear that human influenza A viruses can successfully penetrate the 
mucosal layer to infect the upper and lower respiratory tract in vivo and replicate to high titer 
in HAE in vitro (312, 334), interaction between influenza viruses and specific host mucin 
glycoproteins has not been well defined and has thus far focused only on the secreted 
mucins (342).  Here, we provide evidence that influenza virus HA can bind to human MUC1.  
These data, in combination with evidence that MUC1 contains α2,6-linked sialic acids (145), 
is abundant on the airway surface, and is localized to microvilli structures on epithelial cells, 
support a direct interaction between this virus and host mucin protein in the context of the 
airway epithelium.  In addition, using both well-differentiated cultures of human ciliated 
airway epithelium (HAE) knocked down for MUC1 and mice genetically deleted for Muc1, we 
show that MUC1 may facilitate influenza virus infection through multiple mechanisms.    
 
 
MATERIALS AND METHODS 
MUC1 immunoprecipitation 
 MUC1 antibodies (B2729 and 115D8, gifts from Fujirebio Diagnostics Inc.) were 
conjugated to aldehyde/sulfate latex beads (Invitrogen, Carlsbad, CA).  Following incubation 
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with anti-MUC1 antibody, beads were incubated with 1M glycine and 0.5% BSA to coat any 
remaining exposed area and prevent non-specific binding of protein during 
immunoprecipitation.  Exosomes, isolated from HAE apical secretions as previously 
described (145), were pre-treated with 1% triton-X before mixing with anti-MUC1-conjugated 
beads.  Following overnight incubation at 4oC, the exosome-bead mixture was washed and 
resusended in 7M urea and SDS-PAGE containing reducing agent.  Exosomes (not mixed 
with beads) were also resuspended in urea/SDS-PAGE buffer.  Samples were then 
vortexed, boiled, and loaded into a 1% agarose gel for electrophoresis and subsequent 
transfer to nitrocellulose membranes.  Membranes were blocked with 5% milk/TBST before 
incubating with primary antibodies (anti-MUC1 (B2729; 1:2000), rH3-Fc (a gift from Dr. 
Wendy Barclay, Imperial College London; 1:1000), and anti-MUC16 (OC125, Cell Marque, 
Rocklin, CA; 1:2000)).  rHA proteins were generated by infection of insect cells with a 
recombinant baculovirus expressing the protein as previously described (18).  Membranes 
probed with rH3-Fc were subsequently probed with biotin-SP-conjugated AffiniPure goat 
anti-human IgG (Jackson ImmunoResearch; 1:2000).  Immunodetection was performed 
using infrared dye-labed secondary antibodies (IRDye 800CW goat anti-mouse IgG, IRDye 
680 goat anti-rabbit IgG or IRDye 680 streptavidin; LI-COR Biosciences; each at 1:10,000) 
and visualized using a Li-Cor Odyssey Infrared Imaging System according to the 
manufacturer’s protocol (Li-Cor Biosciences, Lincoln, NE).        
 
Generation of lenti-shRNA transduced HAE 
Vesicular stomatitis virus (VSV)-G pseudotyped lentiviral vector particles were 
generated in 293T cells stably expressing αVβ3 integrin by calcium choride transfection of 
the packaging construct, CMVp8.41, the VSV-G producing construct, pMD.G, and shRNA 
expression vector, pLKO.1 (provided by the University of North Carolina (UNC) Lenti-shRNA 
Core Facility).  Lentivirus-containing supernatants were harvested at 24 and 48hrs post-
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transfection, clarified by brief centrifugation and virus subsequently concentrated via 
ultracentrifugation.  Human airway tracheobronchial epithelial cells isolated from airway 
specimens from patients without underlying lung disease were provided by the National 
Disease Research Interchange (NDRI, Philadelphia, PA) or as excess tissue following lung 
transplantation under UNC Institutional Review Board-approved protocols by the UNC 
Cystic Fibrosis Center Tissue Culture Core.  Primary cells derived from single patient 
sources and expanded once on plastic were transduced with either lentivirus expressing 
shRNA against green fluorescent protein (GFP) or against human MUC1 (Open Biosystems, 
Inc.).  The hairpin-containing sequence for MUC1 was: 
CCGGGACACAGTTCAATCAGTATAACTCGAGTTATACTGATTGAACTGTGTCTTTTTG.  
Additional cells were plated, but not tranduced, in order to provide a control for antibiotic 
selection.  Selection was performed using 0.75-0.9 µg/ml puromycin, after which cells were 
plated on permeable Transwell-Col (12mm diameter) supports (Corning, Inc.).  Cells were 
maintained in custom media containing puromycin for the first two weeks of growth and 
cultures were used in experimental protocols after a total of 4 weeks, allowing for provision 
of air-liquid interface and generation of differentiated, polarized cultures that resemble in 
vivo pseudostratified mucociliary epithelium, as previously described (238).   
 
Viruses 
 Recombinant influenza viruses A/PR/8/34 (H1N1) and A/Victoria/3/75 (H3N2) were 
generated from cloned cDNA in 293T and Madin-Darby Canine Kidney (MDCK) cell co-
cultures as previously described (72, 214).   
     
Viral inoculation and growth in HAE 
 HAE were rinsed with PBS to transiently remove apical secretions and supplied with 
fresh basolateral medium prior to inoculation.  Virus inoculum was diluted in PBS and 
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applied to the apical surface of HAE for 1 (low MOI experiments) or 2 (high MOI 
experiments) hrs at 37oC.  Following incubation, viral inocula were removed and cultures 
incubated at 37oC for the duration of the experiment.  Viral growth was determined by 
performing apical washes with 300µl of serum-free DMEM for 30min at 37oC. Washes were 
harvested and stored at -80oC prior to analysis.  Viral titers in the apical washes were 
determined by standard plaque assay on MDCK cell monolayers as previously described 
(72, 90, 312).    
 
En face staining and histology 
 Twenty-four hours post-inoculation (either at low or high MOI), HAE were fixed in 
cold methanol:acetone (50/50) and stored at 4oC.  Cultures were then permeablized with 
2.5% triton-X 100/PBS++ (containing 1mM CaCl2 and 1mM MgCl2) and blocked with 3% 
bovine serum albumin (BSA) in PBS ++ before being probed with mouse anti-influenza virus 
nucleoprotein (NP; Chemicon, Inc.; 1:100) and immunoreactivity detected with fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., 1:500).  En face staining for MUC1 was performed on 
live HAE cultures.  In this case, cultures were washed with PBS, blocked with 3% 
BSA/PBS++, and then probed with anti-MUC1 antibody (B2729; 1:100).  Cultures were 
washed and then fixed in 4% paraformaldehyde (PFA) for 1hr at room temperature.  
Following this incubation, fixative was removed and secondary antibody applied (goat anti-
mouse IgG alexafluor 488 (Invitrogen, Inc.); 1:500).  Fluorescent images were obtained 
using a Leica DMIRB inverted fluorescence microscope equipped with cooled-color charge-
coupled-device digital camera (MicroPublisher; Q-Imaging, Burnaby, BC, Canada).   
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 HAE cultures fixed in methanol:acetone were also processed for histology.  Briefly, 
fixed HAE were embedded in paraffin and sliced into 5µm histological sections.  Sections 
were then stained with hematoxylin and eosin (H&E) and analyzed by light microscopy. 
 
qRT-PCR 
Mucin and cytokine expression at the mRNA level was determined by quantitative 
reverse transcription (qRT)-PCR.  HAE cultures were stored in RNAzol at -80oC prior to 
nucleic acid isolation and analysis.  Total intracellular RNA was isolated from homogenized 
samples using the RNeasy total RNA isolation Kit (Qiagen, Inc.) and complimentary DNA 
subsequently generated using 500ng Oligo (dT) primers and SuperScript II reverse 
transcriptase (Invitrogen Inc.).  Real-time PCR was performed using Taqman® gene 
expression assays and an Applied Biosystems 7500 Fast Real-Time PCR System using 
GAPDH to normalize for input amounts of cDNA.  Signals from experimental samples were 
corrected against the signal generated in the control samples, resulting in a GAPDH-
corrected measurement of expression over mock-infected HAE expressing the shRNA 
against GFP (control). 
 
Mice 
 All studies were conduced in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and the Institutional Animal Care and Use 
Committee guidelines of University of North Carolina at Chapel Hill.  Wild-type, Muc1-/- and 
Muc4-/- FVB mice were obtained from Dr. Sandra Gendler (Mayo Clinic College of Medicine, 
Scottsdale, AZ) and Dr. Wanda O’Neal (University of North Carolina at Chapel Hill, Chapel 
Hill, NC), respectively, and bred in house.  The generation of Muc1 genetically deleted mice 
has been previously described (296).  Muc4 deleted mice were generated by Dr. O’Neal 
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through homologous recombination in embryonic stem cells.  Transgenic mice used in the 
present study were backcrossed at least 6 generations.     
 Four to eleven-week old animals were anesthetized with isofluorane and challenged 
by intranasal administration of 700 PFU/40µl of influenza virus A/PR/8/34 diluted in serum-
free DMEM (Invitrogen, Carlsbad, CA; 20µl / nare).  Mice were monitored daily and weight 
was assessed for up to 8 days post-inoculation.  Influenza virus-inoculated mice were 
euthanized at 4, 6 or 8 dpi and lungs harvested into serum-free DMEM for homogenization 
and analysis of viral titer by standard plaque assay.   
 
Statistical analyses 
Data are presented as the mean +/- standard error of the mean (SE).  Statistical 
significance for single data points was assessed by the Student’s unpaired t test using 
SigmaPlot software.  In all cases, a p value of < 0.05 was considered significant.  
  
 
RESULTS 
Influenza virus HA binds to human MUC1  
 We previously determined that influenza virus interacted with HAE-derived 
exosomes in a sialic acid-dependent manner and that MUC1 was a prevalent molecule 
associated with exosomes (Figure i) (145).  Thus, our initial experiments in this study sought 
to determine if influenza virus HA interacted directly with human MUC1.  Since interaction 
between influenza virus HA and MUC1 likely depends on MUC1 sialylation, and because 
sialylation is both species and cell-type specific, we aimed to determine interaction with 
MUC1 derived from human primary airway epithelial cells.  However, even though MUC1 is 
abundant at the apical surface of human airway epithelium, it is difficult to isolate due to its 
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size and high degree of glycosylation.  Thus, exosomes not only provided initial evidence 
that influenza viruses may interact with MUC1, but also provided an initial means of isolation 
of this tethered mucin from HAE.  Further purification of MUC1 from exosomes was 
achieved by immunoprecipitation and subsequent interaction with influenza virus HA was 
determined by probing the precipitate with a recombinant influenza virus H3 HA protein 
(rHA).  We have previously shown that recombinant hemagglutinin proteins can be used as 
probes to detect binding in HAE in vitro and trachea tissue ex vivo and that the cellular 
distribution of binding matched the cell types that were infected by live virus with 
corresponding HAs (100).  These data suggest rHA probes are likely predictive of whole 
virus interactions mediated by HA and can be used as a surrogate for live virus in our 
current study.  
Detection of rH3 HA binding and anti-MUC1 reactivity in the same region of the gel 
indicated a likely interaction between the viral attachment protein and this mucin molecule 
(Figure 1).  A second tethered mucin, MUC16, that was previously identified in exosomes 
was detected in total exosome preparations but was not detected in precipitated material.  
These data confirmed that other mucins were not present and further supported that the 
detection of rHA was indicative of MUC1-HA binding.   
 
Characterization of human well-differentiated ciliated airway epithelial cultures 
knocked-down for MUC1.   
To determine the consequences of influenza virus HA-MUC1 interaction during the 
course of infection, we generated well-differentiated cultures of human airway epithelium 
(HAE) that were knocked-down for MUC1 (MUC1kd) by way of lentivirus-mediated shRNA 
expression.  Expression of MUC1 in HAE containing shRNA against MUC1 was significantly 
reduced (5-fold) compared to control cultures expressing shRNA against GFP (GFPkd), 
indicating successful knock-down of endogenous mucin at the message level (Figure 2A).  
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Loss of MUC1 was also evident when cultures were probed for surface MUC1 protein and 
viewed en face (Figure 2B).   
Since MUC1 expression has been implicated in lung morphogenesis as well as 
cellular adhesion and polarity (201, 262), we next determined if through the successful 
knock-down of MUC1 we had altered the development of a well-differentiated 
pseudostratified HAE.  Importantly, MUC1 knock-down did not appear to induce overt 
changes in differentiation, epithelial cell morphology or ciliation that were observable by light 
microscopy analysis of hematoxylin and eosin-stained culture sections (Figure 2C).  Finally, 
to ensure the specificity of our shRNA sequence for MUC1, we investigated expression of 
other tethered mucins, MUC4 and MUC16, in HAE.   While expression of MUC4 and MUC16 
were slightly reduced, reduction of MUC1 was most dramatic, indicating an adequate 
degree of specificity (Figure 2D).  Together, these data were indicative of the generation a 
human cell culture system that accurately recapitulates the human airway epithelium in vivo 
which could serve as a model to investigate the role of MUC1 in influenza virus infection. 
 
Human influenza virus infection is restricted at early time points post-inoculation in 
HAE with reduced MUC1 levels.   
Initial inoculation of the human airway likely occurs with relatively low 
(environmental) levels of virus, thus, we first assayed the ability of a representative human 
influenza virus, A/Victoria/3/75 (H3N1) to infect and replicate in MUC1kd HAE inoculated at 
a low multiplicity of infection ((MOI) = 0.001).  In control HAE, A/Victoria/3/75 grew 
efficiently, reaching titers of 3.8x105 pfu/ml by 24hrs p.i. and achieving peak titer of 7x107 
pfu/ml by 48hrs p.i (Figure 3A).  These growth kinetics were similar to the kinetics previously 
reported for A/Victoria/3/75 in normal HAE that had not been transduced with lentivirus 
(270).  In contrast, no progeny virus was detected before 24hrs p.i. in MUC1kd HAE, and 
titers measured at this time point were reduced by 3 logs compared to those in control HAE 
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inoculated in parallel.  Lower titers at this time point also correlated with fewer cells that 
stained positive for viral antigen (Figure 3B).  While these data suggested that 
A/Victoria/3/75 was less infectious in the absence of MUC1, viral titers determined at 48hrs 
p.i. were nearly identical to those detected in control HAE cultures indicating the restriction 
observed at 24hrs p.i. was not limiting in the HAE model system.  Furthermore, influenza 
virus replication in HAE cultures derived from an additional donor did not exhibit a difference 
in titer at either 24 or 48hrs p.i. despite similar levels of MUC1 knock-down (data not shown).  
While the reasons for this donor-specific variation are currently unclear and warrant further 
investigation, these data provided initial evidence that MUC1 may influence early events 
during influenza virus infection.     
         
Characterization of the cytokine response to influenza virus infection in MUC1kd 
HAE. 
 MUC1 was previously shown to influence the pro-inflammatory response to bacterial 
infection in mice and to negatively regulate TLR-signaling in cell lines (165, 172, 319).  
Indeed, the cytoplasmic tail of MUC1 has been associated with a plethora of host cell 
kinases and non-kinases which may modulate the cellular response to pathogenic insult (46, 
333).  To determine if the cytokine response to influenza virus infection of HAE with reduced 
levels of MUC1 was altered, we inoculated HAE with a high MOI of A/Victoria/3/75 and 
assayed for both infection and cytokine induction at 24hrs p.i.  Similar to our data obtained 
after low MOI inoculation, we detected significantly reduced titers in MUC1kd HAE which 
were 2.5 logs lower than titers detected in control HAE (Figure 4A).  Viral titers again 
correlated with numbers of cells infected.  While nearly the entire epithelium stained positive 
for viral antigen in control cultures, infection was patchy in MUC1kd HAE, suggesting that in 
a MUC1-reduced environment, influenza virus is less able to infect and spread throughout 
the epithelium by 24hrs (Figure 4B).   
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Despite restricted infection, expression of the anti-viral cytokine, IFNβ, was not 
significantly different between MUC1kd and control HAE infected with A/Victoria/3/75 (Figure 
4C).  IFNβ is part of the type I interferon response that can act to establish an anti-viral state 
in epithelial cells through the induction of interferon stimulated genes that inhibit viral 
replication at multiple levels (163, 264).  IFN production can be triggered by interaction 
between viral components (which represent conserved pathogen-associated molecular 
patterns, or PAMPs) and host pattern recognition receptors (PRRs) such as toll-like 
receptors (TLRs) or RIG-like helicases that are present in epithelial cells (252, 350).  Here, 
MUC1kd and control cultures were inoculated with equal MOI providing equivalent levels of 
virus-associated PAMPs initially.  However, reduced viral titers measured in MUC1kd HAE 
suggest that overall, less viral PAMP in MUC1kd HAE is associated with the induction of 
equal levels of IFN detected in controls.  Thus, equal induction of IFNβ may be a 
consequence of the loss of MUC1-mediated negative regulation of TLR (or other PRR) 
signaling enabling greater amplication of IFN.     
In addition to IFN, we also determined expression levels of pro-inflammatory 
cytokines IP-10, IL-8, IL-6 and MCP-1 (Figure 4C).  Similar to our results for IFNβ, 
expression of IP-10, IL-8 and IL-6 measured at the mRNA level were not significantly 
different from the expression level detected in infected, control HAE despite the desparity in 
viral titers.  MCP-1 expression was most striking and was determined to be significantly 
enhanced in MUC1kd HAE, suggesting MUC1 may play an important role in regulating 
MCP-1 levels in response to viral infection.   
Notably, baseline levels for all cytokines assayed were slightly elevated in MUC1kd 
HAE prior to infection.  While this may signify virus-specific induction of cytokine was slightly 
lower than indicated for MUC1kd HAE infected with A/Victoria/3/75, the significant reduction 
in titer in these cultures would still suggest greater induction of cytokine on a per-virus basis 
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in MUC1kd HAE compared to control HAE.  Further analysis of cytokines at the protein level 
will enable a more direct comparison between absolute amounts of virus and cytokine 
present.    
 
Muc1-/-, but not MUC4-/-, mice exhibit reduced morbidity associated with reduced 
viral titers compared to wild-type mice 
Our studies in HAE indicated that MUC1 may influence both the ability of influenza 
virus to infect HAE as well as the host cytokine response to infection.  Notably, the pro-
inflammatory cytokines measured in HAE above normally act to recruit immune cells such 
as natural killer cells and macrophages to the site of infection in the lung.  These 
inflammatory cell populations likely influence the outcome of infection in vivo, but are not 
present in HAE, in vitro.  Therefore, we next utilized a mouse model of influenza virus 
infection to determine the overall outcome of influenza infection in the presence and 
absence of Muc1.   
Muc1-/- mice are the most characterized of the tethered mucin knockout animals, 
and exhibit no gross phenotype when housed in a pathogen-free environment (296). Muc1, 
like MUC1 in humans, encodes a high number of potential O-glycosylation sites (294) and is 
expressed in the airways of mice (300) with a similar distribution to human MUC1 
expression.  We have previously used these mice to investigate the role of Muc1 in 
adenovirus infection and demonstrated that the involvement of Muc1 in adenovirus infection 
of mouse airways was similar to HAE, suggesting, at least for this virus, the roles of MUC1 
and Muc1 were comparable (300).  
Muc1-/- and wild type (FVB) control mice were inoculated intranasally with 700 pfu of 
recombinant mouse-adapted influenza A virus, A/PR/8/34 (H1N1), and monitored daily for 
weight loss.  Wild-type FVB mice continually lost weight over the 8-day time course while 
Muc1-/- mice lost little to no weight and showed no clinical signs of illness, suggesting that 
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one consequence of Muc1 deletion was reduced morbidity in response to influenza virus 
challenge (Figure 5A).  Viral titers were also determined in the lungs of mice harvested at 
days 4 and 8 post-inoculation as a measure of infection.  As expected, high titers were 
detected in the lungs of wild-type mice at both day 4 and day 8, averaging 1.2x105 pfu /ml 
and 3.3x104 pfu/ml, respectively.  In lungs harvested from Muc1-/- mice, however, viral titers 
were reduced by 1.5-2 logs compared to wild-type at these time points (Figure 5B).  
Therefore, the lack of weight loss and overall reduced morbidity in Muc1-/- mice correlated 
with reduced influenza virus titers in the lung. 
 In addition to Muc1, tethered mucins Muc4 and Muc16 are present in the murine 
respiratory tract, similar to the human airways (300).  To determine if reduced infection and 
disease observed in Muc1-/- mice was specific to Muc1 or also observed in mice deleted for 
other tethered mucins, we inoculated Muc4-/- mice and again monitored weight loss and 
viral titers in the lungs compared to wild-type controls.  In contrast to our data for Muc1-/- 
mice, Muc4-/- mice lost weight with similar kinetics as observed for wild-type mice (Figure 
5C).  Furthermore, titers determined in the lungs of both Muc4-/- and wild-type mice were 
not significantly different at either day 4 or day 6 post-inoculation (Figure 5D).  These data 
show an overall similar infection phenotype in wild-type and Muc4-/- mice and suggest that 
the reduced infection phenotype observed in Muc1-/- mice was specific for Muc1 and not 
due to a general phenotype induced upon removal of any tethered mucin.  While additional 
correlates of infection in vivo, such as cytokine production and histopathological analysis, 
have not yet been determined and will be important in further elucidating the precise 
mechanisms by which Muc1 functions in the context of influenza virus infection, these in 
vivo data correlated with our in vitro data in HAE and suggested that overall Muc1/MUC1 
acts to facilitate infection of influenza virus.    
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DISCUSSION 
Human influenza A viruses bind to terminal sialic acid linkages attached to 
glycoconjugates in the lung to mediate infection.  The identity of these glycoconjugates that 
present relevant sialic acids to the virus in the context of infection, however, has remained 
elusive.  In this study, we provided evidence for a direct interaction between human 
influenza virus HA and a specific host sialylated protein, MUC1, and demonstrated that 
influenza virus was less able to infect and cause disease in a MUC1-reduced or Muc1-
deleted environment, respectively.  Together, these data suggest that MUC1 plays an 
important role in influenza virus pathogenesis and corroborate the notion that human 
influenza viruses have evolved to utilize this abundant host protein to facilitate infection of 
the underlying epithelium.   
MUC1 is a tethered mucin that normally functions as a protective barrier at the apical 
surface of epithelial cells (110).  Therefore, it would be predicted that the loss of MUC1 
would render the epithelium more susceptible to infection.  Support for this hypothesis is 
provided by enhanced adenovirus infection of the airways and increased Helicobacter pylori 
infection of the gastrointestinal epithelium of Muc1-/- mice (195, 300).  In addition to its 
expression in the airway, Muc1 is present on epithelial cells in the gut where it provides an 
attachment site for H. pylori.  Muc1-/- mice were shown to exhibit greater bacterial 
colonization and worsened disease following H. pylori challenge, indicating that Muc1 
normally protects the underlying epithelium from this pathogen (195).  In the present study, 
we determined that human influenza virus HA protein could bind to MUC1 isolated from 
HAE-derived exosomes, suggesting that, like gut-associated Muc1 in the context of H. pylori 
infection, airway-associated MUC1 may provide an attachment site for influenza virus in the 
lung.  However, in contrast to the H. pylori report, we detected lower viral titers and reduced 
morbidity in Muc1-/- mice inoculated with a mouse-adapted influenza virus, A/PR/8/34, 
suggesting Muc1 is required for sufficient infection capable of inducing clinical signs of 
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disease in the mouse model.  We observed a similar phenotype, characterized by reduced 
viral titer and fewer numbers of infected cells at early time points post-infection, in HAE with 
reduced levels of MUC1.  Thus, our data in both mouse and human model systems 
suggests that a reduction in MUC1 results in decreased infection and that this may be due 
to the loss of a direct virus-mucin interaction that normally occurs during infection.   
The mechanisms by which MUC1 may therefore facilitate influenza virus infection 
can be further surmised from our data; however, defining the precise nature of MUC1 
involvement will require additional experimentation.  As mentioned, reduced infection in HAE 
at 24hrs, in conjunction with evidence for a direct interaction between MUC1 and viral HA, 
suggest that MUC1 may directly promote infection by providing an attachment site for 
human influenza viruses.  Attachment may enable viral access to other relevant 
glycoproteins or glycolipids at the apical membrane, or directly mediate infection of the 
target cell.  The abundance of MUC1 at the apical surface of epithelial cells and the 
evolution of influenza virus HA binding preference towards α2,6-linked sialic acid usage 
(abundant on MUC1) during adaptation to the human host correlates with enhanced 
infection in the presence (vs. absence) of MUC1 and corroborates the notion that human 
influenza viruses have evolved to use this host protein to their advantage.  Nonetheless, the 
ability of influenza virus to reach similar titers at later time points in both MUC1kd and 
control HAE indicates that high levels of MUC1 are not required for infection of the human 
airway epithelium.  
Numerous reports have identified MUC1 as an important signaling molecule that may 
regulate both inflammation and oncogenic cellular processes, although the downstream 
effectors that respond to MUC1 stimulation are relatively unknown (46, 269, 319).  Still, 
evidence that MUC1 can downregulate TLR-mediated activation of NF-κB in cell lines (319) 
and data showing exaggerated inflammation in Muc1-/- mice in response to Pseudomonas 
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aeruginosa infection (172) suggest that MUC1 may also (or alternatively) influence influenza 
virus pathogenesis indirectly through modulation of the host cytokine response.  Evidence in 
this study of elevated anti-viral and pro-inflammatory cytokine production with respect to viral 
titers in MUC1kd HAE supports this hypothesis.  IFN production has previously been 
reported to limit viral infection and was linked to reduction in viral titers determined for a 
human parainfluenza virus 1 mutant in HAE (23).  However, in this study, similar levels of 
IFN were detected in cultures that exhibited different levels of infection, suggesting a model 
where MUC1 acts both to facilitate entry into target cells and to suppress cytokine induction.  
Specifically, in the absence of MUC1, less virus may be capable of efficiently infecting the 
epithelium, resulting in overall lower levels of virus-associated PAMPs but similar induction 
of IFN as a consequence of the loss of MUC1-mediated negative regulation of TLR 
signaling.  Influenza virus has been described to trigger TLR3 upon infection of several lung 
epithelial cell lines, validating this potential mechanism (102).   
Nonetheless, the absolute levels of cytokine produced were similar between 
MUC1kd and control HAE, with the exception of MCP-1, suggesting that the inflammatory 
infiltrate populations recruited to the lung in vivo would be largely equivalent.  These 
immune cells may be more effective at mediating control of infection and clearance, 
however, in the case of already reduced levels of infection.  Certainly the consequences of 
pro-inflammatory cytokine induction are best determined in vivo as HAE are devoid of these 
responding immune cell populations.  In this study, Muc1-/- mice challenged with influenza 
virus exhibited lower viral titers and fewer signs of illness.  However, quantification of 
cytokine production or cellular infiltrates present in bronchioalveolar lavage (BAL) and lung 
tissues was not performed.  We could surmise that the absence of these populations allow 
infection to proceed in vitro in HAE, evidenced by similar titers in both MUC1kd and control 
HAE at later time points while inflammation in the absence of robust infection in Muc1-/- 
mice may result in enhanced clearance or control of infection in the mouse model.  Still, it is 
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important to note that the sialylation of MUC1 is both species and cell-type specific.  Since 
the interaction between the viral HA and this host mucin is likely mediated through this 
sialylation, the interaction between influenza virus and mouse Muc1 may differ from that of 
human MUC1 (i.e. the phenotype may be similar, but the mechanisms may be different).  
Nonetheless, the restriction of influenza in both the mouse and human cell model systems 
strongly suggest an important role for this mucin during infection. 
Slightly increased baseline levels of cytokine in MUC1kd HAE may also be 
suggestive of a pre-exisiting inflamed state in this model as a consequence of Muc1 
deletion.  Pre-existing inflammation may provide partial protection against influenza virus 
infection as was previously shown in a mouse model primed with bacterial lysate prior to 
viral inoculation (318).  Alternatively, inflammation could alter sialylation on host molecules 
involved in infection, evidenced by a recent study showing an increase of alpha2,3-
sialyltransferase activity following TNFα treatment of a human respiratory glandular cell line 
(MM-39) (67).  Furthermore, outside of cytokine-mediated effects, loss of MUC1 may have 
simply resulted in disregulation of other host proteins required for efficient infection of 
human airway epithelium.  These proposed mechanisms provide an explaination for 
reduced influenza virus infection in the context of reduced MUC1 levels, independent of a 
direct virus-mucin interaction. This is important, as even though influenza virus HA can bind 
MUC1 purified from the human airway epithelium, we have not provided evidence that this 
interaction occurs in the context of the apical environment.   
 Natural occurrence of MUC1 deletion in humans is not documented.  However, 
human MUC1 exhibits a variable length polymorphism which can result in a MUC1 protein 
containing anywhere from 20 to 100 repeats of the variable number of tandem repeats 
(VNTR) domain (91).  This has a significant impact on the size of MUC1 which can influence 
interactions with potential pathogens.  Previous work determined that adhesion of H. pylori 
to cell lines was a function of the size of the MUC1 VNTR domain, providing a link between 
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natural variation in MUC1 and host susceptibility to infection (59).  Evidence exists for 
variation in host susceptibility to influenza virus infection (275), allowing us to speculate that 
MUC1 polymorphisms may also influence MUC1 interaction with influenza virus impacting 
the course of disease.  Thus, future study may not only address the precise mechanisms 
behind MUC1 modulation of influenza virus infection, but may also address how genetic 
variation in MUC1 may impact the ability of this virus to infect and cause disease in the 
human respiratory tract. 
In sum, MUC1 is a highly sialylated mucin glycoprotein localized to the glycocalyx 
where it is normally tethered to the apical membrane of epithelial cells and has been 
previously shown to influence the outcome of viral and bacterial infection in mice (110, 172, 
195, 300).  In this study, the ability of a recombinant human influenza virus HA protein to 
bind human MUC1 supported a direct interaction between these proteins while both in vitro 
and in vivo models provided evidence that MUC1 may facilitate influenza virus infection of 
human airway epithelium through multiple mechanisms.    
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Figure i*.  Neutralizing effect of exosomes on influenza virus (A/Victoria/3/75) 
infectivity.  A) Bar diagram compares analysis of raw data from plaque assays.  Exosome-
treated influenza viruses (open bars) grow 2-3 orders of magnitude less than PBS-BSA-
treated viruses (black bars).  No neutralizing effect was observed on neuraminidase-
presented exosomes (gray bars).  B) Bar diagram indicates 85-100% inhibition effect of 
exosomes on influenza virus, depending on the virus dilution. Percent inhibition is calculated 
as [(viral titers PBS-virus) – (viral titer exosome-virus)]/ (viral titer PBS-virus) * 100.  Data 
shows means +/- st of 4 independent experiments.   
 
 * This figure, © 2009 FASEB 
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Figure 1.  Influenza virus HA interacts with MUC1 isolated from HAE-derived 
exosomes.  MUC1 was immunprecipitated from exosomes isolated from HAE apical 
secretions and electrophoresed in parallel with untreated exosomes.  Following transfer to a 
nitrocellulose membrane, samples were probed with anti-MUC1 antibody, recombinant H3 
HA protein or anti-MUC16 antibody to detect the presence of mucins and viral HA binding.  
 
 
 136 
 
 
 
Figure 2. Successful knock-down of MUC1 in HAE cultures with retention of normal 
morphology.  A) The expression level of MUC1 in HAE transduced with a lentivirus 
expressing shRNA against MUC1 relative to expression levels in HAE transduced with a 
lentivirus expressing shRNA against GFP. N=6 +/-SE. *p<0.05.  B) MUC1 protein 
expression on the apical surface of HAE determined by en face staining.  C) H&E staining 
on transduced HAE culture cross-sections showing culture morphology.  D)  Expression of 
MUC1, MUC4 and MUC16 in HAE transduced with a lentivirus expressing shRNA against 
MUC1 relative to expression levels in HAE transduced with a lentivirus expressing shRNA 
against GFP. N=6 +/-SE. 
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Figure 3.  Multi-step growth kinetics in HAE knocked down for MUC1.  A) HAE 
expressing shRNA against either GFP (control) or MUC1 were inoculated with human 
influenza virus A/Vic/3/75 (H3N2) at an MOI of 0.001.  Viral titers detected in the apical 
wash over a 72hr time course are shown. N=6-7 +/- SE.  B) Cells infected by 24hrs p.i. are 
shown by en face staining for viral antigen (green).    
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Figure 4.  High MOI infection and cytokine production in MUC1kd HAE.  A) Viral titers 
determined at 24hrs p.i. were determined in the apical was of HAE inculated with 
A/Victoria/3/75 at high MOI (=3).  N=7 +/-SE.  B) En face staining for viral antigen (green) 
showing numbers of cells infected at 24hrs.  C) Expression levels of IP-10 and IFNb (log 
scale) and IL-8, IL-6 and MCP-1 (linear scale) in infected GFPkd HAE as well as mock-
infected and infected MUC1kd HAE relative to cytokine expression levels determined in 
mock-infected GFPkd HAE.  N=6+/-SE.    
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Figure 5.  Muc1-/-, but not Muc4-/- are less susceptible to influenza virus infection 
compared to wild-type mice.  A) Weight loss was determined as a measure of morbidity in 
wild-type and Muc1-/- FVB mice inoculated intranasally with 700pfu.  Data shown are the 
average of two independent experiments N=12-21 mice per time point +/-SE.  B) Lungs 
(partial right lobe) were harvested at days 4 and 8 p.i. and viral titers determined by 
standard plaque assay.  Data shown are from the same experiments averaged in panel A of 
this figure and represent the mean viral titer across two experiments N=7-11+/-SE.  C) 
Weight loss was determined over a 6-day time course in wild-type and Muc4-/- mice 
inoculated intranasallly with 700 pfu.  Data shown are from a single experiment.  N=3-8.  
Note that 3 mice in the wild-type co-hort had to be euthanized at day 5 due to weight loss 
resulting in the increased average presented at day 6.   
  
 
 
CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The simple act of breathing brings the human airway epithelium under assault by a 
variety of potentially pathogenic microbes.  To maintain sterility, the airway epithelium 
exhibits sophisticated innate defense mechanisms that are both cytokine-mediated and 
physical or mechanical in nature.  Despite these defenses, respiratory pathogens infect and 
produce disease in the human host.  Their efficiency at doing so is underscored by the fact 
that acute respiratory illness is the most common infection reported in the human population 
(345).  Parainfluenza viruses and influenza viruses are significant respiratory pathogens that 
target the ciliated airway epithelium for infection.  The overall goal of this dissertation was to 
characterize infection of the human airway epithelium by wild-type parainfluenza and 
influenza viruses and to define the ability of these viruses to negotiate host innate barriers 
against infection.  Innate barriers presented by the human airway epithelium in vivo, are 
most closely recapitulated in vitro by cultures of well-differentiated, pseudostratified, ciliated 
airway epithelium.  Utilizing this culture model system, in combination with both human and 
avian virus isolates, recombinant mutant viruses and live attenuated vaccine candidates, we 
conclude the following:   
BOTH HPIV1 and HPIV2 EXHIBIT CILIATED CELL TROPISM:  The human airway 
epithelium is composed of a heterogeneous cell population, including ciliated cells, mucus-
producing cells and underlying basal cells.  Viruses infecting the airway have been identified 
which individually target each of these populations.  Adenovirus and Andes virus, for 
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example, infect basal cells and Clara or goblet cells, respectively (237, 259, 330), while 
many respiratory viruses target the ciliated cell for infection, including SARS-CoV, HPIV3 
and RSV (284, 359, 360).  HPIV1 and HPIV2 were demonstrated in this dissertation to also 
have ciliated cell tropism after apical inoculation with either virus, and also after basolateral 
inoculation for HPIV2 (data not shown).  The ability to infect via the basolateral side 
(equivalent to the serosal side of the epithelium in vivo) was previously described for the 
related measles virus (286) and may suggest that HPIV2 infection can be mediated through 
additional mechanisms, outside of direct binding to receptors at the apical surface.  
Regardless of the route of inoculation, however, progeny HPIV1 and HPIV2 were shed 
apically, correlating with restriction of these viruses to the respiratory tract during infection in 
vivo.   
Demonstration of ciliated cell tropism for HPIV1 and HPIV2 provides additional 
evidence that the ciliated cell plays an important role in the pathogenesis of 
paramyxoviruses.  The ciliated cell of the human airway epithelium is critical for lung function 
through its role in mediating mucociliary transport and is likely the predominant cell type 
throughout the conducting airways for this purpose.  Whether this cell type is a common 
target for infection as a coincidence of receptor distribution or whether these viruses 
specifically target this cell type due to its abundance or ability to sense and respond to 
infection relative to other cell types present in the epithelium is unknown.   
HPIV1 binds to α2,3-linked sialic acid, thus, tropism described here correlates with 
the cellular distribution of α2,3-linked sialic acid previously determined by lectin binding 
(303, 312).  Notably, avian influenza viruses, which not do not infect the human upper 
respiratory tract with HPIV-like efficiently, also utilize α2,3-linked sialic acid and are 
observed to infect ciliated cells in HAE (56, 256).  However, the sialic acids bound by avian 
influenza viruses are distinct from the α2,3-linked sialic acids bound by HPIV with respect to 
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interaction with the adjacent glucosamine (9).  Furthermore, avian influenza viruses that 
adapt for efficient infection of the human airway epithelium evolve to bind α2,6-linked sialic 
acid (9, 183).  This adaptation correlates with evolution towards non-ciliated cell tropism for 
influenza viruses as described by Thompson et al. (2006) who determined cell types 
infected by a panel of human influenza viruses including pandemic-era isolates and recent 
strains (312).  The mutations required to switch viral HA binding preference from α2,3- to 
α2,6-linked sialic acid (and thus, cell tropism from ciliated to predominantly non-cilated cells) 
have been described for certain HAs.  With this information, we can now investigate how 
different cell types in HAE may respond to infection by the same pathogen.  This can be 
achieved by mutation of the RBD in the same viral genetic background and assessment of 
parameters of infection such as cytokine production.  Such studies may elucidate the 
advantages of binding α2,6-linked sialic acid and/or infecting non-ciliated cells in the context 
of influenza virus infection and may also yield information that would be useful in 
understanding why paramyxoviruses exhibit strict ciliated cell tropism. 
BOTH HPIV1 AND HPIV2 BLOCK IFN PRODUCTION IN HAE:  Detection of viral 
antigen in ciliated cells in the HAE model indicated that both HPIV1 and HPIV2 successfully 
infected the HAE culture system.  In response to viral infection, the host often produces 
interferon, a cytokine that acts to establish an anti-viral state through the induction of 
transcription of numerous host genes (93).  Since interferon can act to limit viral replication 
and subsequent spread, we also determined the growth kinetics and corresponding levels of 
IFN induced by these parainfluenza viruses in HAE.  Previous work suggested that HPIV1 
could induce a type I IFN response in MRC5 lung fibroblast cells, but not in A549 lung 
carcinoma cells, indicating that IFN production in response to HPIV1 infection was cell-type 
dependent (38, 324).  Lack of detectable type I IFN in HAE in our experiments for either 
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wild-type HPIV1 or HPIV2 provided evidence that these viruses possessed robust interferon 
antagonists that were effective in ciliated cells.   
IFN ANTAGONISM IS LINKED TO THE HPIV ACCESSORY PROTEINS WHICH 
ARE CRITICAL FOR EFFICIENT INFECTION OF HAE:  The C proteins of HPIV1 (or 
murine homolog, SeV) have previously been described as interferon antagonists in addition 
to their roles in suppressing viral replication and apoptosis (22, 62)  A mutation at position 
170 in the C protein of SeV was previously identified as an attenuating mutation after serial 
passage of a virulent SeV isolate in tissue culture yielded a less robust strain (86).  This 
mutation was engineered into HPIV1, generating HPIV1-CF170S, and subsequent analysis of 
this virus in HAE demonstrated greater kinetics of replication initially, but overall reduction in 
viral titer at later time points which correlated with the induction of an IFN response (23).  A 
second recombinant HPIV1 virus in which the entire C gene was not expressed failed to 
generate detectible titers in the apical compartment (22).  Similar data was obtained for 
HPIV2 deleted for V (HPIV2-Vko), an accessory protein, which, like C, is encoded within the 
P gene.  HPIV2-Vko also failed to grow in HAE (data not shown).  These studies legitimize 
the C proteins of HPIV1 as critical antagonists of the host IFN response and demonstrate 
that the accessory proteins of both HPIV1 and HPIV2, often expendable for infection in cell 
lines (22, 86), are indispensable for productive infection in human airway epithelium. 
The mechanisms of IFN antagonism for both C and V proteins of the 
paramyxoviridae have been investigated in cell lines in vitro (reviewed in (95)), however, it 
remains to be seen if these mechanisms are relevant in the ciliated cell of the human airway 
epithelium and future studies may investigate the interplay between viral proteins and 
intracellular signaling pathways in HAE.  Due to the complexity of the HAE model and 
presence of multiple cell types not all of which are infected by HPIV, such studies would 
require the development of sensitive probing techniques to identify both infected cells and 
changes in host protein localization or phosphorylation status in paraffin section on a per-
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cell basis.  Alternatively, knock-down or over-expression of specific host molecules in HAE 
could be achieved to determine the relative contribution/importance of individual mediators 
or signaling pathways during HPIV infection.  While the potential involvement of these host 
proteins in the process of differentiation of HAE may preclude analysis, our data presented 
in Chapter 5 of this dissertation showing successful knock-down of MUC1 provides evidence 
that such models can be developed.  
Our inability to detect progeny virus in the apical compartment after infection with C- 
or V-deleted viruses may provide another future avenue of study.  Since these accessory 
proteins are not believed to be involved during binding or entry, we would hypothesize that 
these viruses are equally capable of initial infection as their wild-type counterparts, and that 
the restriction occurs at some point during viral replication within the cell.  The ability to enter 
target cells, but not establish productive infection make these viruses ideal candidates for 
development as gene delivery vectors, although depending on the point of restriction, 
replication may be too attenuated to achieve adequate expression of transgenes.    
HPIV2 REPLICATION IS LIMITED, EVEN IN THE ABSENCE OF AN IFN 
RESPONSE:  Despite the fact that HPIV2 was able to completely block type I IFN 
production in HAE, we still observed a loss in titer at late time points.  This was not seen 
during infection with HPIV1, although growth kinetics following high MOI inoculation were 
terminated earlier than similar experiments performed with HPIV2.  These data suggest 
other mechanisms such as additional host cytokines, shedding of infected cells or induction 
of cytopathic effects (CPE) may limit viral replication in HAE.  While cell shedding was 
detected in HPIV2-infected HAE, the decline in viral titer better correlated with increased 
CPE determined by AK release.  Our studies with influenza viruses suggest that ongoing 
replication in the absence of additional target cells available within the confines of the HAE 
culture results in a decline in virus titer.  However, lack of CPE at the gross level following 
HPIV2 infection indicated the epithelium remained largely intact and en face staining 
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indicated not all potential target cells were infected.  Thus, while subtle loss of cellular 
integrity indicated by AK release likely contributes to reduced HPIV2 titers at late time 
points, other mechanisms not determined in this dissertation that act in the absence of an 
IFN response may also be important in limiting viral replication within the epithelium and 
warrant further investigation. 
TEMPERATURE RESTRICTION IN VIVO IS RECAPITULATED IN HAE IN VITRO:  
Due to their attenuation in HAE, recombinant HPIV1 and HPIV2 mutated in their accessory 
proteins are being evaluated as potential live attenuated vaccine candidates for use in 
humans (19).  In addition to being attenuated, live attenuated vaccines are ideally restricted 
to the upper airway via temperature-sensitive mutations (ts) engineered into a wild-type 
genetic background.  The concept of temperature sensitivity is based on data which 
describes differences in regional airway temperatures: the proximal large airways (e.g. 
nasal, tracheal) averaging 32oC and the distal airways (e.g. bronchioles) reaching core body 
temperature (37oC) (194).  Mutations which confer a temperature-sensitive phenotype, often 
located in the polymerase, are frequently identified in related viruses and “imported” using 
reverse genetics in attempt to generate a candidate virus that replicates to sufficient levels 
in order to stimulate a protective immune response, but is restricted from lower lung infection 
and lacks side effects (223).  As no licensed vaccine for any HPIV type currently exists, and 
since an in vitro model that is predictive of the level of attenuation in seronegative children 
would be of value in screening investigative vaccines being considered for clinical trials, we 
compared attenuation determined for several live attenuated vaccine candidates in African 
green monkeys with restriction in HAE.   
Growth kinetics determined for wild-type HPIV1 and HPIV2 in HAE showed that both 
viruses grow equally well at both 32oC and 37oC, which correlates with their ability to 
clinically manifest as either upper or lower lung disease (60).  Replication of vaccine 
candidates in HAE maintained at either 32oC or 37oC compared to wild-type revealed a level 
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of attenuation that paralleled attenuation previous determined in the nasopharyngeal and 
tracheal regions of African green monkeys, respectively (21, 222).  While comparison to 
clinical trial data will provide the ultimate test, these data also suggest that the HAE model 
may be a useful pre-clinical screening tool for live attenuated vaccine candidates.   
WILD TYPE PARAINFLUENZA AND HUMAN INFLUENZA VIRUSES REPLICATE 
WITH EQUAL EFFICIENCY AT TEMPERATURES REFLECTIVE OF BOTH THE UPPER 
AND LOWER AIRWAYS:  Our characterization of live attenuated vaccine candidates in 
HAE confirmed the ability of HAE to model viral growth kinetics in the upper and distal 
airways.  Therefore, we also determined the growth potential of wild-type parainfluenza and 
human influenza viruses in the airway by performing growth curves in HAE maintained at 
32oC or 37oC.  Our data show that HPIV1, HPIV2 and human influenza viruses all grow with 
equal efficiently at temperatures reflective of the upper vs. distal airways, correlating with the 
ability of these pathogens to induce disease throughout the respiratory tract.   
During our experiments investigating growth kinetics we also noted that while 
parainfluenza viruses induced minimal cytopathic effects (CPE), wild-type human influenza 
infection caused destruction of the entire columnar epithelium, sparing only the basal cells.  
These data correlate with cytonecrosis observed during influenza virus infection in vivo 
(308), but also indicate that toxic effects that take place during parainfluenza virus infection 
are likely immune cell-mediated.   
AVIAN INFLUENZA VIRUS GLYCOPROTEINS RESTRICT INFECTION AT THE 
TEMPERATURE OF THE HUMAN PROXIMAL AIRWAYS:  While the live attenuated 
vaccine candidates described in this dissertation are purposefully restricted at higher 
temperature, taking advantage of regional airway temperature differences to prevent lower 
lung infection—the cooler temperature of the proximal airways has been proposed to restrict 
infection of the human airway epithelium by avian influenza viruses which are adapted for 
efficient replication at higher temperatures (40-41oC) in the enteric tract of aquatic birds.  
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Here, we demonstrated that avian influenza viruses are restricted for growth, spread and 
induction of CPE in HAE at the temperature of the human proximal airways, but not at the 
temperature of the distal lung.  These data are in contrast with our data showing equal 
growth of human influenza viruses at both 32oC and 37oC and suggest that adaptation to the 
human host inovolves specific adaptation to replicate efficiently at lower temperatures.   
Although previous work suggested a role for the polymerase subunit, PB2, in 
mediating efficient replication of influenza viruses in mammalian cells (8, 302), mutation of 
PB2 from a lysine (conserved human influenza virus residue) to glutamic acid (conserved 
avian) in a human influenza virus genetic background in our study did not confer a 
temperature-specific phenotype.  However, the inability of avian viruses to spread efficiently 
through the epithelium at lower temperature also suggested a possible role for the surface 
glycoproteins, HA and NA, in mediating temperature restriction of avian influenza viruses.  
This hypothesis was confirmed by our data showing that introduction of avianizing mutations 
or substitution of endogenous human influenza virus HA and NA glycoproteins with those 
from an avian isolate nearly recapitulated the original temperature restriction phenotype with 
respect to growth, spread and induction of CPE observed for wholly avian viruses.   
Overall, these data suggest a model in which avian influenza viruses that are able to 
access the lower airways of the human respiratory tract, via small droplet aerosols or high 
titer inocula, would be able to initiate infection.  In the upper airways, the predominant site 
for initial inoculation, the reduced capacity of avian influenza viruses to replicate and spread 
would provide adequate time for the host to mount an immune response and clear the virus.  
To further assess the legitimacy of this model, we also investigated correlates of infection for 
an avian virus that had successfully infected a human host, A/VN/1203/04, an H5N1 isolate 
cultured from a fatal human case (174).  Replication of H5N1 influenza virus in HAE showed 
significant restriction at 32oC vs. 37oC, albeit less so than observed for avian viruses that 
had not infected people.  This restriction correlates with pathology, localized to the lower 
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lung, for H5 infection (308, 320).  Although localization of H5N1 primarily to the distal 
airways was previously hypothesized to be a consequence of α2,3-linked sialic acid 
distribution throughout the airway (being more abundant in the distal lung), our data 
demonstrate restricted replication at 32oC even in the presence of avian virus receptors in 
HAE.  This further supports a role for the glycoproteins in mediating temperature restriction, 
although it does not rule out additional mutations in the polymerase or involvement of other 
virus proteins, which may also contribute.   
The specific functions of the avian virus glycoproteins that are restricted at lower 
temperature have not been described in this study and represent a future direction of this 
work.  Notably, glycoproteins in our study that conferred efficient infection at lower 
temperature had specificity for α2,6-linked sialic acid.  Specificity for α2,6-linked silaic acid 
also seems to be a prerequisite for human-to-human transmission (56, 317) and the inability 
to transmit efficiently between human hosts is predicted to be the last barrier staving off an 
H5 pandemic.  For this reason, much work in the field has focused on the molecular 
changes that confer α2,6 binding to H5 HAs.  Work performed in collaboration with Dr. 
Wendy Barclay illustrates that mutation at position 228 from G to S conferes human 
influenza-like binding to α2,6-linked sialic acid and correlates with expanded tropism to 
include non-ciliated cells (data not shown).  While this change in amino acid was deemed 
unlikely to occur naturally due to the codon usage of the wild-type virus, rescue of viruses 
containing the H5 HA, now with preference for α2,6-linked sialic acid, will allow studies, 
performed under proper containment, to address if “humanizing” the receptor preference in 
an avian virus glycoprotein background would rescue the temperature restriction.   
We currently speculate, however, that the viral neuraminidase, which has enzymatic 
activity, is key to the phenotype despite our inability to show a difference in NA activity in a 
synthetic, monovalent cleavage assay (MUNANA).  We hypothesize that the effect may 
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require neuraminidase interaction with biologically relevant substrates, present only in vivo 
and in in vitro models such as HAE.  Thus, the development of assays to specifically 
analyze HA and NA function at 32oC vs 37oC should attempt to incorporate the HAE model, 
or ex vivo tissue as substrate.   
HUMAN INFLUENZA VIRUS HA CAN BIND HUMAN MUC1: Since all influenza 
viruses adapted for efficient infection and transmission in humans evolve to utilize α2,6-
linked sialic acid (84, 183), we next sought to identify relevant molecules in the airway 
environment that presented α2,6-linked sialic acid to the virus that may influence 
pathogenesis.  While the lumen of the airway is rich in glycoproteins and glycolipids, many 
of which contain terminal sialic acid moieties, the specificity of the viral HA for α2,6-linked 
sialic acid adjacent to a galactose and requirement for certain topology is evidence that the 
virus is somewhat selective in its interactions (48, 56).  Still, the requirement of the viral 
sialidase (NA) for initial infection of HAE provides evidence of erroneous HA attachment to 
sialic acid that presumably impede initial infection or spread and speaks to the barrier 
function of the host mucus and glycocalyx (187).  Therefore, interactions that do occur may 
favor infection (ie. act in a receptor role), but may also represent false substrates, provided 
by the host in attempt to block infection.   
Our initial experiments utilized exosomes, vesicle-like structures recently identified in 
HAE secretions that contain many of the molecules known to be present at the apical 
surface of the airway epithelium (145).  Inhibition of influenza virus by exosomes, but not 
exosomes pre-treated with bacterial neuraminidase, in a plaque reduction assay suggested 
the presence of virus-relevant, sialic acid-containing molecules in exosome preparations. 
HPIV1, HPIV3 and RSV were not inhibited by exosomes in our plaque reduction assay, 
suggesting that interaction with MUC1 is not a general characteristic of respiratory viruses.  
Proteomic analysis of exosome preparations identified that the tethered mucins, MUC1, 4 
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and 16, an important component of the glycocalyx lining the apical surface of target host 
cells, were present in abundance (145).  Mucins are known to be highly sialylated 
molecules, and mucin 1 in particular was shown to carry abundant sialic acid of α2-6 linkage 
(145), thus providing a candidate molecule for interaction with influenza virus.  Subsequent 
detection of rHA binding to purified MUC1 indicated that the influenza virus attachment 
protein could bind MUC1 isolated from human airway epithelium.  
REDUCED LEVELS OF MUC1 IN VITRO AND IN VIVO RESTRICT INFLUENZA 
VIRUS INFECTION:  MUC1 was previously shown to act as a substrate for other viral and 
bacterial pathogens, likely due to the robust glycosylation on its extracellular terminal 
repeats (59, 105, 158, 164).  Recently, MUC1 has also been recognized as a signaling 
molecule with the capacity to suppress TLR-mediated activation of NFkB (319) and the 
impact of a MUC1-regulated anti-inflammatory effect was demonstrated in a mouse model of 
Pseudomonas aeruginosa infection in which the deletion of Muc1 resulted in enhance pro-
inflammatory cytokine production and more rapid clearance (172).  Reduced levels of MUC1 
were shown in this dissertation to impact influenza virus infection.  Specifically, both titers 
and numbers of cell infected were reduced in MUC1kd HAE.  Lower viral titers were also 
detected in the lungs of Muc1-/- mice.  We also noted that, depite reduced infection, the 
levels of anti-viral and pro-inflammatory cytokines were similar (if not greater) in both 
MUC1kd and control HAE.  Together, these data indicate that MUC1 may normally facilitate 
the ability of human influenza viruses to infect target cells and may also suppress the host 
response to infection.   
Overall this study strongly supports a role for MUC1 during influenza virus infection.  
The underlying mechanisms that allow for greater infection of both HAE and mouse models 
with reduced levels of MUC1, however, have not yet been determined and represent a 
future direction of this work.  If influenza virus interacts directly with MUC1 in the context of 
the airway epithelium, this interaction will likely be dependent on the sialylation present on 
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this mucin molecule. Thus, future analysis which addresses the potential for MUC1 to be an 
attachment site for influenza virus in the context of the human airway epithelium should aim 
to do so in human cell systems that are more likely to glycosylate this protein in a way that is 
likely to be similar to that in the lung.  However, analysis of the potential effect of MUC1 on 
the host immune response to influenza virus infection will ideally be performed in mouse 
models in vivo which possess all components of an innate and adaptive immune response.  
Finally, genetic variation (polymorphisms) associated with MUC1 have been shown to result 
in mucins of different “length” which, in light of the data present here showing MUC1 
influences influenza virus infection, may influence susceptibility to infection by influenza 
viruses.  Since HAE cultures are derived from individual donor sources, the potential exists 
to analyze the influence of MUC1 variation on influenza virus infection in vitro.  
SUMMARY: The human ciliated airway epithelium is highly evolved to prevent 
infection.  The observations reported in this dissertation define host barriers, provide new 
insight into the nature of myxovirus-host interactions and identify the viral mechanisms 
which confer the ability to efficiently infect, replicate and spread throughout the epithelium.  
We have demonstrated the importance of accessory genes of the paramyxoviridae in 
replication and interferon antagonism, identified both host and viral determinants of human 
airway epithelium infection by avian influenza viruses and identified interaction between 
human influenza viruses and a host mucin glycoprotein which may facilitate infection.  
These studies were performed in the most physiological in vitro model of HAE available to 
date which enabled us to discern attenuation phenotypes not present in cell lines.  Our data 
further validate this model by demonstrating in vivo correlates of attenuation observed in 
HAE, while our ability to knockdown a host cell protein (MUC1) in this complex culture 
system advances the potential of this model.  The ability to manipulate the virus through 
reverse genetics as well as now the “host” through lentiviral delivery of shRNA or additional 
genes (over-expression) will be powerful tools in further assessing both host factors that are 
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critical for innate defense as well as viral strategies to overcome these barriers.  Knowledge 
of these mechanisms may provide direction for therapeutic targets and further our 
understanding of susceptibility to disease.  
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